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Abstract
Biomedical data commonly include repeated measures of biomarkers and disease states over
time. When the processes determining the biomarker levels and disease states are related, a joint
longitudinal and survival model is needed to properly handle the data. In a recent study of adrenal
cancer patients at the University of Michigan, their tumors were monitored with repeated radiog-
raphy scans. Other body measurements, called morphomics, were also measured from these scans.
At each scan, it was noted whether the patient’s disease was stable, progressing or regressing. In
addition, the data include time to death or end of follow-up. Motivated by this data we explore
joint models for longitudinal and survival data of several types.
In Chapter 2 we compare computational approaches to joint longitudinal and survival models
with a single type of event. We examine different joint model formulations especially those most
often implemented in software available to statisticians and clinicians. We apply and compare
several models to the adrenal data and perform a simulation study to further evaluate each model
and software.
In Chapter 3 we examine the relationship between a morphomic variable and time to first dis-
ease state change which can be either cancer progression or regression, in the adrenal cancer data.
We develop Bayesian joint models for longitudinal and competing risks survival data. A seldom
considered aspect of competing risk joint models is the relationship between the two competing
outcomes. This cannot be examined when using the most common technique, cause-specific haz-
ards models. With that motivation for our future projects, we work under the assumption that each
risk has a latent failure time for each individual. We begin with the simple case of conditionally in-
xiii
dependent risks and model the survival times using parametric distributions. We apply our models
to the adrenal data and examine the performance via simulations.
In Chapter 4 we extend our joint longitudinal and competing risks models for dependent com-
peting risks. We begin with a discussion of survival copulas and the general joint survival function
we will use which is based on an Archimedean copula model. We prove that dependent variables
with this joint survival function can be written in terms of independent variables which is useful
for simulating data. We develop the model with Weibull marginals. We fit this model to the adrenal
data and examine the models using a simulation study. We discuss interpretations of the model and
how it can be used to learn about the dependence between risks.
Finally, in Chapter 5 we will develop a joint model that incorporates multiple longitudinal





Observational studies with a time-to-event outcome will often include longitudinal measure-
ments associated with the event time outcome. An early and still studied example is CD4 counts
over time and time until progression from HIV to AIDS (Wulfsohn and Tsiatis, 1997; Wang and
Taylor, 2001; Huang et al., 2011). In cancer, increasing PSA levels are known to be associated with
prostate cancer recurrence (Proust-Lima and Taylor, 2009). Other examples include the study of
biomarkers in cancer vaccine trials, quality of life measurements in cancer, and time-to-failure and
degradation in engineering applications (Brown and Ibrahim, 2003; Ibrahim et al., 2010; Lehmann,
2009). A new example motivating this work is a study of adrenocortical carcinoma patients at the
University of Michigan that recorded body measurements over time as well as times for events
including cancer progression and death.
In such contexts, separate models for the longitudinal and survival components that do not take
into account the dependence between the longitudinal and survival processes produce inefficient
results and are prone to bias (Ibrahim et al., 2010). Ideally, a joint model would be used. Less com-
plicated alternatives to joint models include using time-dependent covariates or two-stage models
but these each have drawbacks. Including the longitudinal process as a time-dependent covariate
in the survival model requires the unrealistic assumptions that the longitudinal measurement has
negligible measurement error and that there are observations at every event time (Mccrink et al.,
2013). Traditional Two-Stage models will fit the longitudinal model first, disregarding the sur-
vival outcome. Then the fitted longitudinal trajectory is included as a time-dependent variable in
the survival model (Tsiatis et al., 1995). This will account for the measurement error within the
longitudinal process in the survival model. However, this strategy fails to account for the possible
1
informative censoring in the longitudinal process created by the survival event.
A fully specified joint model incorporates the dependence between the longitudinal and survival
components properly and provides efficient inference that is less prone to bias. Joint models lend
themselves to answering several possible research questions such as the effect of covariates on
one outcome, the association between the outcomes, hypothesis testing, or outcome prediction
(Rizopoulos, 2012, p. 9-10).
There are differing approaches to formulating joint models. We shall focus on random effects
models as these are the most commonly used. Random effects models assume the likelihoods for
the longitudinal and time-to-event models each include correlated random effects, consequently
linking the two processes. Some other likelihood approaches include Selection Models and Pattern-
Mixture Models (Mccrink et al., 2013). Another formulation is latent class models, in which
subjects are assumed to belong to one of a number of latent classes and association is induced
by class membership (Proust-Lima et al., 2014; Proust-Lima and Taylor, 2009; Lin et al., 2002;
Proust-lima et al., 2015; Rouanet et al., 2016; Andrinopoulou et al., 2018; Sun et al., 2019).
Early work on joint models dates back to the mid-nineties (De Gruttola and Tu, 1994). Since
then a body of work has steadily emerged in this area of research (Henderson et al., 2000; Wang and
Taylor, 2001; Wulfsohn and Tsiatis, 1997). Some early Bayesian work on this topic includes those
by Faucett and Thomas (1996), and Brown and Ibrahim (2003). More recently, there have been
several extensions in the directions of dynamic predictions and prognostic tools (Proust-Lima and
Taylor, 2009; Taylor et al., 2013; Rizopoulos et al., 2014), competing risks (Elashoff et al., 2007;
Hu et al., 2009), recurrent events (Liu and Huang, 2009), multiple longitudinal variables (Li et al.,
2007), cure rates (Yu et al., 2004), and diagnostics (Huang et al., 2009). Several comprehensive
reviews of joint modeling of longitudinal and survival processes have been published (Tsiatis and
Davidian, 2004; Mccrink et al., 2013; Gould et al., 2014; Papageorgiou et al., 2019).
Joint models are useful in a few different scenarios. The main interest can be in the longitudinal
process with an event causing informative dropout. Interest could be equally on a longitudinal and
a survival process that are associated. A third common scenario occurs when a time-to-event
2
process is modeled with a longitudinal covariate measured intermittently and with error. Such data
require joint modeling to fully capture the association and reduce bias.
We will begin by describing the basic framework of a joint model in Section 1.2 and usual
estimation techniques in Section 1.3. Section 1.5 describes our motivating dataset from adrenal
cancer patients at the University of Michigan.
1.1 Notation
Throughout this work we will use the following notation unless otherwise specified. Im de-
notes an m × m identity matrix and 0m denotes a vector of zeros of length m. Ind(·) is the
indicator function. A superscript T denotes the transpose of a vector or matrix. The function
log(x) is the natural logarithm of x and may be used interchangeably with ln(x). The symbol ∝
stands for "is proportional to". We will use the phrases survival time, event time, and failure time
interchangeably. Also we will use cause, death, event, and failure interchangeably in regards to
the time-to-event endpoint. Pr(A) will denote the probability of event A. We use f(·) for the
probability density function of a random variable, F (·) the cumulative distribution function, S(·)
the survival function where S(·) = 1 − F (·), h(·) the hazard function, and H(·) the cumulative
hazard function.
1.2 Modeling Framework
We will begin by describing common joint models with longitudinal measurements and a sin-
gle survival outcome. Consider i = 1, ..., N subjects with repeated longitudinal measurements
and a terminal event measured. The repeated measurements and event time are assumed to be
associated. Each subject i has Ji measurements taken at different times with the intervals between





Let Yi(t) denote the longitudinal process for subject i at time t. We assume there is a true un-
derlying process, or trajectory, mi(t) from which Yi(t) is measured with error ei(t), Yi(t) =
mi(t) + ei(t). In practice, we do not observe the longitudinal process at all times. Instead for sub-
ject iwe observe Yi(t) at ni times (ti,1, ..., ti,Ji). Let Yi = (Yi,1, ..., Yi,Ji) = (Yi(ti,1), ..., Yi(ti,Ji)) be
the vector of observations. The trajectory mi(t) is modeled with fixed (possibly time-dependent)
covariates, Xi,j and parameter coefficients β, and random effects vector Ui with possibly time-
dependent design matrix Zi,j . The random effects are traditionally assumed to follow a Normal
distribution. A typical longitudinal submodel is shown in (1.1).
Yi,j = mi(ti,j) + ei(ti,j) = Xi,jβ + Zi,jUi + ei,j,
with ei = (ei,1, ei,2, . . . , ei,Ji)
T ∼ N(0Ji , σ2IJi),
Ui ∼ N(0,ΣU), i = 1, ..., N, j = 1, ..., Ji;
(1.1)
where σ2 and ΣU are the dispersion parameters for the error and the random effects, respectively.
1.2.2 Time-to-Event Submodel
Let T ∗i denote the event time for subject i, Ci the censoring time, Ti = min{T ∗i , Ci} the observed
time, and Di = Ind(T ∗i ≤ Ci) the event indicator. A common time-to-event submodel is a relative
risk model of the form (1.2).
hi(t|Mi(t)) = h0(t)exp{Wiγ + αmi(t)} (1.2)
where Mi(t) is the history of the longitudinal process up to t, Mi(t) = {mi(s), 0 ≤ s < t}. The
matrix of fixed covariates, Wi, can include the same variables as Xij in the longitudinal submodel
but they do not necessarily overlap. The trajectorymi(t) from the longitudinal model is included to
link the two processes and α measures the strength of this association. While proportional hazards
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models are common, accelerated failure time and other survival models have been implemented
(Mccrink et al., 2013; Tseng et al., 2005)(Rizopoulos, 2012, p.137).
The model form in (1.2) will be referred to as the current value form since the association is
through the current value of the longitudinal trajectory, mi(t), on the right-hand side of the equa-
tion. This form is most often used when the survival time is of interest and the longitudinal process
is thought of as a time-dependent covariate measured with error. In (1.2), hi(t) is the event hazard
and h0(t) is the baseline hazard. In ordinary Cox regression h0(t) is left unspecified, avoiding
restrictions that come from specifying a parametric form for the baseline hazard (Yuen and Mack-
innon, 2016). However if an unspecified hazard is applied in a joint model, it has been shown that
standard errors of the parameter estimates can be underestimated (Hseih et al., 2006). This can be
remedied by estimating the standard errors with an additional method such as bootstrapping (Ri-
zopoulos, 2010; Yuen and Mackinnon, 2016). To avoid this issue, parametric but flexible functions
are often used for h0(t), such as piecewise constant or spline models (Rizopoulos, 2012, p.53).
These flexible functions can sufficiently approximate the baseline hazard and has been noted as the
preferred choice for h0(t) by some (Rizopoulos, 2010; Yuen and Mackinnon, 2016)(Rizopoulos,
2012, p.53).
Alternatively, the submodels can be linked through a shared parameters model. This is often
used when the longitudinal process is the main interest with informative censoring or when the
focus is on both processes equally. Assuming a longitudinal submodel as in (1.1), a survival
submodel as shown in (1.3) is common
hi(t) = h0(t)exp{Wiγ + αZ2i(t)Ui} (1.3)
where Ui is the same vector of random effects as in (1.1) and α again measures the association.
A typical example is a random coefficients model where Z2i(t)Ui = U0i + U1it with U0i and U1i
correlated, often multivariate normal (Wulfsohn and Tsiatis, 1997). The association can be gener-




It is commonly assumed that conditionally given the random effects, the longitudinal and time-
to-event outcomes are independent and so are the longitudinal measurements taken on a single







hi(Ti|Ui; Ω)DiS(Ti|Ui; Ω)f(Ui; Ω)dUi,
where f(·) denotes the density function and S(·) denotes the survival function. There is generally
no closed form solution to the likelihood equations. Numerical integration and optimization tech-
niques such as an EM algorithm treating the random effects as missing data, are used in practice.
Due to high-dimensional integration and potential correlation induced by the random effects, the
process of convergence can be slow. Other methods include Newton-type or hybrid-EM and quasi-
Newton algorithms (Rizopoulos, 2012, p.64)(Henderson et al., 2000; Hseih et al., 2006; Tsiatis
and Davidian, 2004; Wulfsohn and Tsiatis, 1997; Yu et al., 2004).
1.3.2 Bayesian Estimation
Joint models from a Bayesian perspective have also been implemented. The full posterior distri-
bution conforms to the structure
f(Ω, U |T,D, y) ∝
n∏
i=1
(f(yi|Ui; Ω)f(Ti, Di|Ui; Ω)f(Ui; Ω))π(Ω),
where π(Ω) denotes the joint prior for the model parameters. MCMC techniques such as Gibbs
Sampling or Metropolis-Hastings algorithm can be used for inference (Bekele and Shen, 2005;
Faucett and Thomas, 1996; Gould et al., 2014; Henderson et al., 2000; Rizopoulos and Ghosh,
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2011; Tsiatis and Davidian, 2004; Yu et al., 2004).
Bayesian estimation can have faster convergence rates than maximum likelihood methods (Mc-
crink et al., 2013). Bayesian models also make prediction fairly straightforward using the posterior
predictive distribution (Sweeting and Thompson, 2011). A drawback is needing to specify priors
which may influence the estimation. Because of this sensitivity analyses are recommended. On
the other hand, Bayesian models avoid asymptotic approximations and can incorporate historical
data (Gould et al., 2014).
1.4 Some Extensions in Joint Modeling
Chapter 2 will focus on joint models with a single longitudinal and a single survival event but
joint models have been extended in many ways. In this work we will first consider extensions
in the survival submodel. Chapters 3 and 4 will examine joint models with competing risks out-
comes. In this situation the event can have one of multiple possible causes. A traditional way to
formulate such data is through latent risks. Assuming there are K ≥ 1 possible causes of failure
(or risks), we can assume that each subject i = 1, .., N theoretically has an event time for each
risk T ∗i1, ..., T
∗
iK . Subjects can still be independently censored at time Ti0. Dependent censoring
can be included as one of the K risks. The observed data in this case is the minimum event time




iK) and the cause of the event Di = k if Tik ≤ Til for all l = 0, 1, ..., K.
Chapter 5 will further extend the survival submodel to consider multi-state data of which com-
peting risks is one subset. In multi-state data we assume that there are R ≥ 1 possible states
and a subject can transition between these states over time. In this case we have something like a
competing risks outcome at each transition time and subjects can have multiple transition times.
Additionally in Chapter 5 we will also extend the longitudinal submodel to include more than one
longitudinal outcome.
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1.5 Motivating Study on Adrenocortical Carcinoma
We are motivated by a study of patients with adrenocortical cancer at the University of Michi-
gan Rogel Cancer Center. Between 1983 and 2011 (inclusive) there were 176 people diagnosed
with adrenocortical carcinoma (ACC). We will also use the phrase adrenal cancer to refer to ACC
in this work. Patients were repeatedly subject to CT scans for monitoring their disease (McDuffie
and Aufforth, 2016). The scans were used to determine the state of disease at each scan. To do
this images of the patient’s tumor were compared to those in the last scan. An example of the
timeline with possible states is shown in Figure 1.1. Each patient has an initial scan, labeled Scan
0. The state of their disease at that scan is considered the reference state. Between that scan and
the next scan the disease could change. At the next scan it is determined whether the tumor did not
significantly change in size (stable), became bigger (progressed), or became smaller (regressed).
At that point, the latest disease state is now considered the reference state for the next scan. This
continues for all the patient’s scans. The diagram in Figure 1.1 shows two scans before the end of
follow-up, but this could be any number of scans. We also have information on a terminal event,
namely death. At the end of follow-up the patient may have died; otherwise the patient would be
censored.
Figure 1.1: Diagram of possible states over time in the adrenal cancer study.
Baseline covariates available are age at diagnosis, sex, cancer stage, tumor grade, operative
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Variable Mean Std. dev. N (%) Miss-
ing
Age at diagnosis 45.8 13.2 0
Scan Time (years) 3.3 3.7 0
Count % N (%) Miss-
ing
Sex Male 72 44 11 (6)
Female 93 56




Tumor Grade Low 84 48 0
High 63 36
Unknown 29 16
Operative resection Open 108 74 31 (18)
Laparoscopic 37 26
Margin positive Yes 26 62 30 (17)
No 91 18
Unknown 29 20
Vascular invasion Yes 87 49 0
No 35 20
No comment 54 31
Chemo at scan Yes 42 10 716 (63)
No 217 51
Mitotane 132 31
Mitotane & chemo 29 7
unknown 4 1
Table 1.1: Description of demographic and clinical information in adrenal cancer study data.
resection, margin positive, and vascular invasion. Information on if the patient was receiving
chemo at the time of scan is available for 37% of the scans. Demographic and clinical information
included in the data are summarized in Table 1.1.
From the scans markers of body composition, called morphomics, were also measured (Bayar
et al., 2017). Morphomics data reflect a patient’s body composition in terms of adipose tissue as
well as bones and organs which can be closely linked to nutritional status. Morphomic variables
are more refined and informative than the commonly used BMI. These measurements could have
clinical significance such as in improving the dosing of cytotoxic drugs (Bayar et al., 2017). Ad-
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Variable N Missing % Missing
visceral fat area 240 21
body depth 240 21
fascia depth 243 21
fascia area 243 21
central visceral depth 243 21
vb2 front skin 240 21
central back fat depth 718 63
central sub-cutaneous depth 238 21
total psoas perimeter area 244 21
average psoas perimeter mean 244 21
lean psoas muscle density 243 21
lean psoas muscle area 243 21
Table 1.2: List of morphomic measures in adrenal cancer study.
ditional studies have found morphomic data to be useful in researching other malignancies such
as pancreatic cancer (Balentine et al., 2010), oropharyngeal cancer (Wang et al., 2016), melanoma
(Sabel et al., 2015), hepatocellular cancer (Singal et al., 2016), colon cancer (Sabel et al., 2013),
renal cell cancer (Xiao et al., 2018) and other conditions including kidney disease (Locke et al.,
2017) and Crohn’s disease (Stidham et al., 2015).
Twelve time-dependent morphomic variables were recorded at each scan. See Table 1.2 for the
list of longitudinal measurement variables available and see Appendix A for a description of these
morphomic variables (Holcombe et al., 2016). There are between 1 and 47 scans for each patient
with a mean of 6.5 and median of 4 scans. The data includes 1140 longitudinal measurements in
total. For 240 of the scans, the morphomic data is not available as the scans could not be processed.
Time was measured from the date of adrenal cancer diagnosis. Of the patients, 98 (56%) died
and the other 78 (44%) were censored. Time until death or censoring fell between 0.1 and 24.5
years with a median of 2.5 years. There are 117 (66%) with at least one progression. Time to first
progression among those patients was between 0.05 and 14.5 and years with a median of 0.8 years.
For regression, 55 (31%) had at least one regression and time to regression among those patients
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Variable Mean Std. dev.
Number of Progressions 2.5 4.1
Number of Regressions 0.5 1.0




Died Yes 98 56
No (Censored) 78 44




Died without Progression 5 3
Censored without Progression 54 31
Died without Progression or Re-
gressions
3 2




Had ≥ 1 Progression 66
% scans found Progression 37
Had ≥ 1 Regression 31
% scans found Regression 6
Had ≥ 1 Event 76
% scan have an Event 42
Median Range
Time to first Progression (if had
progression)
0.8 (0.05, 14.5)
Time to first Regression (if had re-
gression)
0.5 (0.03, 8.7)
Time to First Event (any) 0.8 (0.03, 24.5)
Time to Death without Progression 1.5 (0.2, 3.5)
Time to Death without Progression
or Regression
1.5 (0.2, 2.2)
Table 1.3: Description of disease state and survival information in adrenal cancer study data.
was between 0.03 and 8.7 years with a median of 0.5.
We also calculated time to first event of any type. There were 4 possible first event types: (1)
progression, (2) regression, (3) death, or (4) censoring. If the first event was of type 3 or 4 the
patient had no progression or regression during the entire follow up period. Time to first event was
between 0.03 and 24.5 years with a median of 0.8 years. Survival and disease state information is
summarized in Table 1.3. A few examples of patient data are shown in Figure 1.2.
The primary research question is whether the morphomic variables are associated with progno-
sis. A previous study separately investigated the relationship between several morphomic variables
and recurrence-free and overall survival in ACC (Miller et al., 2012). Specifically, they looked at
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Figure 1.2: Example plots of ACC data.
the variables psoas muscle density (PMD), lean psoas muscle area (LPMA), lumbar skeletal mus-
cle index (LSMI), intra-abdominal (IA) fat, and subcutaneous (SC) fat. The study found that PMD,
LPMA and IA fat had significant associations with the survival outcomes.
Since the morphomic variables are measured from the scans, they will be subject to measure-
ment error. Therefore, a joint model for the longitudinal morphomic data and the survival data is
needed. We begin in the simplest case in Chapter 2 and investigate the relationship between a single
morphomic variable, psoas density, and survival time using joint models within various computa-
tional settings. In Chapters 3 and 4 we consider how the longitudinal and survival processes are
related when we incorporate the information on cancer progression and regression. Specifically,
we treat the survival process as a competing risks problem. We investigate the relationship between
a single morphomic variable lean psoas muscle area (LPMA) and time to either first progression
or first regression. Finally in Chapter 5 we will utilize more of the available of information via a
multistate model. The data include recurrent events, from the declaration of disease state at each
scan, and these events can be one of multiple types (progression, regression, or no event). We also
have the terminal event of death. Further, we have multiple morphomic variables and we would
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like to include more than one in our joint multistate model to examine the relationship between the
morphomics and disease state, while accounting for all aspects of the data. We will do this with a
joint model with two longitudinal outcomes and multistate survival data.
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Chapter 2
Comparison of Computational Approaches
for Joint Longitudinal and Time-to-Event
Models
2.1 Introduction
With multiple submodels and shared random effects, joint models can become complicated and
difficult to utilize. This motivates the need for creating an efficient computational platform to fit
these models. Due to the complexity of joint models, implementation can be slow, but can still
be useful for those wanting to fit relatively simple joint models for data analysis. Major statistical
software such as R, SAS, and Stata include joint modeling functions. The purpose of this chapter
is to provide a comprehensive review of associated implementation issues and explore new appli-
cations in related software platforms. There has been limited review of software implementation
in the joint modeling literature. Some early reviews listed software available at the time (Gould
et al., 2014; Mccrink et al., 2013), utilized a single software for data analysis (Rizopoulos, 2012)
or compared a couple in the context of analyzing a dataset (Mccrink et al., 2013). Other reviews
have compared selected softwares, such as WinBUGS and SAS PROC NLMIXED (Guo and Car-
lin, 2004). Documentation of the %JM macro in SAS compares the available features of the macro
to the JM package in R (Garcia-Hernandez and Rizopoulos, 2015). A review of joint modeling
literature by (Sudell et al., 2016) discussed the frequency with which each joint modeling software
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was used. More recently, Yuen and Mackinnon (2016) compare some of the available software
with an application to a dataset documenting time to psychosis transition.
There are several ways in which this work differs from those in the existing literature. Most
of the reviews focus primarily on the survival component of the joint analysis. By contrast, we
provide findings from simulation that assess simultaneous performance of the time-to-event and
the longitudinal model. Our documentation is also more comprehensive than most reviews cov-
ering specialized topics such as latent classes, competing risks, multiple longitudinal outcomes
and more. Through extensive simulation, we present a comprehensive appraisal of the different
implementations. In addition, the different software are contrasted by means of their performance
when used to fit to data from an ongoing trial on adrenal cancer patients enrolled in the University
of Michigan Rogel Cancer Center.
This work has been published in (Furgal et al., 2019). In Section 1.2, we will demonstrate
the software capabilities with an example data analysis. We will discuss software implementation
in Section 2.2. This includes the JM and joineR packages in R, the %JM macro in SAS, and
the stjm command in Stata. In Section 2.4 we describe our simulations. Section 2.5 outlines
implementation of a Bayesian joint model by means of the JMbayes package in R. Other models
such as competing risks joint models and some specialized software functions are introduced in
Section 2.6 and further described in Appendix C. In Section 2.7 we conclude with a discussion of
our findings.
In this chapter we will use the following symbolic notation for distributions. Unless otherwise
noted N(µ, σ2) denotes a (univariate) Normal distribution with mean µ and variance σ2 while a
multivariate Normal distribution with mean vector µ and covariance matrix Σ will be denoted
MVN(µ,Σ). logN(µ, σ2) is a log-Normal model with mean µ and variance σ2. Weibull(γ, µ) is a
Weibull distribution with shape γ and scale µ. We will use∼ Γ(a, b) to denote a parameter follows
a Gamma distribution with parameters a and b. Wishart(B, a) is a Wishart distribution with a
degrees of freedom and variance matrix B. φ(x) and Φ(x) are the probability density function and
the cumulative distribution function of the standard Normal distribution, respectively.
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2.2 Assessment of Implementation Platform
Fitting a joint model can be computationally intensive. As indicated in the data analysis section,
there are a few software packages that are designed to fit such models in an efficient manner.
However, the class of such models is quite large and the software use different iterative algorithms
for estimation and integration. It is thus important to compare and contrast the implementation
platforms to assess and appraise the performance of the competing tools. Such assessment is
difficult to make on the basis of fits to few specific datasets. We undertake this evaluation with
simulations using various statistical software modules available for fitting joint models. In order
to lay the groundwork for the simulation, we first need to briefly describe the available software
packages. All packages described in this section implement (1.1) and either (1.2) or (1.3) under a
frequentist framework.
2.2.1 JM Package in R
The JM package in the R language was designed for fitting joint models with the jointModel()
function. A full description of this package and the jointModel() function are available in the
CRAN documentation (Rizopoulos, 2016a).
The main arguments for the jointModel() function include the output from a linear mixed
model (from the R function lme() (Pinheiro et al., 2016)) and the output from a Cox propor-
tional hazard model (usually from the R function coxph()) (Therneau and Lumley, 2016). Using
these separate model fits, jointModel() fits a corresponding current-value joint model with
submodels having the same covariates and forms as in the separate models and with the additional
association added to the survival submodel.
The jointModel() function fits three different model forms using the parameterization
argument. The default is parameterization = "value" and fits the current value model in
(1.2). For parameterization = "slope", the survival submodel is linked to the longitudi-
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Functionality











Gaussian linear model x x x x x x
Generalized linear models x x x
Covariance matrix options x x
Survival Submodel
Relative Risk model x x x x x x
AFT Weibull model x
Unspecified baseline hazard x x
Piecewise baseline hazard x x x
Spline baseline hazard x x x x x
Association
Current value assoc. x x x x
Current slope assoc. x x x x
Random intercept assoc. x x x x x
Random slope association x x x x x
Separate associations x x x
Interactions in associations x x x x x
Model fit options
Lagged effects x x x
Competing risks models x x
Initial value options x x x x
Stratification in survival submodel x x
Piecewise/Spline hazard customization x x x x
Estimation options
EM only x x
Quasi-Newton x x x
Bayesian MCMC x
Number of iteration control x x x x x x
Convergence tolerance control x x x x x
Piecewise/Spline knots control x x x x
Quadrature points control x x x x x
Adaptive Gauss-Hermite quadrature x x x
Pseudo-adaptive Gauss-Hermite quadrature x
Laplace approximation x x
Gauss-Kronrod Rule x x x
Other options
AIC or BIC x x x
Plotting x x x x
Predictions x x
Approx SE default x x x x
Bootstrap SE option x x x
Table 2.1: Overview of available functionalities for joint modeling in each software; ’x’ means the
software in that column has the feature in the corresponding row.
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nal process through the slope of the trajectory as in (2.1).
hi(t|Mi(t)) = h0(t)exp{X2iγ + αm′i(t)} (2.1)
The final option is parameterization = "both" which fits a model with both the current




The method argument specifies the form of the baseline hazard, the form of the model, and
the method of numerical integration. The available options are:
weibull-PH-aGH, piecewise-PH-aGH, spline-PH-aGH, weibull-AFT-aGH,
Cox-PH-aGH, and ch-Laplace. The method ch-Laplace uses the fully exponential Laplace
approximation described by Rizopoulos et al. (2009). All other options follow a similar for-
mat. The first word describes the baseline hazard: weibull uses a Weibull baseline hazard,
piecewise a piece-wise constant baseline hazard, spline a B-spline approximation, and Cox
an unspecified baseline risk. Options with PH fit a proportional hazards survival submodel. There is
one option for an accelerated failure time model using a Weibull baseline (weibull-AFT-GH).
Methods ending in aGH use pseudo-adaptive Gauss-Hermite quadrature for integral approxima-
tion, where the quadrature knots are reassigned once after the first iteration (Rizopoulos, 2010).
Each method can instead end in GH which uses standard Gauss-Hermite quadrature. Adaptive
quadrature is generally preferred due to a reduced computational load using fewer quadrature
points while still achieving error on the same order of magnitude as with the standard quadra-
ture (Yuen and Mackinnon, 2016). Quasi-Newton techniques are used if EM iterations do not
achieve convergence quickly. Only EM is used with the unspecified baseline hazard. Stratification
is allowed only with method="spline-PH-aGH" or method="spline-PH-GH".
The jointModel() function allows for some extensions such as a competing risks model
with the CompRisk argument. Other extensions can be formulated with the interFact and
derivForm options as described in Rizopoulos (2010) and Rizopoulos (2016a).
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2.2.2 joineR Package in R
The joineR package was created to analyze longitudinal studies, possibly with an event time
causing informative censoring. Full description of this package is in the CRAN documentation
(Philipson et al., 2012). The joint() function fits a joint model and requires data in a specific
format that is the output from the function jointdata() in the same package. The user sup-
plies the joint() function with the data and a formula object specifying the form for each of
the longitudinal and survival submodels. This function fits a shared parameter joint model as in
(1.1) and (1.3) with an unspecified baseline hazard. This function is not capable of specifying
a parametric form for the baseline hazard. The model argument determines the shared random
effects. A random slope and intercept model is the default, whereas model="int" specifies
a random intercept only, and model="quad" adds a quadratic time effect to the intercept and
slope. The default settings fit a common association when there is more than one random effect
terms (αZ2i(t)Ui = αU0i + αU1it). A separate association, as discussed in Section 1.2.2, can be
implemented using the sepassoc=TRUE option (αZ2i(t)Ui = α0U0i + α1U1it, α0 6= α1). This
function also uses an EM algorithm for estimation with some options available for control of this
approximation. Since not specifying a baseline hazard may lead to underestimated standard errors,
the joineR package includes a separate function to calculate bootstrap standard errors for the
joint model (jointSE()).
2.2.3 %JM Macro in SAS
The %JM macro in the SAS language was written to fit several joint models in several pos-
sible forms. A full description of the macro was written by Garcia-Hernandez and Rizopou-
los (2015). The %JM macro allows the longitudinal data to be fit to varying outcome types.
The longitudinal data can conform to a Normal, binomial, or Poisson distribution, correspond-
ing to continuous, categorical, or count outcomes, respectively. These can be specified with
the LongiType option. The longitudinal model can also fit different random effects with the
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LongiTimeModel option, including a linear random intercept and slope model and multiple
random splines. There are many options for the baseline hazard of the survival submodel us-
ing the EventModel option, such as exponential, Weibull, piecewise, and several spline op-
tions. The survival submodel can include stratification factors using the EventStrata argu-
ment. The association can be set with the SharedParam argument with the options including
current value as in (1.2), slope (equivalent to our model (1.3) with Z2i(t)Ui = U0i + U1it), cumu-
lative (hi(t|Mi(t)) = h0(t)exp{X2iγ + α
∫ t
0
mi(s)ds}), and “coefficients” in which the user can
specify which random effects from the longitudinal submodel should be included in the survival
submodel. Multiple associations can be used at the same time. The SharedCoefficients and
SharedLongitTerm arguments can be used to create even more joint model parameterizations.
Estimation is carried out by the PROC NLMIXED procedure which is described in Appendix C.1.
2.2.4 stjm Command in Stata
In Stata, joint models can be fit with the stjm command. A detailed description is given by
(Crowther et al., 2013). A linear mixed model and a proportional hazards model can be fit as the
submodels with several association structures available. The association between submodels can
be of the current value or the current slope form, similar to the JM package in R. The association
can also be through shared parameters with or without covariates. Estimation is carried out by
Newton-Ralphson method and numerical integration is implemented with standard or adaptive
Gauss-Hermite quadrature. We found Stata to have more difficulties in fitting models with various
parameter values in our simulations.
2.2.5 Comparison of Software Functionality
In summary, all three major statistical softwares R, SAS and Stata fit joint models with comparable
functionality. A detailed list of available options is provided in Table 2.1. All software will fit
a Gaussian longitudinal submodel as in (1.1). Some software will fit a generalized linear model
where the longitudinal outcome Y has a non-Gaussian distribution such as binomial or Poisson.
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Each software will also fit a standard proportional hazards survival submodel modeling the hazard
function as in (1.2) or (1.3). Only JM in R will fit a survival model in an accelerated failure time
(AFT) framework. Available association options are listed including current value (1.2), random
intercept or slope (1.3) and separate associations like we saw in section 2.2.2. Model fit options
describe different forms of the survival submodels that may be available such as a competing
risks model, lagged effects, or stratification. Estimation options include choices for the model
fitting algorithm and numerical integration. Finally, some other possibly useful options in the
software are listed including built-in AIC or BIC calculations, plotting, predictions, and standard
error calculations.
2.3 Application to the Adrenal Cancer Data
We explore the available software platforms through analysis of the adrenocortical carcinoma
(ACC) dataset described in Section 1.5. We selected a single scan measurement, psoas density, as
the longitudinal response variable. Psoas density is measured in Hounseld Units (HU) using the
density of pixels in the scan (Holcombe et al., 2016). A previous study with similar data describes
how psoas muscle density and size can be measures of patient frailty, and scan measurements can
be associated with survival (Miller et al., 2012). Baseline covariates used were age, cancer stage,
and tumor grade. For simplicity we performed a complete case analysis. There were 160 patients
with psoas density measurements and all baseline covariates. There are between 1 and 45 scans
for each patient with a mean of 5.5 and median of 3 scans. In this group 100 patients died. Time
until death or censoring fell between 0.1 and 17.9 years with a median of 2.4 years. Table 2.2
summarizes the relevant variables. Joint models are fit to the data using three major software,
namely R, SAS, and Stata. Both the current value (1.2) and the shared parameter (1.3) forms are
implemented.
First, a current-value joint model was fit to this data using JM in R, SAS, and Stata. The
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Variable Mean or Count SD or %
Psoas Density 54.4 8.5
Scan Time (years) 3.1 3.2
Age 46.1 13.6
Stage 1 or 2 71 44.4%
3 or 4 89 55.6%
Tumor Grade Low 79 49.4%
High 58 36.3%
Unknown 23 14.4%
Table 2.2: Description of adrenal cancer data used in Ch 2.
longitudinal submodel included a random intercept and slope in each software.
PsoasDensityij = mi(tij) + eij = β0 + β1tij + β2Agei + β3Stagei
+ β4TumorGradeHighi + β5TumorGradeUnknowni + U0i + U1itij + eij
(2.2)
Survival submodels with flexible baseline hazards were chosen since the true model is unknown.
In Stata models with a flexible baseline hazard did not converge, so a specific parametric (Weibull)
hazard was used. Specifically, the software fit survival submodels with the form
hi(t) = h0(t) exp(γ1Agei+γ2Stagei+γ3TumorGradeHighi+γ4TumorGradeUnknowni+αmi(t))
(2.3)
with baseline hazards
R JM PWC: h0(t) ∼ Piecewise constant function
SAS %JM PWC: h0(t) ∼ Piecewise constant function
Stata stjm Weib: h0(t) ∼Weibull
For SAS and R JM, the program defaults were used to create the flexible baseline hazards.
Both procedures by default use six equally spaced internal knots to partition the observed event
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times. For the SAS model, the random effects are assumed uncorrelated because we found fitting
issues with an unstructured matrix (Garcia-Hernandez and Rizopoulos, 2015).
The Two-Stage model in (2.4) was fit for comparison.

First: PsoasDensityij = β0 + β1tij + β2Agei + β3Stagei + β4TumorGradeHighi
+β5TumorGradeUnknowni + U0i + U1itij + eij,
Then: hi(t) = h0(t)exp(γ1Agei + γ2Stagei
+γ3TumorGradeHighi + γ4TumorGradeUnknowni + αm̂i(t)),
h0(t) unspecified
(2.4)
Bootstrapping was used to estimate the coefficients and bias-corrected bootstrapped confidence
intervals (Efron and Tibshirani, 1993), as shown in Table 2.3.
We also fit a shared parameter model as in (1.3) with joineR, SAS, and Stata. The longitudi-
nal submodel included a random intercept in joineR and Stata, while the default in SAS included
a random slope. The model fit is
PsoasDensityij = β0 + β1tij + β2Agei + β3Stagei + β4TumorGradeHighi
+ β5TumorGradeUnknowni + Ui + eij
hi(t) = h0(t) exp(γ1Agei + γ2Stagei + γ3TumorGradeHighi+
γ4TumorGradeUnknowni + αUi)
with baseline hazards
R joineR: h0(t) Unspecified
SAS %JM PWC: h0(t) ∼ Piecewise constant function
Stata stjm Weib: h0(t) ∼Weibull
23
The findings are contrasted with a shared parameter two-stage model similar to that in (2.4) but
with αm̂i(t) replaced with αZ2i(t)Ui = α0Ui with scalar Ui.
Comparing Tables 2.3 and 2.4, the results are similar for the current-value and shared param-
eters models. Nearly all joint models estimate the coefficients of the longitudinal submodel very
similarly. Time has a significant negative value showing that psoas density tends to decrease over
time, which fits with previous knowledge (Miller et al., 2012). Older patients tend to have lower
psoas density. Stage 3 or 4 and High Tumor Grade tend to decrease the average psoas density com-
pared to lower stages and grade, but these are not significant in any software or models. There are
more differences in the results of the survival submodel since each software fits the survival model
differently. The effects are estimated to be larger in the Two-Stage current-value models than in
the true joint models. Age does not have much of an effect on death hazard. Most software and
model forms find higher stage to slightly increase the death hazard, but significance depends on the
software. There is a small and significant positive coefficient for High Tumor Stage. Finally, each
software except the current-value Two-Stage model found a small but significant negative associ-
ation with psoas density. Log-likelihoods are shown in Table 2.5 and are similar for all software
and both model forms.
2.4 Simulations
The joint modeling software were compared through simulation. Data were generated under
three scenarios, namely a random intercept only and a random intercept and slope model in the
current-value form, and a random intercept shared-parameters model. Each scenario includes N =
500 subjects and 100 simulated datasets. Data were generated in R version 3.2.2 and simulations
were run in Windows 7 on a 3.2 GHz Intel Core i5 processor.
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Variable Two-Stage* JM PWC SAS %JM PWC Stata stjm Weib
N 89 87 100 100
Intercept 64.4 (59.5,68.2) 64.6 (59.2,68.3) 65.4 (59.8,69.7) 64.6 (60.6,68.6)
Time -0.5 (-1.4,-0.1) -0.6 (-1.7,-0.2) -0.9 (-2.7,-0.4) -0.6 (-1.9,-0.3)
Age -0.2 (-0.3,-0.1) -0.2 (-0.3,-0.1) -0.2 (-0.3,-0.1) -0.2 (-0.4,-0.2)
Stage 3 or 4 -0.6 (-1.7,0.2) -0.6 (-1.7,0.3) -0.6 (-1.8,0.05) -0.6 (-2.2,-0.1)
Tumor Grade: High -0.6 (-3.8,2.2) -0.7 (-4.1,2.1) -0.7 (-4.1,2.1) -0.7 (-3.6,2.1)
Tumor Grade: Unknown -2.9 (-7.5,0.3) -3.2 (-8.4,-0.6) -3.1 (-8.0,0.2) -3.1 (-8.5,-0.4)
Surv-Age 0.1 (-0.009,0.6) 0.002 (-0.01,0.06) -0.009 (-0.03,0.008) -0.01 (-0.03,0.001)
Surv-Stage 3 or 4 0.7 (-0.06,3.4) 0.2 (0.02,0.3) 0.2 (-0.01,0.3) 0.2 (-0.06,0.4)
Surv-Tumor Grade: High 1.3 (-3.6,4.2) 0.6 (0.004,1.0) 0.5 (0.06,1.1) 0.4 (-0.04,1.1)
Surv-Tumor Grade: Unknown 3.4 (0.4,12.0) 1.0 (0.3,1.5) 0.9 (0.2,1.7) 1.0 (0.2,1.9)
Association 0.8 (0.1,3.0) -0.07 (-0.1,-0.04) -0.1 (-0.2,-0.06) -0.09 (-0.1,-0.04)
Table 2.3: Current-value joint model parameter estimates and bias-corrected bootstrapped confi-
dence intervals for the adrenal data. N is the number of models in 100 bootstraps that successfully
converged.
*Two-Stage intervals are the 2.5 and 97.5 quantiles of the bootstrapped values, not bias-corrected.
Variable Two-Stage* joineR SAS %JM PWC Stata stjm Weib
N 100 100 100 100
Intercept 63.7 (59.5,67.7) 63.1 (58.3,67.1) 64.5 (60.0,68.5) 64.4 (59.5,68.1)
Time -0.3 (-0.6,-0.08) -0.4 (-0.7,-0.2) -0.6 (-1.4,-0.3) -0.6 (-1.2,-0.3)
Age -0.2 (-0.3,-0.1) -0.2 (-0.3,-0.1) -0.2 (-0.3,-0.1) -0.2 (-0.3,-0.09)
Stage 3 or 4 -0.6 (-1.7,0.1) -0.7 (-1.6,0.1) -0.6 (-1.7,0.09) -0.6 (-2.3,0.3)
Tumor Grade: High -0.6 (-3.6,2.0) 0.6 (-2.0,3.7) -0.7 (-3.7,2.1) -0.6 (-4.0,2.2)
Tumor Grade: Unknown -3.2 (-9.1,1.6) -2.9 (-7.7,3.3) -3.1 (-8.1,-0.09) -3.2 (-7.5,-0.3)
Surv-Age 0.01 (-0.003,0.03) 0.01 (-0.004,0.02) 0.01 (-0.003,0.03) 0.006 (-0.02,0.02)
Surv-Stage 3 or 4 0.2 (0.06,0.4) 0.2 (0.01,0.4) 0.2 (0.04,0.4) 0.2 (-0.02,0.5)
Surv-Tumor Grade: High 0.5 (-0.01,1.0) -0.5 (-1.0,0.02) 0.6 (0.04,1.2) 0.4 (-0.04,1.1)
Surv-Tumor Grade: Unknown 1.1 (0.6,1.8) 0.7 (-0.2,1.3) 1.2 (0.4,1.8) 1.3 (0.4,2.1)
Association -0.09 (-0.1,-0.06) -0.09 (-0.1,-0.05) -0.1 (-0.1,-0.06 ) -0.09 (-0.1,-0.05)
Table 2.4: Shared parameter joint model parameter estimates and bootstrapped confidence intervals
for the adrenal data. N is the number of models in 100 bootstraps that successfully converged.
*Intervals are the 2.5 and 97.5 quantiles of the bootstrapped values, not bias-corrected.
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Current-value Shared Parameter
JM PWC -3130.6 NA
joineR NA -3392.1
SAS %JM PWC -3147.5 -3147.0
Stata stjm Weib -3100.9 -3083.3
Table 2.5: Log-likelihood values for the adrenal data models.
2.4.1 Scenario 1
Data for the current-value association random intercept only joint model, which we will call Sce-
nario 1, were generated as follows. The longitudinal data were generated from the model
Yij = mi(tij) + eij = β0 + β1tij + β2X1i + β3X2i + U0i + eij (2.5)
We have two covariates in our joint model, a binary group indicator X1 and a continuous X2. The
random effect U0i is a scalar. Measurement times are between 0 and 3 years. The random effect and
measurement error are normally distributed and independent. Survival times T ∗i , were generated
from a relative risk model.
hi(t) = exp(γ0 + γ1X1i + γ2X2i + αmi(t)) (2.6)
(See Appendix B.1 for details on generating the survival times). The parameter values used are
shown below.
X1i ∼ Bernoulli(0.5),
X2i ∼ N(0, 12),
(ti1, ti2, ..., ti7) = (0, 0.5, 1, 1.5, 2, 2.5, 3),
eij ∼ N(0, 42),










Independent censoring times Ci were drawn from a uniform distribution, Ci ∼ Unif(0, 3.25), and
the observed time Ti is the minimum, , Ti = min(T ∗i , Ci). Any longitudinal measurements Yij at
times after the observed time Ti (where tij > Ti for subject i) were dropped.
The R JM, joineR, Stata stjm, and Two-Stage software fit (2.5) to the longitudinal part.
The SAS macro by default fits a model with a random intercept and slope. The %JM macro has
no built-in option for an intercept only association. Therefore we fit a misspecified longitudinal
model in SAS, replacing U0i with U0i + U1itij in (2.5). An unstructured covariance matrix was
used for the SAS PWC model. For the SAS Weibull model, the default diagonal covariance matrix
was used to achieve convergence.
For the survival part, a current-value association was used if available. The R JM package, Stata
command, and the %JM macro in SAS fit a current-value survival submodel as specified in (2.6).
The joineR package only fits joint models with the shared parameters association conforming to
the structure in (2.7).




2 + αU0i) (2.7)
where U0i is a scalar. This amounts to a re-parameterization of the current-value model where
the coefficients γ∗1 and γ
∗
2 in the joineR survival submodel converge to combinations of the true
coefficients from both submodels, specifically γ∗1 = γ1 + αβ2 and γ
∗
2 = γ2 + αβ3. For all results,
the joineR coefficients will be compared to these combinations. See Appendix B.2 for more on
this reparameterization.
The baseline hazards used for these software are in (2.8). Pseudo-adaptive Gauss-Hermite
(GH) quadrature is implemented in R JM Weib, PWC and Spl. For the model with an unspecified
baseline hazard (R JM Unspec NA) we used the standard (nonadaptive) GH quadrature, since
we found using the adaptive algorithm led to poor convergence. In order to investigate whether
there is a difference in the nonadaptive (NA) versus the pseudo-adaptive GH quadrature, we also
ran models with each of Weibull, piecewise constant, and spline based baseline hazards, using
standard GH quadrature, labeled R JM Weib NA, R JM PWC NA, and R JM Spl NA.
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R JM Weib: h0(t) ∼Weibull
R JM PWC: h0(t) ∼ Piecewise constant function
R JM Spl: log(h0(t)) ∼ B-spline approximation
R JM Unspec NA: h0(t) unspecified
SAS %JM Weib: h0(t) ∼Weibull
SAS %JM PWC: h0(t) ∼ Piecewise constant function
Stata stjm Weib: h0(t) ∼Weibull
R joineR: h0(t) unspecified
(2.8)
A Two-Stage model is also fit to compare this more simple technique to the true joint models.
The Two-Stage model is fit as follows.

First: Yij = β0 + β1tij + β2X1i + β3X2i + U0i + eij,
Then: hi(t) = h0(t)exp(γ1X1i + γ2X2i + αm̂i(t))
We used the default options for numerical integration and for defining the flexible baseline haz-
ard functions. Specifically, the R JM PWC and SAS %JM PWC models both use a baseline hazard
constructed from six equally spaced internal knots that partition the observed event times with the
function being constant in between knots. For the R JM Spl model, the B-spline approximation is
constructed with five internal knots.
Results are shown in Figure 2.1, plotting the bias of the estimated coefficients compared to the
truth. Coverage probabilities are shown in Table 2.6. Table 2.7 shows the bias and MSE for each
parameter. Empirical standard deviations are in Table 2.8 and the width of confidence intervals are
in Table 2.9. Widths were calculated as the average of confidence interval lengths using a Normal
approximation, specifically the average of 2∗1.96∗(standard error). Table 2.10 shows the run-times
for each software.
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Software n models Intercept Time X1 X2 Surv X1 Surv X2 Assoc.
Two-Stage 100 88 94 93 94 97 91 93
R JM Weib 93 86 91 92 96 97 90 98
R JM Weib NA 92 86 91 91 97 97 91 98
R JM PWC 100 87 92 93 96 97 91 97
R JM PWC NA 100 86 92 92 97 97 91 97
R JM Spl 93 86 91 92 96 97 90 97
R JM Spl NA 93 85 91 91 97 97 90 97
R JM Unspec NA 100 86 92 92 96 92 91 79
SAS % JM Weib* 100 87 94 93 96 97 91 97
SAS %JM PWC* 100 83 91 93 96 94 89 92
Stata Weib 33 58 85 82 88 97 91 97
R joineR** 100 85 94 92 92 99 96 89
Table 2.6: Coverage probabilities for Scenario 1 (in %).
* The SAS longitudinal model is misspecified, including a random slope not in the data generation
model.
** The Surv X1 and Surv X2 estimates are compared to the value to which they converge and
standard errors are estimated through bootstrapping. Details in Section B.2.
Intercept Time X1 X2 Surv X1 Surv X2 Association
Software n models fit Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE
Two-Stage 100 -0.24 2.68 -1.14 0.42 0.92 2.98 -0.44 0.84 2.31 21.69 4.11 6.96 -10.64 4.33
R JM Weib 93 -0.06 2.79 0.18 0.43 1.01 3.16 0.02 0.84 0.89 23.04 1.02 8.15 0.46 6.66
R JM Weib NA 92 -0.01 2.82 0.27 0.43 0.86 3.18 -0.15 0.82 0.55 23.17 2.08 7.23 -0.97 4.88
R JM PWC 100 -0.09 2.67 0.02 0.42 0.93 3.01 -0.04 0.83 2.72 22.81 0.22 7.49 0.88 5.76
R JM PWC NA 100 -0.08 2.67 0.02 0.42 0.91 3.01 -0.04 0.83 2.73 22.84 0.18 7.56 0.86 5.75
R JM Spl 93 -0.06 2.80 0.22 0.43 1.01 3.16 0.04 0.84 0.33 23.25 1.09 8.07 0.23 7.12
R JM Spl NA 93 -0.05 2.80 0.21 0.43 0.99 3.16 0.04 0.84 0.36 23.28 1.08 8.06 -0.05 6.48
R JM Unspec NA 100 -0.08 2.67 -0.01 0.42 0.92 3.01 -0.05 0.83 2.58 22.59 0.34 7.55 -0.01 5.65
SAS %JM Weib* 100 0.004 2.66 0.10 0.42 0.91 3.02 0.04 0.83 3.66 24.25 -1.61 11.47 6.73 11.76
SAS %JM PWC* 100 -1.80 2.69 -0.68 0.55 -0.40 2.98 -0.01 0.74 -8.02 23.98 -5.34 12.22 6.10 8.74
Stata Weib 33 -34.74 1.51 -10.99 0.42 5.67 0.89 -25.34 0.33 -3.01 3.07 -14.74 2.86 -32.59 1.89
R joineR** 100 0.59 1.09 -1.30 0.36 -0.15 0.81 -0.98 0.67 -17.46 7.23 -49.41 27.20 -12.00 7.38
Table 2.7: Bias*100 and MSE*100 (Mean Squared Error) of the estimates from Scenario 1.
* The SAS longitudinal model is misspecified, including a random slope not in the data generation
model.
** The Surv X1 and Surv X2 estimates are compared to the value to which they converge and
standard errors are estimated through bootstrapping. Details in Section B.2.
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Figure 2.1: Boxplots showing the bias of the Scenario 1 estimates. Model names abbreviated
as: TS=Two-Stage, JM W=R JM Weibull, JM PW=R JM Piece-Wise, JM Sp=R JM Spline, JM
Un=R JM Unspecified NA, SAS W=SAS Weibull, SAS PW=SAS Piece-Wise. Figure 1(h) plots
the actual values estimated for the random effect variance with the dotted line at the true value.
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Software n models Intercept Time X1 X2 Surv X1 Surv X2 Association
Two-Stage 100 0.16 0.06 0.17 0.09 0.47 0.26 0.18
R JM Weib 93 0.17 0.07 0.18 0.09 0.48 0.29 0.26
R JM Weib NA 92 0.17 0.07 0.18 0.09 0.48 0.27 0.22
R JM PWC 100 0.16 0.07 0.17 0.09 0.48 0.28 0.24
R JM PWC NA 100 0.16 0.07 0.17 0.09 0.48 0.28 0.24
R JM Spl 93 0.17 0.07 0.18 0.09 0.48 0.29 0.27
R JM Spl NA 93 0.17 0.07 0.18 0.09 0.49 0.29 0.26
R JM Unspec NA 100 0.16 0.07 0.17 0.09 0.48 0.28 0.24
SAS %JM Weib* 100 0.16 0.07 0.17 0.09 0.49 0.30 0.34
SAS %JM PWC* 100 0.16 0.07 0.17 0.09 0.49 0.25 0.29
Stata Weib 33 0.31 0.12 0.11 0.18 0.25 0.18 0.25
R joineR** 100 0.10 0.06 0.09 0.08 0.21 0.17 0.24
Table 2.8: Empirical Standard Deviations of the estimates from Scenario 1.
* The SAS longitudinal model is misspecified, including a random slope not in the data generation
model.
** The Surv X1 and Surv X2 estimates are compared to the value to which they converge and
standard errors are estimated through bootstrapping. Details in Section B.2.
Software n models Intercept Time X1 X2 Surv X1 Surv X2 Association
Two-Stage 100 0.51 0.25 0.66 0.33 1.84 0.96 0.73
R JM Weib 93 0.51 0.25 0.67 0.33 1.87 0.99 0.87
R JM Weib NA 92 0.51 0.25 0.67 0.33 1.87 0.98 0.85
R JM PWC 100 0.51 0.25 0.66 0.33 1.87 0.99 0.86
R JM PWC NA 100 0.51 0.25 0.66 0.33 1.87 0.99 0.86
R JM Spl 93 0.51 0.25 0.67 0.33 1.87 0.98 0.87
R JM Spl NA 93 0.51 0.25 0.67 0.33 1.87 0.99 0.86
R JM Unspec NA 100 0.51 0.24 0.66 0.33 1.61 0.97 0.56
SAS %JM Weib* 100 0.51 0.25 0.67 0.33 1.90 1.01 0.99
SAS %JM PWC* 100 0.51 0.25 0.67 0.33 1.92 1.03 0.99
Stata Weib 33 0.13 0.11 0.19 0.10 0.61 0.33 0.29
R joineR** 100 0.51 0.24 0.65 0.33 2.01 0.94 0.75
Table 2.9: Average width of confidence intervals from Scenario 1.
* The SAS longitudinal model is misspecified, including a random slope not in the data generation
model.
** The Surv X1 and Surv X2 estimates are compared to the value to which they converge and
standard errors are estimated through bootstrapping. Details in Section B.2.
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Scenario 1 Scenario 2 Scenario 3
Two-Stage 0.5 1.5 0.1
R JM Weib 3.1 10.9 5.6
R JM Weib NA 5.3 44.5 8.2
R JM PWC 7.8 20.6 11.7
R JM PWC NA 10.5 85.2 15.8
R JM Spl 21.1 28.5 15.4
R JM Spl NA 23.7 104.9 20.6
R JM Unspec NA 6.6 223.8 93.7
SAS %JM Weib 35.6 49.7 10.6
SAS %JM PWC 94.5 392.5 49.3
Stata Weib 1201.3 609.6 661.9
R joineR* 96.9 121.1 48.5
Table 2.10: Average runtime for Scenarios 1, 2, and 3.
* joineR run-times include estimating bootstrapped standard errors with 50 bootstrapped samples.
All software except Stata were able to fit models to a majority of the 100 datasets. Stata was
only able to fit around one third of the datasets. Each software had relatively good coverage al-
though Stata did not cover the intercept term well. The intervals around the association parameter
from R JM Unspec NA are narrower than the other R JM models. Stata tends to have a larger bias
but smaller MSE than the other software leading to narrow confidence intervals. Every software
overestimated the random effect variance, with the Two Stage and joineR models being most bi-
ased. Despite SAS including an extra random slope term, the random intercept variance estimates
were similar to R JM and Stata. Empirical standard deviations were stable across software.
Models with a flexible baseline hazard took longer to run, as would be expected. Stata was
exceptionally slow in this scenario. Comparing the models using NA (nonadaptive) quadrature
(ex. R JM PWC NA) to the corresponding models using pseudo-adaptive quadrature (ex. R JM
PWC) shows that the nonadaptive versions slightly increased the runtime but otherwise choice of
numerical integration algorithm made very little difference in the results.
32
2.4.2 Scenario 2
Our Scenario 2 includes a random intercept and slope joint model, sometimes called the random
coefficients model, generated from the following equations.
Yij = mi(tij) + eij = β0 + β1tij + β2X1i + β3X2i + U0i + U1itij + eij (2.9)
hi(t) = exp(γ0 + γ1X1i + γ2X2i + αmi(t)) (2.10)
As in Scenario 1, there are two covariates, one binary and one continuous. The random effects are
bivariate Normal. The parameter values used are shown below.
X1i ∼ Bernoulli(0.5),
X2,i ∼ N(0, 12),
(ti1, ti2, ..., ti7) = (0, 0.5, 1, 1.5, 2, 2.5, 3),
eij ∼ N(0, 42),


















We draw independent censoring times Ci ∼ Unif(1.25, 3.25) and the observed times are Ti =
min(T ∗i , Ci). There was approximately 10% censoring.
JM, joineR in R, %JM in SAS, and stjm in Stata, fits (2.9) to the longitudinal part of the data.
The default covariance structure was used in all models. As in Scenario 1, several survival sub-
models were evaluated. The R JM package, SAS, and Stata fit a current-value survival submodel as
in (2.10). The shared-parameter model below was fit with joineR which is a reparameterization
of the current-value model similar to Scenario 1.




1X2i + α(U0i + U1it))
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Software n models Intercept Time X1 X2 Surv X1 Surv X2 Assoc.
Two-Stage 100 98 87 97 89 95 94 97
R JM Weib 88 95 93 97 91 93 90 90
R JM Weib NA 95 98 96 98 91 94 93 92
R JM PWC 87 97 94 98 90 95 92 98
R JM PWC NA 94 97 96 98 91 96 91 95
R JM Spl 83 95 93 95 87 93 92 95
R JM Spl NA 94 97 96 98 91 95 93 96
R JM Unspec NA 85 96 95 98 92 91 92 64
SAS %JM Weib 100 92 91 91 86 88 89 86
SAS %JM PWC 100 98 97 97 91 95 92 89
Stata Weib 99 97 97 97 90 94 93 90
R joineR 25 100 88 100 96 96 80 92
Table 2.11: Coverage probabilities for Scenario 2 (in %).
* The Surv X1 and Surv X2 estimates are compared to the value to which they converge and
standard errors are estimated through bootstrapping. Details in Section B.2.
The baseline hazards are the same as in (2.8) including models using both adaptive and nonadaptive
(NA) in R JM Weib, PWC and Spl. Default settings were used for the piecewise constant and spline
functions. Finally, a Two-Stage model was fit for comparison.
Results for Scenario 2 are in Figure 2.2, and Tables 2.11 - 2.14. The Table 2.10 shows the
run-times for this scenario. More results including bias, MSE and confidence interval widths are
in the Supplemental Material.
The software were able to fit models to most of the 100 simulated datasets except for joineR.
The joineR models could fit only around a quarter of the datasets. Coverage probabilities were
similar for all software with one exception. Coverage for the association parameter was noticeably
lower for R JM Unspec NA. The confidence interval widths were generally very similar in each
software. As in Scenario 1, on average the confidence intervals around the association estimate in
R JM Unspec NA were considerably tighter.
In the boxplots, we see that all R JM models and Stata estimated the random effect covariance
parameters well. In SAS, the covariance of the random effects was assumed zero according to the
34
Intercept Time X1 X2 Surv X1 Surv X2 Association
Software n models worked Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE
Two-Stage 100 2.12 0.90 -5.80 0.87 -1.31 1.90 0.18 0.71 -1.17 13.55 -1.77 3.27 1.93 0.91
R JM Weib 88 1.35 0.94 -2.63 0.60 -0.32 1.87 0.34 0.69 1.66 15.11 -2.33 3.77 8.11 2.29
R JM Weib NA 95 0.92 0.88 -1.47 0.56 -0.84 1.83 -0.11 0.70 0.86 15.94 -2.33 3.65 7.56 1.89
R JM PWC 87 1.04 0.84 -1.98 0.53 -1.12 1.78 0.45 0.71 0.30 15.60 -2.86 3.78 9.18 2.10
R JM PWC NA 94 0.80 0.87 -1.15 0.57 -0.77 1.84 -0.31 0.68 1.08 16.40 -2.61 3.70 9.57 2.42
R JM Spl 83 0.52 0.88 -2.42 0.61 -0.72 1.93 0.61 0.76 -0.43 15.41 -1.91 3.88 7.30 1.94
R JM Spl NA 94 0.90 0.87 -1.32 0.57 -0.76 1.85 -0.29 0.67 0.38 15.93 -2.38 3.63 8.31 1.98
R JM Unspec NA 85 0.88 0.87 -1.62 0.59 -0.24 1.95 0.34 0.66 -0.38 15.18 -3.29 3.83 9.74 2.21
SAS %JM Weib 100 -4.88 0.85 -2.85 0.54 -0.67 1.77 -2.45 0.64 -1.28 15.47 -3.12 14.18 5.92 2.23
SAS %JM PWC 100 0.99 0.86 -1.44 0.57 -1.53 1.82 0.27 0.71 1.72 17.54 -3.72 15.14 15.92 6.35
Stata Weib 99 1.23 0.85 -1.78 0.57 -1.21 1.86 0.41 0.70 0.10 4.93 -2.46 3.42 8.06 1.93
R joineR 25 5.70 1.08 -2.39 0.78 -3.54 1.49 1.25 0.60 3.48 10.92 60.70 4.60 -4.67 1.12
Table 2.12: Bias*100 and MSE*100 of estimates from Scenario 2.
*The Surv X1 and Surv X2 estimates are compared to the value to which they converge, as de-
scribed in Section B.2.
Software n models Intercept Time X1 X2 Surv X1 Surv X2 Association
Two-Stage 100 0.09 0.07 0.14 0.08 0.37 0.18 0.09
R JM Weib 88 0.10 0.07 0.14 0.08 0.39 0.19 0.13
R JM Weib NA 95 0.09 0.07 0.14 0.08 0.40 0.19 0.12
R JM PWC 87 0.09 0.07 0.13 0.08 0.40 0.19 0.11
R JM PWC NA 94 0.09 0.08 0.14 0.08 0.41 0.19 0.12
R JM Spl 83 0.09 0.08 0.14 0.09 0.39 0.20 0.12
R JM Spl NA 94 0.09 0.07 0.14 0.08 0.40 0.19 0.11
R JM Unspec NA 85 0.09 0.08 0.14 0.08 0.39 0.19 0.11
SAS %JM Weib 100 0.11 0.07 0.13 0.08 0.40 0.18 0.12
SAS %JM PWC 100 0.09 0.07 0.13 0.08 0.42 0.19 0.20
Stata Weib 99 0.09 0.07 0.14 0.08 0.40 0.18 0.11
R joineR 25 0.09 0.09 0.12 0.08 0.34 0.22 0.10
Table 2.13: Empirical Standard Deviations of the estimates from Scenario 2.
*The Surv X1 and Surv X2 estimates are compared to the value to which they converge, as de-
scribed in Section B.2.
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Figure 2.2: Boxplots showing the bias of the Scenario 2 estimates. Model names abbreviated as:
TS=Two-Stage, JM W=R JM Weibull, JM PW=R JM Piece-Wise, JM Sp=R JM Spline, JM Un=R
JM Unspecified NA, SAS W=SAS Weibull, SAS PW=SAS Piece-Wise. Figures 2(h,i,j) plot the
actual values estimated for the random effect variances and covariance with the dotted line at the
true value.
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Software n models Intercept Time X1 X2 Surv X1 Surv X2 Association
Two-Stage 100 0.44 0.29 0.60 0.30 1.33 0.67 0.40
R JM Weib 88 0.43 0.29 0.59 0.29 1.35 0.68 0.42
R JM Weib NA 95 0.44 0.29 0.60 0.30 1.39 0.70 0.43
R JM PWC 87 0.90 0.28 0.59 0.29 1.39 0.70 0.46
R JM PWC 94 0.44 0.29 0.60 0.30 1.40 0.70 0.46
R JM Spl 83 0.42 0.28 0.56 0.28 1.38 0.70 0.46
R JM Spl NA 94 0.44 0.29 0.60 0.30 1.39 0.70 0.47
R JM Unspec NA 85 0.44 0.29 0.60 0.30 1.23 0.69 0.22
SAS %JM Weib 100 0.45 0.31 0.60 0.30 1.40 0.70 0.46
SAS %JM PWC 100 0.45 0.31 0.60 0.30 1.43 0.72 0.55
Stata Weib 99 0.44 0.29 0.60 0.30 1.39 0.70 0.44
R joineR* 25 0.44 0.29 0.62 0.31 1.66 0.74 0.43
Table 2.14: Average width of Confidence Intervals for Scenario 2.
*The Surv X1 and Surv X2 estimates are compared to the value to which they converge, as de-
scribed in Section B.2.
macro defaults and we see that the variance of the intercept and the slope were overestimated by
SAS. The Two-Stage model estimated the random effect variances well but severely overestimated
the covariance, possibly including additional variance in the longitudinal submodel random effects
estimates that would be explained by the association with the survival submodel in a joint model.
Empirical standard deviations were consistent in all software. We see that the random coefficients
models in this scenario took longer to run on average than the models in Scenario 1 for all software
except Stata. Using nonadaptive quadrature increased runtime more compared to Scenario 1.
2.4.3 Scenario 3
The final simulation scenario utilized a shared coefficients form as in (1.3), with a random intercept
only, i.e. Ui = U0i is a scalar. The data were generated from
Yij = β0 + β1tij + β2X1i + β3X2i + U0i + eij (2.11)
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hi(t) = exp(γ0 + γ1X1i + γ2X2i + αU0i) (2.12)
Parameter values are below.
X1i ∼ Bernoulli(0.5),
X2,i ∼ N(0, 0.52),
(ti1, ti2, ..., ti7) = (0, 0.5, 1, 1.5, 2, 2.5, 3),
eij ∼ N(0, 42),









For this scenario, independent censoring times were drawn Ci ∼ Unif(1.25, 3.25). There was
approximately 20% censoring.
A random intercept only shared parameter survival submodel was used since the most software
could fit the correct model. The R function joineR and Stata fit the same longitudinal submodel
in (2.11). Again, the default in SAS is to fit a longitudinal model with both a random intercept
and slope as was the case in Scenario 1 which in this case is an misspecified model. The joineR,
SAS, and Stata software fit (2.12) to the survival part. The JM package in R only fits joint models
with a current-value association, which amounts to a reparameterization of the shared parameter
models. In this scenario R JM fits the survival submodel in (2.13). The survival coefficients will
converge to a combination of true parameters, namely γ∗1 = γ1 − αβ2 and γ∗2 = γ2 − αβ3. See
Appendix B.2 for details.




2X2i + αmi(t)) (2.13)
Baseline hazards are listed in (2.8). Both adaptive and nonadaptive (NA) numerical integration was
again utilized in R JM with Weibull, piecewise constant, and spline baseline hazard functions. We
used the default settings to create piecewise constant and spline baseline hazard functions. A Two-
Stage model was also fit with the survival model being a standard semi-parametric Cox model.
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Software n models Intercept Time X1 X2 Surv X1 Surv X2 Assoc.
Two-Stage 100 91 94 98 93 97 92 94
R JM Weib 82 95 93 99 91 88 95 95
R JM Weib NA 80 91 90 99 91 96 94 96
R JM PWC 88 95 93 99 93 95 98 82
R JM PWC 89 94 93 98 92 95 97 80
R JM Spl 97 94 95 98 92 97 95 87
R JM Spl NA 100 94 94 98 92 97 95 88
R JM Unspec NA 45 93 89 100 89 93 88 11
SAS %JM Weib 100 87 96 96 94 100 97 84
SAS %JM PWC 100 88 96 96 94 98 100 80
Stata Weib 89 51 85 98 91 99 100 80
R joineR* 100 93 94 95 89 80 51 91
Table 2.15: Coverage probabilities for Scenario 3 (in %).
* The SAS longitudinal model is misspecified, including a random slope not in the data generation
model.
** The Surv X1 and Surv X2 estimates are compared to the value to which they converge and
standard errors are estimated through bootstrapping. Details in Section B.2.
Figure 2.3 and Tables 2.15 - 2.18 show the results for Scenario 3. Table 2.10 shows the run-
times for all scenarios.
Models could be fit to all or almost all of the 100 simulated datasets by each software in this
scenario. In this scenario R joineR had a considerably lower coverage probability for the X2
coefficient in the survival submodel. Nearly all software except R JM Weib (and R JM Weib NA)
had relatively low coverage for the association parameter, with the coverage from R JM Unspec
NA being especially poor. Again, the average width of confidence intervals around the association
estimate from R JM Unspec NA was much smaller than all other software. The average confidence
interval widths for X1 and X2 from R JM Spl are much larger than the other software, possibly
due to poor model fitting on the simulated datasets corresponding to the outliers.
R JM and Stata estimated the random intercept variance best although all (except Two Stage)
underestimated this value. The Two-Stage model severely overestimated this value as in the first
two scenarios. Interestingly fitting models to this data with R JM Spl produced estimates with
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Intercept Time X1 X2 Surv X1 Surv X2 Association
Software n models worked Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE Bias MSE
Two-Stage 100 0.62 1.09 -1.68 0.36 -0.34 0.82 -1.23 0.67 0.17 3.57 0.61 2.85 -6.47 5.18
R JM Weib** 82 0.60 0.91 -0.01 0.34 -0.47 0.73 0.28 0.56 -1.88 4.41 -1.41 3.28 -1.71 5.75
R JM Weib** NA 80 -1.20 1.09 0.95 0.41 0.45 0.72 0.75 0.68 -1.44 4.37 -2.54 3.62 1.59 5.97
R JM PWC** 88 0.43 1.00 -0.73 0.35 0.24 0.80 -0.40 0.64 -5.59 4.21 9.67 4.89 -26.48 13.16
R JM PWC NA** 89 0.68 0.99 -0.93 0.35 0.06 0.74 -0.50 0.66 -5.06 4.18 8.30 4.49 -24.36 12.36
R JM Spl** 97 0.24 1.08 -1.16 0.34 0.34 0.80 -0.40 0.65 -4.36 4.20 11.62 4.93 -28.04 12.67
R JM Spl NA** 100 0.24 1.07 -0.97 0.34 0.15 0.80 -0.66 0.67 -4.39 3.85 11.65 4.82 -28.53 11.96
R JM Unspec NA** 45 0.42 1.13 -1.62 0.41 0.81 0.66 0.29 0.70 -0.60 4.21 9.61 3.20 -21.76 8.00
SAS %JM Weib* 100 -1.43 1.24 -1.22 0.31 0.80 1.07 -2.22 0.82 0.86 3.24 1.85 167.99 3.40 47.32
SAS %JM PWC* 100 -0.61 1.17 -1.37 0.30 0.57 1.05 -2.25 0.83 2.08 3.65 4.48 168.58 5.65 23.61
Stata Weib 89 14.31 2.68 4.65 0.84 -0.18 0.87 -0.26 0.65 -0.74 11.99 -0.24 3.13 0.20 9.05
R joineR 100 0.59 1.09 -1.30 0.36 -0.15 0.81 -0.98 0.67 -22.46 9.22 -29.41 11.43 -12.00 7.38
Table 2.16: Bias*100 and Mean Squared Error (MSE)*100 of the estimates from Scenario 3.
* The SAS longitudinal model is misspecified, including a random slope not in the data generation
model.
** The Surv X1 and Surv X2 estimates are compared to the value to which they converge and
standard errors are estimated through bootstrapping. Details in Section B.2.
Software n models Intercept Time X1 X2 Surv X1 Surv X2 Association
Two-Stage 100 0.10 0.06 0.09 0.08 0.19 0.17 0.22
R JM Weib** 82 0.10 0.06 0.09 0.08 0.21 0.18 0.24
R JM Weib NA** 80 0.10 0.06 0.09 0.08 0.21 0.19 0.25
R JM PWC** 88 0.10 0.06 0.09 0.08 0.20 0.20 0.25
R JM PWC NA** 89 0.10 0.06 0.09 0.08 0.20 0.20 0.25
R JM Spl** 97 0.10 0.06 0.09 0.08 0.20 0.19 0.22
R JM Spl NA** 100 0.10 0.06 0.09 0.08 0.19 0.19 0.20
R JM Unspec NA** 45 0.11 0.06 0.08 0.08 0.21 0.15 0.18
SAS %JM Weib* 100 0.11 0.05 0.10 0.09 0.18 0.18 0.69
SAS %JM PWC* 100 0.11 0.05 0.10 0.09 0.19 0.15 0.49
Stata Weib 89 0.08 0.08 0.09 0.08 0.19 0.18 0.30
R joineR 100 0.10 0.06 0.09 0.08 0.21 0.17 0.24
Table 2.17: Empirical Standard Deviations of the estimates from Scenario 3.
* The SAS longitudinal model is misspecified, including a random slope not in the data generation
model.
** The Surv X1 and Surv X2 estimates are compared to the value to which they converge and
standard errors are estimated through bootstrapping. Details in Section B.2.
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Figure 2.3: Boxplots showing the bias of the Scenario 3 estimates. Model names abbreviated
as: TS=Two-Stage, JM W=R JM Weibull, JM PW=R JM Piece-Wise, JM Sp=R JM Spline, JM
Un=R JM Unspecified NA, SAS W=SAS Weibull, SAS PW=SAS Piece-Wise. Figure 3(h) plots
the actual values estimated for the random effect variance with the dotted line at the true value.
Note: Outliers in Intercept and Association from JM Sp have been omitted to aid in interpreting
the boxplots.
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Software n models Intercept Time X1 X2 Surv X1 Surv X2 Association
Two-Stage 100 0.36 0.21 0.42 0.30 0.81 0.59 0.89
R JM Weib** 82 0.36 0.22 0.41 0.30 0.85 0.69 1.02
R JM Weib NA** 80 0.36 0.22 0.42 0.30 0.86 0.69 1.00
R JM PWC** 88 0.36 0.22 0.42 0.30 0.81 0.69 0.97
R JM PWC NA** 89 0.36 0.22 0.42 0.30 0.83 0.69 0.97
R JM Spl** 97 0.36 0.21 0.41 0.30 4.04 3.56 1.01
R JM Spl NA** 100 0.36 0.21 0.42 0.30 0.83 0.69 0.99
R JM Unspec NA** 45 0.36 0.21 0.41 0.30 0.80 0.60 0.11
SAS %JM Weib* 100 0.35 0.21 0.40 0.28 0.84 0.64 1.32
SAS %JM PWC* 100 0.35 0.21 0.40 0.28 0.82 0.62 1.33
Stata Weib 89 0.29 0.28 0.40 0.29 0.82 0.61 0.91
R joineR 100 0.36 0.20 0.41 0.29 0.84 0.59 1.06
Table 2.18: Average width of Confidence Intervals from Scenario 3.
* The SAS longitudinal model is misspecified, including a random slope not in the data generation
model.
** The Surv X1 and Surv X2 estimates are compared to the value to which they converge and
standard errors are estimated through bootstrapping. Details in Section B.2.
larger bias for most covariates and considerably smaller MSE for some covariates compared to R
JM with the other baseline options. We noted that SAS produced survival submodel X2 coefficient
estimates with an unusually large MSE. Also, joineR generated more biased estimates for the
survival submodel despite fitting a model in the same form as the data generating model. As in
the first two scenarios, empirical standard deviations were very similar across all software. Lastly,
SAS and R joineR ran for notably shorter times than in the first two Scenarios.
2.5 Bayesian Models and Associated Software
The Bayesian implementation was not compared to the simulations for the maximum likelihood
methods in the last section. Instead, in this section we will discuss the single option for Bayesian
joint modeling in the software and also use this to analyze the adrenal cancer data.
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2.5.1 JMbayes Package in R
The JMbayes package in R was written to fit joint models in a Bayesian framework (Rizopoulos,
2016c). The function for fitting joint models is named jointModelBayes(). The arguments
for this function are very similar to the jointModel() function in the JM package in R. A linear
mixed model is fit to the longitudinal data unless the user specifies a different distribution with the
desLong argument. A relative risk model is fit for the time-to-event data. The baseline hazard is
estimated using splines, either penalized P-Splines (the default) or regression-splines (Rizopoulos,
2016b). The param argument determines the form of the association between the submodels.
The default association is current value as in (1.2). Other options are association based on the
current slope of the longitudinal trajectory analogous to the R JM package in (2.1), both the current
value and slope, or shared parameters like in (1.3). A final association option is a combination of
shared random effects and fixed effects, β∗, such as hi(t|Mi(t)) = h0(t)exp{X2iγ + αT (β∗ +
Ui)}. Available functionalities in the JMbayes package are listed in Table 2.1. Extra flexibility is
available for the association structure since the user can define any transformation function using
the extraForm and transFun arguments. Using this, the association can be defined to be any
function of the current value or any function of the shared random effects.
Estimation is done using Markov Chain Monte Carlo (MCMC) sampling from the poste-
rior conditional distributions of the random effects and the parameters. Usually a random walk
Metropolis can be used, but in some cases Metropolis-Hastings or slice sampling are needed (Ri-
zopoulos, 2016c). Initial values can be set using the init argument but if left unspecified initial
values are taken from the outputs from the separate models that are included as arguments to the
jointModelBayes() function. Priors can also be specified by the user with the priors ar-
gument. If not specified, standard prior distributions are used: all the fixed parameters from both
submodels as well as the association parameter are given independent diffuse Normal priors, a
inverse Wishart prior is assumed for the covariance matrix of the random effects when fitting a
Normally distributed longitudinal outcome, and an inverse Gamma prior for the error variance
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Stage 3 or 4 -0.4 (-1.4,0.5)
Tumor Grade: High -0.5 (-3.2,2.2)
Tumor Grade: Unknown -3.2 (-6.7,0.4)
Surv-Age -0.007 (-0.02,0.01)
Surv-Stage 3 or 4 0.2 (0.01,0.3)
Surv-Tumor Grade: High 0.40 (-0.03,0.9)
Surv-Tumor Grade: Unknown 0.8 (0.2,1.4)
Association -0.09 (-0.1,-0.06)
Table 2.19: Parameter estimates and credible intervals for the joint models fit to the adrenal data
with JMbayes.
(Rizopoulos, 2016c). The JMbayes package also includes functions for plotting and running
dynamic predictions (Rizopoulos, 2016b).
2.5.2 Application of Bayesian Model to Adrenocortical Carcinoma Data
A joint model with the current value association as in (2.2) and (2.3) with a P-spline baseline
hazard is fit to the adrenal cancer data from Section 2.3 using JMbayes. MCMC is run for 52,000
iterations with a burn-in of 2000. The results are shown in Table 2.19. The JMbayes estimates
are generally similar to the frequentist current-value results in Table 2.3 and interpretations of the
covariate effects on psoas density and survival are the same.
2.6 Extensions and Specialized Joint Models and their
Implementation
The growing interest in joint modeling has led to many extensions, such as joint modeling
with competing risks, recurrent events, or multiple longitudinal processes. The addition of many
software to fit standard joint models has also encouraged the development of more specialized
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software. Here we briefly describe several model extensions and software available for implemen-
tation. See Appendix C for more implementations via software. The extent of software implemen-
tation for specialized joint modeling is likely to increase in the future.
Up until this point we have focused on longitudinal measurements with a Gaussian distribution.
Yet situations often arise that require a non-Gaussian outcome in the longitudinal submodel, such
as a logistic or Poisson model. The JM and JMbayes software in R as well as the %JM macro
in SAS, described in section 2.2, can accommodate non-Gaussian longitudinal processes. The
Jointlcmm() function in the lcmm package in R can implement different distributions in the
longitudinal submodel of a latent class mixed model (Proust-Lima et al., 2016).
Joint latent class mixed modeling is an extension that can be used to investigate class-specific
differences. These models typically include three submodels, a multinomial logistic model to
determine the latent class, a class-specific linear (or latent process) mixed model, and a class-
specific survival model. The number of latent classes must be set a priori based on knowledge of
the situation from which the data were collected. The lcmm package in R was written for latent
class mixed modeling and includes a function, Jointlcmm()which fits a joint latent class mixed
model for longitudinal and time-to-event data (Proust-Lima et al., 2016). The baseline risk can be
common or class-specific. Choice of initial values is important and it is preferred that the user
specify initial values with the B argument over using the defaults.
In medical studies it is likely more than one biomarker is measured for each patient. This neces-
sitates joint models with multiple longitudinal variables. Hickey et al. (2016) review developments
in multivariate joint models including software implementations. Hickey et. al. mentioned a
new package for multivariate joint models, sjmsoft for R, available from the author’s website
(Brown, 2005). Another option is the R package joineRML (Hickey et al., 2018).
An interesting but currently less studied extension is joint modeling with competing risks. The
longitudinal submodel for a single longitudinal outcome is the same as a single risk joint model.
Literature has almost exclusively focused on a survival submodel with proportional cause-specific
hazards (Armero et al., 2016; Blanche et al., 2015; Elashoff et al., 2007; Hu et al., 2009; Huang
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et al., 2010; Williamson et al., 2008). Usually the survival submodel has the following form,
defining the cause specific hazard h(k) for cause k = 1, ..., K.
h(k)(t;X2i, Ui, γ
(k), α(k)) = lim
h→0
h−1P (t ≤ Ti < t+ h,Di = k|Ti ≥ t,X2i(t), Ui)
= h
(k)
0 (t)exp{X2i(t)γ(k) + α(k)
T
Ui}
The parameters are defined similar to those in Section 1.2.2, X2i are fixed effects which have
possibly cause-specific coefficients γ(k), Ui are the random effects for subject iwith possibly cause-
specific association α(k), and cause-specific baseline hazard h(k)0 (t).
Some of the joint modeling software will fit a competing risks model. The JM package in
R has an option CompRisk in the jointModel() function. The joint() function in the
joineR package will fit a cause-specific hazard joint model if the event indicator has multiple
levels but the documentation states this only works for two causes in addition to censoring, and
no more (Philipson et al., 2012). The SAS macro %JM can also fit a competing risk model with
the option COMPETING which is listed under AdditionalOptions. Documentation for the
stjm Stata command states that extension to the competing risks setting is planned but there
is no indication that this has been completed (Crowther et al., 2013). There is also no built-in
option for fitting a competing risks model in JMbayes. Recently a SAS macro called %SPM
was proposed specifically for fitting joint competing risks models (Wang et al., 2017). Finally, the
Jointlcmm() function in lcmm in R can also handle competing risks (Proust-Lima et al., 2016).
Another common situation is data including recurrent events such as repeated hospitalizations
or time between system breakdown in industry. The R package frailtypack will fit a standard
joint model with function longiPenal and also joint models with longitudinal measurements, a
terminal event plus recurrent events using the function trivPenal (Rondeau et al., 2017, 2012).
With the increasing number of studies utilizing joint modeling, it may be useful to analyze
the results from multiple studies in a meta-analytic context. A package for joint modeling in
a this context, joineRmeta in R, has been developed which can pool model parameters from
multiple joint models using standard meta-analysis techniques or analyze the data from all studies
46
simultaneously (Sudell et al., 2018; Sudell, 2018).
2.7 Discussion
Joint modeling is a growing field of statistical research and the available software encourages
the use of these complicated models in applications. We have given an overview of joint modeling
methodology and then compiled a comprehensive list of available software. We compared through
simulation and data analysis the most common and user-friendly software: JM, joineR, and
JMbayes in R, %JM in SAS, and stjm in Stata. We also included a short description of extensions
to joint modeling such as those that accommodate competing risks, multiple longitudinal markers
or recurrent events. The %JMfit macro developed for SAS, described in Appendix C, includes
some goodness-of-fit calculations such as decomposition of AIC, BIC, ∆AIC, and ∆BIC (Zhang
et al., 2016). Assessing model fit in a joint modeling framework has had limited study and further
development of this area is likely in the future (Zhang et al., 2014).
Our simulations show joint modeling software is preferable to Two-Stage models when the
longitudinal and survival processes are correlated, as the theoretical work finds. Ours is the first
investigation that explored the performance of regression coefficients on both longitudinal and sur-
vival components. The packages in R fit only one type of association while SAS and Stata include
many more options. All software we compared are similar in their performance when fitting the
longitudinal submodel in simulations. There are more differences in the survival submodel options
and performance. All except joineR included a flexible parametric baseline hazard which is most
applicable to real data when the true model is unknown. A Cox-type survival submodel using an
unspecified baseline hazard is currently available in the R packages joineR and JM. In each of
our simulation scenarios we found that the average width of the confidence intervals around the
association estimate were smaller than all other software. This could be evidence of underestima-
tion of standard error. This is similar to what was found in simulations in Yuen and Mackinnon
(2016). Otherwise we did not see underestimation for the other covariates. Still, documentation
of the R JM package does not indicate that any techniques are used to correct for the theoretical
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underestimation. Hence this should be considered when using the R JM package with a Cox type
survival submodel. We found convergence issues when using the adaptive Gauss-Hermite quadra-
ture option only when using an unspecified baseline hazard in the R JM function. Additionally,
we saw in our simulations that using a restrictive parametric baseline risk function that matches the
truth does not aid in estimation but may shorten runtime. Unless there is a compelling reason to use
a restrictive parametric function, such as Weibull, for the baseline hazard, we would recommend
using a flexible hazard such as piecewise constant or spline based.
In our investigation through simulation, we found that the Stata stjm command can be very
sensitive to the parameter values used in data generation. SAS can also have difficulties depending
on the parameters chosen when using an unstructured covariance matrix, but the default model
assuming uncorrelated random effects was always able to fit the models. The R functions were
always able to fit models to at least some of the datasets, no matter the parameter values used.
Basic joint modeling capabilities are available in the main statistical programming languages,
R, SAS, and Stata, giving the user an option to use the implementation in the language of their
choice. Each software has good features as well as limitations. Overall, we would recommend R
JM or SAS. The SAS macro %JM offers the most functionality, including submodel, association,
and estimation options. R JM was consistently the fastest and includes almost as many options as
SAS, so this may be a better option if runtime is a concern. The joineR function is limited in the
type of models it can fit. But if a joint model with a Gaussian longitudinal response and a shared
parameter survival submodel is appropriate for the data, joineR may be a good option because
of its simplicity.
Our investigation was focused on giving an overview of the available software and their fea-
tures. Our simulations were limited to three scenarios that could be modeled in each common
software. Other simulation scenarios were explored but not every software was able to fit models
to the data. Running more simulations with different data forms and more focus on time slopes in
longitudinal models, different forms of the submodels, and various associations would add to the
knowledge of these software. Development of this group of software is expected based on the con-
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tinued research in this field and the applicability of these models. With increased generalization in
the form of each part (longitudinal and survival submodels, and the association) the software could
accommodate many more types of data. Some software are currently being developed and released
to accommodate useful extensions such as competing risks and multiple longitudinal outcomes as
we discussed. Further work on more robust estimation as well as faster algorithms would be useful.
Fitting a simple joint model with only a few covariates is not prohibitively restrictive on time. The
time required will increase with an increase in the number of covariates or a non-normal longitu-
dinal models, especially if one has to rely on re-sampling techniques for inference purposes. Such
extensions may require creative enhancements and approximations that would be computationally
efficient. An important area in joint modeling that is largely unexplored is model diagnostics.
While some of the software offer some basic diagnostics (Rizopoulos, 2010, 2016c) and dynamic
predictions (Crowther et al., 2013; Garcia-Hernandez and Rizopoulos, 2015; Rizopoulos, 2010,
2016c), there is room for further expansion.
Bayesian models can be very powerful and are gaining traction in joint modeling literature
but the implementation is relatively limited. Analyzing joint models in a general multi-purpose
Bayesian statistical programming language such as OpenBUGS, JAGS or Stan is possible and
attractive due to its flexibility. Defining a joint model can become complicated in OpenBUGS
due to the lack of closed-form for the integrals encountered in estimation. A common simplifying
assumption is that the survival process follows a parametric distribution, often Weibull (Guo, 2003;
Guo and Carlin, 2004). Full proportional hazards survival submodels have been implemented in
the literature and code is available in the supplemental materials of Rizopoulos and Ghosh (2011)
for the case of multiple longitudinal outcomes and Andrinopoulou et al. (2013) for the case of
two longitudinal variables and competing risks data. A competing risks joint model has been
implemented in WinBUGS (Deslandes and Chevret, 2010). In the next chapter we will shift our
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focus onto the competing risks scenario and develop our own models with Bayesian estimation.
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Chapter 3
Bayesian Inference and Dynamic Prediction
from Joint Models Under Competing Risks
3.1 Introduction
Joint models were developed to study the relationship between a longitudinal measurement
and a time-to-event outcome, such as CD4 counts and time to AIDS diagnosis (De Gruttola and
Tu (1994); Tsiatis et al. (1995)). The relationship between the longitudinal and time-to-event
processes is further complicated when the event can have one of multiple causes, called competing
risks. Competing risks data can arise in clinical trials and observational studies when multiple
reasons for death are recorded or when death is a competing risk of the main event of interest such
as disease progression. This is the case in our motivating dataset from a study of adrenocortical
carcinoma (ACC) patients. The morphomics, which were collected over time, are believed to be
related to time to disease change.
Typically, joint longitudinal and competing risks models use a mixed effects models frame-
work for the longitudinal part and cause-specific proportional hazards (PH) models for the survival
component with some shared variables inducing an association between the two parts (Williamson
et al. (2008); Elashoff et al. (2007); Li et al. (2010); Hu et al. (2009); Rue et al. (2017); Hickey
et al. (2018)). While cause-specific PH models are common, such modeling cannot capture any
dependence between the competing risks themselves (Lakhal et al. (2008)). Further, not all sur-
vival models conform to a PH specification. In this chapter, we propose using parametric survival
submodels from a log-location scale family in the survival part of our joint model. Utilizing para-
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metric survival models assumes that the resulting hazard functions have a specific form usually
described by a relatively small number of parameters. This reduces the number of parameters nec-
essary to estimate in our models compared to proportional hazards models, whose baseline, in its
completely unspecified form, is infinite-dimensional and typically gives rise to estimation issues.
In the context of joint models, it is well-known that unspecified baseline hazard estimation leads
to underestimated standard errors if not properly corrected (Hseih et al. (2006)). Therefore most
joint models using proportional hazards will define the baseline hazard to be a piece-wise spline
function (Furgal et al. (2019)). However, when one allows these baseline hazards to differ for each
event cause in a competing risks setting, the number of parameters to either be estimated or set
apriori increases. A fully parametric model offers parsimony and allows flexibility to go beyond a
specific structural formulation.
Specifically, we focus on Weibull and log-Normal models for our competing risks component.
Weibull and log-Normal are two widely implemented formulations adopted in the analysis of para-
metric time-to-event data. Both of the distributions fall under the umbrella of the log-location-scale
family of models. While Weibull conforms to a PH structure, assuming the failure times to follow
either a log-Normal or a Weibull distribution results in an accelerated failure time class of models.
The use of parametric survival models has recently been used in joint models with a single cause
of failure and to date we have not seen any application of parametric survival distributions with
joint longitudinal and competing risks models (Dil and Karasoy (2020)).
We develop and estimate our models under a Bayesian framework. The Bayesian technique
can help leverage data with a relatively small sample size. Further, joint models are known to
produce convergence problems and computational challenges and Bayesian estimation may be
a more efficient approach. The posterior predictive distribution can also be used for relatively
easy prediction. Joint models have often been used for dynamic prediction in biomedical settings,
predictions that can be quite useful in clinical settings (Proust-Lima and Taylor (2009); Taylor et al.
(2013); Rizopoulos et al. (2014); Blanche et al. (2015); Andrinopoulou et al. (2017, 2018); Li and
Luo (2019); Wu et al. (2019)). The event prediction can be updated with each new longitudinal
52
biomarker measurement in a seamless way under the Bayesian setup.
The rest of the chapter is organized as follows. In Section 3.2 we develop our models and
we describe the Bayesian estimation in Section 3.3. We apply our models to the adrenocortical
carcinoma data in Section 3.4 and then explore model performance with simulations in Section 3.5.
Section 3.6 explains the premise of dynamic predictions in our context and supplies an example.
We conclude with a discussion in Section 3.7.
3.2 Framework
Let N be the number of subjects, indexed by i = 1, ..., N . Each subject has Ji ≥ 1 measure-
ments of the longitudinal process Y (τ) with τ measuring time since the start of the study. Subject
i has observations at times τi = (τi1, τi2, ..., τij, ..., τiJi)
T . Let Yij denote subject i’s measurement
at time τij , i.e. Yij = Y (τij). Let Yi = (Yi1, ..., YiJi)
T be the vector of longitudinal measurements
for subject i.
Each subject can experience an event with one of K ≥ 2 causes indexed by k. Let Ti be the
event time for subject i and Di = (Di1, ..., Dik, ..., DiK)T be the vector of event indicators where
Dik = 1 if subject i has event with cause k and Dil = 0 for all l 6= k. A subject’s event time may
be right-censored in which case Dik = 0 for all k = 1, ..., K.
Baseline covariates are denoted Xi in the longitudinal model and Wi in the survival submodel.
Xi may depend on the observation time τij . In the survival submodels, for simplicity, we assume
Wi is time independent. The ensemble Xi and Wi may share covariates, but need not be the same.
Let the number of covariates in the longitudinal submodel be p and the survival submodel be q.
3.2.1 Longitudinal submodel
We assume the linear mixed effects model in (3.1) for the longitudinal outcome Yi. Here we
assume that Y is continuous and normally distributed. Extending this to a generalized linear model
for non-Gaussian outcomes Y is straightforward. We include subject-specific random effects Ui
with design matrix Zi. In (3.1), β is a p-vector of regression parameters and the εij are random
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measurement errors with εij ∼ N(0, σ2ε ). Let εi = (εi1, ..., εiJi)T .
Yi = Xiβ + ZiUi + εi (3.1)
We assume that given Ui the Yij are independent, i.e. Yij ⊥ Yij′ | Ui if j 6= j′. For simplicity we
will work with a subject-specific random intercept only, i.e. Zi = 1, and Ui = U0i ∼ N(0, σ2U).
3.2.2 Competing Risks Survival Submodels
For the competing risks data, we use parametric models from the log-location-scale family (Basu
et al. (2003); Mukhopadhyay and Roy (2016)). We model the distribution of the failure times
directly within a latent failure time framework. A common critique of the latent failure time
approach to competing risks analysis is that this framework can suffer from identifiability issues
(Tsiatis (1975)). This problem can be avoided by assuming the latent failure times are conditionally
independent given random effects or by including a regression model with covariates (Heckman
and Honorè (1989)). Our models both assume conditional independence and include covariates so
the parameters in our model are identifiable.
We assume that if there are K possible causes of failure, each subject, in theory, has a time
to event for each cause. Denote the time to event of cause k for subject i as T ∗ik, i = 1, ..., N ,
k = 1, ..., K. Subjects may also be independently censored and we will call T ∗i0 the independent
censoring time. Dependent censoring can be included as one of the K possible causes of failure.





assume that given some random effects Vi, sometimes called a frailty, the Tik are independent, i.e.
Tik ⊥ Tik′ | Vi,Wi for k 6= k′. We also assume that the longitudinal and event time outcomes for
a single subject are conditionally independent given the random effects Yij ⊥ Ti | Ui, Vi, Xi,Wi
for all i and j. We focus on two specific distributions in the log-location-scale family: Weibull




In the Weibull model we assume that given Vi the latent event times follow a Weibull distribution
with scale parameter γk and shape parameter µik. The shape and scale depend on the cause of
failure k and the shape µik will also depend on the subject i. Then
T ∗ik|Vi ∼Weibull (µik, γk) , k = 1, ..., K (3.2)
To incorporate the covariates and random effects, we put a regression model on the log of the
Weibull scale, assuming
log (µik) = Wiαk + θ
T
k Vi (3.3)
where Wi is the vector of covariates with regression coefficient q-vector αk. Note that we are
assuming the covariates Wi are the same for all k for simplicity. Theoretically these Wi could
depend on k.
An association between the longitudinal and survival submodels is induced by assuming the
random effects in (3.1) and (3.3), Ui and Vi, are correlated. For simplicity, we will assume they are
the same, i.e. Vi = Ui. The regression model can be rewritten as
log (µik) = Wiαk + θ
T
k Ui (3.4)
The parameter θk measures the strength of the association between the longitudinal and survival
processes. Here θk = 0 would mean there is no association.
When interpreting the results from fitting this model, an increase in the scale parameter µik
with constant γk moves the center of the distribution to the right on the x-axis, thus moving the
density away from 0. Hence an increase in µik = exp(Wiαk + θTk Ui), meaning a larger value for
either αk or θk, holding other parameters constant, corresponds to generally longer survival times.
A positive association parameter θk means that a larger difference in Y from its expected value
is associated with longer survival and a negative θk value means a larger baseline Y is associated
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with shorter survival. The shape parameters γk determine the shape of the Weibull distribution
with γk = 1 reducing to an exponential distribution.
Model L: Log-Normal
We also consider a joint model with the latent failure times following a log-Normal distribution
with mean µik and standard deviation γk, given random intercept Vi = Ui, i.e.






, k = 1, ..., K (3.5)
Here we put a regression model on the mean
µik = Wiαk + θ
T
k Ui (3.6)
with αk, Wi, and θk as described in Section 3.2.2. Interpretation is similar to the Weibull model.
Here a larger positive value of µik with a constant standard deviation γk leads to more density away
from zero meaning longer survival times.
3.3 Bayesian Model and Estimation
We use Bayesian techniques to fit these models. In our Bayesian model, we assume that the
random effect is a scalar U0i and our longitudinal outcome Yij follows a multivariate Normal dis-
tribution with mean Xijβ +U0i and standard deviation σεIJi . Here IJ is the J × J identity matrix.
Yi|Xi, β, U0i, σU , σ2ε ∼ MVN (Xiβ + U0i, σεIJi)
Our survival submodels will assume the latent failure event times for cause k (k = 1, ..., K)
follow either a Weibull or log-Normal distribution as in (3.2) or (3.5) called Model W and Model
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L, respectively.
Model W: Ti|Di,k = 1,Wi, U0i, γk, αk, θk ∼Weibull (µik, γk) , with log (µik) = Wiαk + θkU0i






, with µik = Wiαk + θkU0i
3.3.1 Priors
We will call the set of parameters Ω = {β, σU , σε, γ1, ..., γK , α1, ..., αK , θ1, ..., θK} on which we











σU ∼ Γ (a, b)
σε ∼ Γ (a, b)













We have hyperparameters mβ , sβ , mα, sα, mθ, sθ, a, and b. The Gamma distribution hyperparam-
eters a and b could differ for each parameter but for simplicity we will use the same values.
3.3.2 Complete Data Likelihood and Posterior
The likelihood contribution from the longitudinal submodel is below where p(Yi|Xi, β, U0i, σU , σε)















Yi − βTXi − U0i
)T (
Yi − βTXi − U0i
)}
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hk(Ti|Di,Wi, U0i, γk, αk, θk)DikSk(Ti|Di,Wi, U0i, γk, αk, θk)
where hk and Sk are the hazard function and survival function, respectively, for cause k. The
hazard and survival functions for Model W are











The functions for Model L are below where φ(x) and Φ(x) are the density function and cumulative
distribution function (CDF) of a standard normal distribution, respectively.
Model L: hk(Ti|Di,Wi, Ui, γk, αk, θk) =
φ
(






γ−1k (log Ti − µik)
))
Sk(Ti|Di,Wi, Ui, γk, αk, θk) = 1− Φ
(
γ−1k (log Ti − µik)
)
Let p(Ω) denote the product of the density functions for the priors of all parameters in Ω and
p(U) =
∏N
i=1 p(U0i) the product of the densities of Ui for i = 1, ..., N . The posterior is propor-
tional to the product of the likelihood and priors.
p(Ω|Y, T,D,X,WU) ∝ LYLTp(U)p(Ω).
The posterior is high-dimensional and intractable. The standard path is to take a computational
approach using a Markov Chain Monte Carlo (MCMC) technique. The full conditionals for both
models are included in Appendix G.1. Drawing from the posterior is accomplished through a
Hamiltonian Monte Carlo which is available in Stan. We fit our models in Stan through the R
package rstan version 2.19.3 and using R version 3.6.1 (Guo et al. (2020)).
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Figure 3.1: Centered LPMA longitudinal measurements from the ACC data.
3.4 Application to ACC Data
We apply these models to the adrenocortical carcinoma (ACC) data from Section 1.5. Patients
received repeated CT scans in order to monitor their disease (McDuffie and Aufforth (2016)).
Images of the patient’s tumor were compared to those in the previous scan to determine the state
of disease. The disease could be categorized into one of three states: progression (increased tumor
size), regression (decreased tumor size), or stable (no significant tumor size change). Here we are
interested in time to first disease status change which can be either a progression or a regression.
Time is measured from date of diagnosis.
A previous study found that some morphomics, including lean psoas muscle area (LPMA),
had significant associations with the survival outcomes separately (Miller et al. (2012)). We are
interested in the association between LPMA and time to disease status change. Figure 3.1 shows
the longitudinal LPMA measurements for all patients in the study.
The ACC data used in this chapter is summarized in Table 3.1. The study included 159 patients.
The patients had between 1 and 19 scans with an average of 3.1 scans and a median of 2 scans per
patient. The majority of patients (54%) had a progression and 23% had a regression. Information
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Baseline Covariates Mean Std. dev.
Age* (years), at diagnosis 46.3 13.3
Count %
Sex Male 68 43
Female 91 57
Longitudinal Data Mean Std. dev.
LPMA* (mm2) 17.6 6.1
Scan time (years) 2.1 3.3
Survival Data Count %




Time to Event (years) 0.8 (0.03, 24.5)
Table 3.1: Description of adrenal cancer data used in Chapter 3. * Variables were centered in
models, i.e. X-mean(X).
on age, sex were used as baseline covariates.
We fit our models to the ACC data. The longitudinal submodel includes a time slope and two
covariates, binary sex (X1i) and continuous baseline age (X2i). A random subject-specific intercept
Ui is included. There are two competing risks; k = 1 corresponds to first progression and k = 2 to
first regression. Age is the only covariate included in the survival submodels. Adding additional
covariates to the survival submodels led to fitting problems due to the small sample. We fit both








Model W: Ti ∼Weibull (µik, γk) with log(µik) = α0k + α1kX2i + θkU0i






with µik = α0k + α1kX2i + θkU0i
(3.7)
Let β = (β0, β1, β2, β3)T , and αk = (α0k, α1k)T , k = 1, 2. We use the priors in Section 3.3.1
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with hyperparameters mβ = (0,−1,−1,−1)T , mα = (1, 1)T , mθ = −1, sβ = sα = sθ = 2,
a = 3, and b = 0.5. These hyperparameters were chosen to be weakly informative to aid in fitting
the model. We fit the models with Stan using four chains with separate initial values and 27500
warm-up iterations and 30000 iterations total.
We also fit a cause-specific proportional hazards (PH) model as in 3.8 for comparison. For
simplicity we use a parametric baseline hazard with a Weibull form for both outcomes.
Yi ∼ N
(




Model W PH: hk(Ti) =
γk
α0k
T γk−1i exp (α1kX2i + θkU0i)
(3.8)
This PH model was fit in Stan with 5000 iterations, 3000 warm-up iterations and the same priors
as in Section 3.3.1. The likelihood contributions have the same form as in Section 3.3.2 with the
hazard and survival functions below (Derivations for the survival functions are in Appendix B.3.)
Model W PH: hk(Ti|Di,Wi, Ui, γk, αk, θk) =
γk
α0k
T γk−1i exp (α1kX2i + θkU0i)













T γki exp (α1kX2i + θkU0i)
)
3.4.1 Results
Table 3.2 shows the results and trace plots can be found in Figures F.1 and F.2 in the Appendix.
We found that in all models, LPMA tended to decrease over time (β1 < 0), older patients had
lower LPMA (β3 < 0) and females had much lower LPMA than males (β2 < 0). We see that
the association parameters (θ1 and θ2) in Models W and L have similar estimates. There is a small
positive association betweenU0i and progression and a small negative association with progression.
We found that 92% of the estimates of θ1 from the post-warm-up iterations in Model W and 95%
in Model L were above 0 and 68% of estimates from Model W and 67% of estimates from Model
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L of θ2 were below zero. In Model W PH the association parameters have opposite signs and 92%
of θ1 estimates were below 0 while 64% of θ2 estimates were above zero. In our models a higher θk
value means a larger µk and longer survival times. On the other hand, in the W PH model a larger
θk corresponds to a higher hazard and therefore smaller survival times. So the difference in signs
between our models and the W PH model is reasonable. In each model time to regression tended
to be longer than time to progression (α0,1 < α0,2). Age had a small negative effect in the survival
submodels for progression in each model (α1,1 < 0) and regression for Models W andL (α1,2 < 0).
In these cases older patients tended to have a shorter time to event. The bottom row of Table 3.2
shows the mean Deviance Information Criteria (DIC) values from the post-warm-up iterations and
the 2.5% and 97.5% quantiles. According to DIC Model W fit the data slightly better than Model
L and Model W PH had the worst fit.
3.5 Simulations
For our simulations, we generated data to be similar to the ACC study. We ran simulations for
a sample size of N = 160 (similar to the ACC data) and for N = 1000 subjects to investigate
the effect of a larger sample size. For each subject, we have two covariates, one binary and one
continuous, with distributions similar to sex and centered age in decades, respectively. For i =
1, ..., N , X1i ∼ Bin(0.57) and X2i ∼ N(0, 1.52). A random intercept is defined as U0i ∼ N(0, 42).
For each subject we generate longitudinal measurements at starting at time 0 and every 0.125
years until 3 years, then every 0.5 years until 5 years and every 1 year until 8 years, i.e. τ =
(0, 0.125, 0.25, ..., 2.875, 3, 3.5, 4, 4.5, 5, 6, 7, 8)T . Thus subjects have up to 32 longitudinal mea-
surements. These times were chosen to represent patients getting regular scans early after diagno-
sis and having less frequent scans as time since diagnosis increases. At each measurement time a
longitudinal outcome Yij (i = 1, ..., N , j = 1, ..., 32) is calculated as
Yij = β0 + β1τj + β2X1i + β3X2i + U0i + εij
The measurement errors are εij ∼ N(0, 2.22) and the true values for β differ for Models W and L.
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Model W Model L
Parameter Mean CI Pr > 0 Mean CI Pr > 0
β0 3.38 (2.31, 4.42) 1.00 3.37 (2.29, 4.42) 1.00
β1 -0.14 (-0.30, 0.01) 0.06 -0.13 (-0.27, 0.02) 0.07
β2 -5.81 (-7.13, -4.39) 0.00 -5.82 (-7.12, -4.45) 0.00
β3 -1.42 (-1.96, -0.87) 0.00 -1.43 (-1.97, -0.87) 0.00
α0,1 1.34 (1.05, 1.66) 1.00 0.65 (0.36, 0.96) 1.00
α1,1 -0.05 (-0.29, 0.19) 0.36 -0.04 (-0.26, 0.17) 0.33
α0,2 3.18 (2.42, 4.16) 1.00 2.77 (1.87, 3.87) 1.00
α1,2 -0.20 (-0.73, 0.31) 0.21 -0.24 (-0.77, 0.30) 0.19
θ1 0.08 (-0.02, 0.17) 0.92 0.07 (0.00, 0.15) 0.95
θ2 -0.06 (-0.23, 0.10) 0.32 -0.05 (-0.23, 0.12) 0.33
γ1 0.75 (0.64, 0.88) 1.00 1.59 (1.36, 1.87) 1.00
γ2 0.53 (0.40, 0.67) 1.00 3.18 (2.46, 4.16) 1.00
σU 4.31 (3.78, 4.91) 1.00 4.30 (3.77, 4.89) 1.00
σε 2.18 (2.02, 2.36) 1.00 2.18 (2.02, 2.36) 1.00
DIC -2931.6 -3255.5; -2616.9 -2665.4 -2975.3; -2400.6
Model W PH
Parameter Mean CI Pr > 0
β0 3.51 (2.40, 4.60) 1.00
β1 -0.15 (-0.34, 0.04) 0.06
β2 -6.10 (-7.51, -4.69) 0.00
β3 -1.45 (-2.01, -0.87) 0.00
α0,1 2.70 (2.03, 3.56) 1.00
α1,1 -0.11 (-0.58, 0.34) 0.33
α0,2 5.04 (3.55, 6.90) 1.00
α1,2 0.16 (-0.48, 0.75) 0.69
θ1 -0.05 (-0.12, 0.02) 0.08
θ2 0.01 (-0.07, 0.10) 0.64
γ1 0.76 (0.64, 0.88) 1.00
γ2 0.51 (0.38, 0.64) 1.00
σU 4.43 (3.88, 5.06) 1.00
σε 2.05 (1.87, 2.25) 1.00
DIC -1074.5 -1098.2; -1053.8
Table 3.2: Posterior Mean (Mean), 95% Credible Interval (CI), and probability the estimate was
greater than 0 (Pr > 0) for the ACC data using Model W. The bottom row contains the average
Deviance Information Criteria (DIC) under Mean and the 2.5% and 97.5% quantiles under CI.
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Model α0,1 α1,1 α0,2 α1,2 θ1 θ2 γ1 γ2
W 1.5 0.1 3.1 -0.1 0.05 -0.2 0.8 0.5
L 0.7 -0.02 1.9 0.2 0.1 -0.12 1.5 2.7
Table 3.3: True parameter values used to generate competing risks survival data for simulation
study.
For Model W we have β0 = 2.4, β1 = −0.1, β2 = −5.1, β3 = −1. For Model L we have β0 = 2,
β1 = −0.02, β2 = −4.2, β3 = −1.7.
We generate competing risks survival data with K = 2 risks. We do this once assuming Model
W is the truth and then assuming Model L is the truth. For each subject µik is calculated as follows
for each Model.
Model W: µik = exp(α0k + α1kX2i + θkU0i)
Model L: µik = α0k + α1kX2i + θkU0i
A survival time for each risk (k = 1, 2) is drawn from a Weibull or log-Normal distribution.
Model W: T ∗ik ∼Weibull(µik, γk)
Model L: T ∗ik ∼ logN(µik, γ2k)
True parameter values for the survival data generation are shown in Table 3.3. An independent
censoring time is drawn from a uniform distribution T ∗i,0 ∼ Unif(0, 7). The observed time is the




i,2). We keep the longitudinal outcome Yij for a subject if τj < Ti
and we drop all other Yij . Models were fit using Stan via R with four chains with 57500 warm-up
iterations and 60000 iterations total. We generated 200 datasets for each combination of Model
(W or L) and N (160 or 1000) and fit the model on each dataset.
3.5.1 Results
Simulation results are shown in Tables 3.4 and 3.5. The table includes the average of the posterior
means (Mean) for the estimate from the 200 generated datasets. We also show the bias and Mean
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squared error (MSE) of these estimates multiplied by 1000. Finally we list the coverage probability
which is the percent of credible intervals from the 200 dataset fits that include the true value.
We see similarities between each model (Models W and L) and for each N. Bias and MSE are
generally small in each model and bias and MSE are reduced with the larger sample size, N=1000.
The parameters with the largest biases and MSEs are the longitudinal intercept (β0) and the X1
coefficient (β2). In the survival models, parameters related to the second event type, specifically
α0,2, α1,2 and γ2, tend to have larger bias and MSE than corresponding parameters for event type 1.
This is likely from a smaller number of events of type 2 observed in the data. Coverage probabilities
are generally close to 95. The few parameters that have a lower coverage probability in the N=160
case, β0, β2, and γ2 in Model L, have better coverage for N = 1000. Data was generated for two
other simulation scenarios with different true parameter values. Results for those scenarios are
similar to the results discussed here and are shown Tables D.1, D.2, D.3 and D.4 in the Appendix.
65
True surv. N Param True Value Mean Bias*1000 MSE*1000 CP
Weibull 160 β0 2.4 2.09 -313 300 89
(Model W) β1 -0.1 -0.11 -6 3 98
β2 -5.1 -4.53 575 633 87
β3 -1.0 -0.96 38 53 94
σU 4.0 3.95 -53 59 95
σε 2.2 2.20 -1 2 96
α0,1 1.5 1.52 18 31 98
α1,1 0.1 0.11 7 11 96
α0,2 3.1 3.00 -99 165 96
α1,2 -0.1 -0.06 35 43 96
θ1 0.05 0.06 5 2 94
θ2 -0.2 -0.19 14 7 96
γ1 0.8 0.81 7 6 96
γ2 0.5 0.53 32 5 95
Weibull 1000 β0 2.4 2.34 -56 43 93
(Model W) β1 -0.1 -0.10 -2 1 95
β2 -5.1 -4.99 107 77 92
β3 -1.0 -1.00 3 7 96
σU 4.0 4.00 -4 9 95
σε 2.2 2.20 -1 0 95
α0,1 1.5 1.51 6 5 94
α1,1 0.1 0.10 2 2 95
α0,2 3.1 3.09 -7 44 92
α1,2 -0.1 -0.10 -1 8 95
θ1 0.05 0.05 1 0 95
θ2 -0.2 -0.19 6 1 95
γ1 0.8 0.80 0 1 92
γ2 0.5 0.50 5 1 94
Table 3.4: Simulation results for data generated with Model W as the truth. Data was generated
for either N=160 (top) or N=1000 (bottom). Data was generated 200 times. For each parameter
the results include the mean of the 200 posterior means, the bias*1000, the mean squared error
(MSE)*1000, and the coverage probability (CP).
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True surv. N Param True Value Mean Bias*1000 MSE*1000 CP
log-Normal 160 β0 2.0 1.69 -313 266 92
(Model L) β1 -0.02 -0.01 9 5 97
β2 -4.2 -3.64 555 595 87
β3 -1.7 -1.69 14 47 94
σU 4.0 3.99 -9 56 96
σε 2.2 2.20 2 2 98
α0,1 0.7 0.72 24 23 97
α1,1 -0.02 -0.02 -1 12 95
α0,2 1.9 1.81 -88 114 96
α1,2 0.2 0.18 -20 41 93
θ1 0.1 0.10 -2 2 95
θ2 -0.12 -0.12 -3 7 93
γ1 1.5 1.50 -1 13 96
γ2 2.7 2.56 -135 95 88
log-Normal 1000 β0 2.0 1.95 -55 38 95
(Model L) β1 -0.02 -0.02 -2 1 93
β2 -4.2 -4.06 137 83 92
β3 -1.7 -1.68 21 8 93
σU 4.0 4.00 -2 10 94
σε 2.2 2.20 -1 0 97
α0,1 0.7 0.71 5 4 98
α1,1 -0.02 -0.02 3 2 96
α0,2 1.9 1.87 -35 28 93
α1,2 0.2 0.20 -5 5 97
θ1 0.1 0.10 0 0 94
θ2 -0.12 -0.12 4 1 94
γ1 1.5 1.50 1 2 97
γ2 2.7 2.67 -27 16 93
Table 3.5: Simulation results for data generated with Model L as the truth. Data was generated
for either N=160 (top) or N=1000 (bottom). Data was generated 200 times. For each parameter
the results include the mean of the 200 posterior means, the bias*1000, the mean squared error
(MSE)*1000, and the coverage probability (CP).
3.6 Dynamic Prediction
We model our approach to dynamic prediction based on that used by Andrinopoulou and col-
leagues (Andrinopoulou et al. (2017)). For a new subject l, denote the set of subject l’s longitudinal
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measurements up until time s as Yl(s). The subject has baseline covariate data Xl and Wl. Let
O be the data on which the model was originally fit, O = {Yi, Ti, Di, Xi,Wi | i = 1, ..., N}. We
are interested in the probability of subject l experiencing an event of cause k before time t after
surviving event-free up until time s (s < t). We denote this probability as πl,k(s, t).
πl,k(s, t) = Pr(Tlk < t | Tl > s,Yl(s), Xl,Wl,O) (3.9)




Pr(Tlk < t | Tl > s,Yl(s), Xl,Wl,Ω)p(Ω | O) dΩ (3.10)
The first part of the integrand in (3.10) can be written in terms of the overall survival function S(t)




Pr(Tlk < t | Tl > s,Yl(s), Xl,Wl,Ω)
=
∫
Pr(Tlk < t | Tl > s,Yl(s), Xl,Wl,Ω, Ul)p(Ul | Tl > s,Yl(s), Xl,Wl,Ω)dUl
=
∫
Pr(Tlk < t | Tl > s,Wl,Ω, Ul)p(Ul | Tl > s,Yl(s), Xl,Wl,Ω)dUl
=
∫
Pr(Tlk < t, Tl > s |Wl,Ω, Ul)
Pr(Tl > s |Wl,Ω, Ul)
p(Ul | Tl > s,Yl(s), Xl,Wl,Ω)dUl
=
∫
CIF (s, t, k |Wl,Ω, Ul)
S(s |Wl,Ω, Ul)
p(Ul | Tl > s,Yl(s), Xl,Wl,Ω)dUl
Since the longitudinal and survival outcomes are assumed independent given Ul, we have
p(Ul | Tl > s,Yl(s), Xl,Wl,Ω) ∝ p(Yl(s), Tl > s | Ul, Xl,Wl,Ω)p(Ul | Xl,Wl,Ω)
= p(Yl(s) | Ul, Xl,Wl,Ω)p(Tl > s | Ul, Xl,Wl,Ω)p(Ul | Xl,Wl,Ω)
= p(Yl(s) | Ul, Xl,Ω)S(s | Ul,Wl,Ω)p(Ul | Ω)
Here p(Yl(s) | Ul, Xl,Ω) is the likelihood for Yl, S(s | Ul,Wl,Ω) is the overall survival function,
and p(Ul | Ω) is the prior for Ul. We assumed that given Ul the latent failure times are independent
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so the overall survival function is simply the product of the cause-specific survival functions which
are defined in Section 3.3.2, i.e. S(s | Ul,Wl,Ω) =
∏K
k=1 Sk(s | Ul,Wl,Ω). The longitudinal
measurements for a single subject at different times are also independent given the random effect
so p(Yl(s) | Ul, Xl,Ω) =
∏
{j:τlj≤s} p(Ylj | Ul, Xl,Ω). Therefore,
πl,k(s, t) =
∫
Pr(Tlk < t | Tl > s,Yl(s), Xl,Wl,Ω)p(Ω | O) dΩ
=
∫ ∫
CIF (t, s, k |Wl,Ω, Ul)
S(s |Wl,Ω, Ul)
p(Ul | Tl > s,Yl(s), Xl,Wl,Ω)p(Ω | O) dUldΩ
∝
∫ ∫




p(Ylm | Ul, Xl,Ω)
K∏
k=1
Sk(s | Ul,Wl,Ω)p(Ul | Ω) dUldΩ
The probability of interest πl,k(s, t) can be estimated using a Monte Carlo simulation scheme with
the following three steps iterated B times. At iteration b (b = 1, ..., B),
1. Draw Ω(b) from the MCMC sample of the posterior p(Ω|O).




















2. Draw U (b)l from p(Ul|Ω(b)) using a Metropolis-Hastings algorithm as follows. Let






Sk(s | U,Wl,Ω)p(U | Ω)













• Draw A from a Uniform(0, 1) distribution
• If A < a, set U (b)l = U
∗. Otherwise set U (b)l = U
(b−1)
l













The CIF is estimated empirically with this empirical estimate denoted ĈIF . Note that
CIF (s, t, k) is the probability of having an event of type k before time t given no event up
to time s (s < t). We describe this for K = 2 risks, but the method can be easily extended
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for any K. At iteration b, we have parameter estimates Ω(b) including γ(b)1 and γ
(b)
2 and we
can calculate µ(b)l1 and µ
(b)
l2 as in (3.4) or (3.6) depending on the model chosen.





















We draw random variables R[m]1 and R
[m]
2 for m = 1, ...,M from the following survival










2 ). In Model





























































Here Ind(·) is the indicator function. The sum in Equation (3.11) counts how many of theM
simulated subjects survive until time s and have an event of type 1 before time t and before
an event of type 2. Equation (3.12) is similar except for an event of type 2 occurring first.
Steps 1-3 are repeated B times and the overall estimate of πl,k(s, t) defined in (3.9) is the mean of













In order to demonstrate our dynamic predictions, we simulated data with covariate effects stronger
than in the ACC data. We simulated data as in Section 3.5 but with the following true values:
β = (3,−1,−5,−2)T , σU = 4, σε = 2, α1 = c(1,−2)T , α2 = (3,−3)T , γ = (0.75, 0.5)T ,
θ = (1,−1)T . We simulated data for 1000 subjects with Weibull survival times and fit Model W.
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Data for three new subjects was then generated. Subject 1 had X1 = 0 and X2 = −0.08,
Subject 2 had X1 = 1 and X2 = −1.31, and Subject 3 had X1 = 0 and X2 = −0.36. Subjects
1 and 2 had a progression at 0.38 and 1.28 years, respectively, while Subject 3 had a regression at
0.93 years. The longitudinal Y values generated for each subject are shown in Figure 3.2. Each
subject has an increase in Y prior to the event. Subject 2 has the largest range of Y values and
Subject 3 has overall much higher values of Y than the other two new subjects.
Figure 3.2: Longitudinal measurements over time for new subjects. Vertical line indicates the
simulated event time with a solid red line corresponding to a progression and a dashed blue line
corresponding to a regression.
At the time of each of a patient’s longitudinal measurements τij we calculated the estimated
probability in (3.13) of experiencing either a progression or death given event-free survival up until
time τij , i.e. π̂l,k(τij, t), k = 1, 2. We calculated this for every 0.05 years up to 3 years, meaning
for t = 0, 0.05, 0.1, 0.15, ..., 3 if t > τij . We used B = 200 iterations to estimate the probabilities
and M = 200 random variables for the empirical estimation of the CIF. Since we generated the
data according to Model W, we show predictions only from the Weibull model. Figure 3.3 shows
the estimated probabilities π̂l,k(τij, t) over time t. We plotted only up to a short time after the
last longitudinal measurement, specifically 0.5 years for Subject 1, 1.75 years for Subject 2 and
1.5 years for Subject 3. Note that while theoretically a CIF curve will be monotonically non-
decreasing, our estimated CIF curves may have some small decreases due to the empirical nature
of our estimate.
Predictions for Subject 1 interestingly start with almost no probability of either event but then
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(a) New Subject 1
(b) New Subject 2
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(c) New Subject 3
Figure 3.3: Dynamic predictions for new patients from Model W. The solid red curve is the
probability of progression (π̂l,1(τij, t)) and the dashed blue line is the probability of regression
(π̂l,2(τij, t)). The solid vertical line indicates the time of the last longitudinal measurement used to
predict (τij) and the dashed vertical line is at the observed event time in our data.
predicts a higher chance of regression after a decrease in Y . At scans 2 and 3 new subject 1’s Y
increases and so we see a small increase in the probability of progression. Subject 2 initially has a
much higher chance of progression but after scan 2 regression has a higher probability until scan
6. Subject 3 starts with a high Y value and has a higher predicted probability of regression from
scans 1 to 6. Model W predicts very little probability of either event for the last four scans for
Subject 2 and the last scan for Subject 3 but we do not see the same flattening of both curves for
Subject 1 who has an event earlier than the other two new subjects.
3.7 Discussion
This chapter proposes the joint modeling of longitudinal and competing risks data using para-
metric distributions for the survival submodel. The Bayesian approach is natural in this context as
it exploits the hierarchical structure of the modeling framework and offers an efficient solution in
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a situation that is often numerically challenging. We developed survival submodels using Weibull
and log-Normal distributions and described how these joint models can be utilized for dynamic
prediction. Our models were used to model data from the study of adrenocortical carcinoma and
found results with similar interpretations for both the Weibull and log-Normal models. Comparing
our models to a cause-specific proportional hazards model we found similar results for the longitu-
dinal submodel parameters and most of the covariate effects in the survival submodels. But the PH
model estimated the association parameters to have the opposite signs as our models. In all cases
the association was small (θk was close to zero). While in our models these association parameters
measure the effect of deviations of the LPMA from the mean on the survival time distribution, in
the PH model these parameters change the hazard function and the opposite signs can be explained
by this difference in parameterization. Our simulation results show small bias and MSE with good
coverage even for the relatively small sample size of 160.
Parametric survival submodels can be construed as parsimonious alternatives to the oft-used
cause-specific PH formulation. Indeed the Weibull model considered in this article conforms to
the cause-specific semi-parametric PH structure. Parametric modeling allows further flexibility by
allowing non-PH formulation (e.g. log-Normal) or the possibility of formulating regression of the
scale parameters.
In Section 3.2 we assumed that the random effects in the longitudinal and competing risks
submodels were the same (Vi = Ui). This was done for the sake of simplicity but it could be
considered a strong assumption. We could instead assume that these are only correlated, for ex-
ample with a multivariate normal distribution, i.e. (Vi, Ui)T ∼MVN(0,Σ). Additionally we used
only a random subject-specific intercept but instead could have included additional random effects
like a random slope. These options can be more flexible but also require estimation of additional
parameters.
Although the current article focuses on a linear model for the longitudinal component, aligning
it closer to the motivating data, it is apparent that the methodology will work in principle for
scenarios where the longitudinal observations stem from generalized linear models (e.g. binary
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or count data). Perhaps a more significant extension to the current discourse lies in the treatment
of recurrent events, research on which is still developing in the joint modeling context (Han et al.
(2007); Kim et al. (2012); Król et al. (2016); Cai et al. (2017); Ren et al. (2019)).
In analyzing competing causes of mortality, sometimes one may encounter missingness in the
documentation of the exact cause. Such a phenomenon, commonly referred to as masking, has
applications in the analysis of registry data or investigation of the failure pattern of complex multi-
component industrial systems (Basu et al. (1999, 2003); Mukhopadhyay and Basu (2007); Sen et al.
(2010); Bakoyannis et al. (2010); shou Ko (2019)). Bayesian framework is particularly useful in
this case as it avoids imposing non-testable assumptions on the probability of missingness. The
modeling framework we have proposed here can easily adapt to the masked data case.
A natural extension of the work proposed here is the incorporation of dependence among the
risk components. Such dependence can be induced through a frailty or Copula structure. Of course,
one has to be cognizant of the potential non-identifiability that can generate from the dependent
models. Inclusion of covariates comes to the rescue as subject level heterogeneity enables sep-
aration of information across different risk components. Study of such dependence modeling is
considered in the next chapter.
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Chapter 4
Bayesian Inference for Joint Models Under
Dependent Competing Risks
4.1 Introduction
In classical competing risks models the causes of failure are assumed stochastically indepen-
dent (Carrière, 1995) but in some cases it can be unreasonable to assume such independence. This
is especially true in medical studies where the risks may be causes of death or diagnosis of disease
in a patient with complicated health. An example of possibly dependent risks are death without
tumor, death from other causes with tumor, and death from tumor in the data described by Craiu
and Reiser (2006). The cause-specific hazards are identifiable but such models cannot estimate
dependence between the competing risks. Quantifying the dependence between these risks may be
of interest. This dependence can be modeled in different ways such as through frailties (Hougaard,
1986) or copula models (Genest and Nešlehová, 2006). Copula models define the joint distribu-
tion using a function of the marginal distributions of multiple random variables. A copula can
also be defined in terms of the survival functions. If T1, ..., TK are continuous random variables
with marginal survival functions S1, .., SK and joint survival function S, a survival copula C is a
function such that
S(t1, ..., tK) = C (S1(t1), ..., SK(tK))
Copula models allow for flexibility in the choice of margins and provide a way to qualify the de-
pendence nature of a continuous random vector in terms of the underlying copula (Genest and
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Nešlehová, 2006). Copulas have been utilized in the competing risks setting without joint lon-
gitudinal data. Lo and Wilke (2010) examines Archimedean copula model for three competing
risks. Shih and Emura (2018) used the FGM (Farlie-Gumbel-Morgenstern) copula with Burr III
marginals for competing risks data. Wu et al. (2017) used a Gumbel copula model in a compet-
ing risks setting which has a similar form to our copula model in Section 4.2 and with marginals
similar to our Weibull model described in Section 4.3.
The desire to measure the dependence between risks motivates the use of a copula model for
the competing risks part of our joint model. In Section 4.2 we describe the multivariate survival
function based on an copula model that we will focus on in this work. We consider the competing
risks data in a latent failure time framework. Competing risks models in this framework can suffer
from identifiability issues. We discuss why the parameters of our models are identifiable in Section
4.2.2.
An additional reason to stray from the common cause-specific Cox-type competing risks model
is that the data may not conform to the proportional hazards assumption. Accelerated failure
time models have been used (Tseng et al., 2005; Hanson et al., 2011). Another option is to use
parametric survival models. As discussed in the last chapter, parametric models can be more
parsimonious than a proportional hazards model which often uses a piece-wise baseline hazard
function (Furgal et al., 2019). In Section 4.3 we lay out the framework for our joint model. We use
Weibull cumulative hazard functions as a specific case of the general copula model from Section
4.2. We use Bayesian Hamiltonian Monte Carlo to estimate the parameters in our model and
describe the Bayesian estimation in Section 4.4.
Our competing risks submodel includes a parameter δ that measures the strength of the depen-
dence between the causes of failure. In theory, this parameter can take a value in (0, 1] where δ = 1
reduces to a model with independent risks. Since our Bayesian model described in Section 4.4 puts
a Beta prior on δ we also test for the case when δ = 1 using Bayes factors. This is described in
Section 4.5.
We apply our models to the ACC data in Section 4.6. We then evaluate our models via simula-
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tion in Section 4.7. Section 4.8 concludes with a discussion.
4.2 Formulation of Dependence
We will develop our models for the competing risks data under a latent failure time framework
similar to the previous chapter. We assume that each subject i (i = 1, ..., N ) theoretically has an
event time for each of the K ≥ 2 risks. Let T ∗ik be the event time for subject i caused by risk k
(i = 1, ..., N , k = 1, ..., K). Subjects may also be independently censored and we will call the
censoring time T ∗i0. We only observe the minimum of these event times. Denote the observed time





We will assume that the latent failure times have a joint survival function S(t1, ..., tK) with the
form in (4.1). This is a valid survival function for any arbitrary cumulative hazard functions Hk(t)
(k = 1, ..., K) and with 0 < δ ≤ 1. (See Appendix H.2 for proof.)











The multivariate survival function in (4.1) is similar to or an extension of models studied over
the years (Hougaard, 1986; Lu and Bhattacharyya, 1990, 1991; Wang and Ghosh, 2000; Wang,
2012; Schwarz et al., 2013). Lu and Bhattacharyya (1990) motivate the bivariate version from the
association between two component liftetimes with some common environmental stress. Another
reason for using this survival function is the relative ease with which we can simulate data follow-
ing that distribution. This is because random variables with the joint survival function in (4.1) can
be written in terms of independent variables. This is discussed in Section 4.2.1.
The parameter δ measures the strength of the dependence between the latent failure times.
Wang (2012) shows that for a version of the joint survival model above, Kendall’s tau is equal to
1− δ. Therefore δ = 1 the model reduces to an independent failure time case.
If we use the relationship between the cumulative hazard and survival functions, Hk(tk) =
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− log(Sk(tk)), we can rewrite (4.1) as










We see that this is an Archimedean survival copula with generatorψ(t) = exp(−tδ). An Archimedean
survival copula is of the form S(t1, ..., tK) = ψ (ψ−1 (S1(t1)) + ...+ ψ−1 (SK(tK))) for some gen-
erator function ψ : [0,∞) → [0, 1] where ψ(0) = 1, ψ(t) → 0 as t → ∞, and ψ is K-monotone
(Genest and Nešlehová, 2006; Jia, 2018). Archimedean copulas have become popular in applica-
tions in biostatistics (Tao et al., 2013; Suresh et al., 2019), insurance and finance (Savu and Trede,
2010; Li and Lu, 2019), engineering (Singh and Zhang, 2007; Fenech et al., 2015), and other
fields (Zhang et al., 2012; Ayantobo et al., 2019) because of their simple form and connections
to frailty models. Specifically, if the generator ψ is completely monotone, then the copula can be
interpreted as the survival copula with lifetimes following a multiplicative hazard model with a
frailty Z and ψ is the Laplace transform of Z (Genest and Nešlehová, 2006). Any Archimedean
copula C∗(u1, ..., uK) is symmetric (i.e. C∗(u1, u2) = C∗(u2, u1) for K = 2) and associative
(i.e. C∗(u1, ..., uK) = C∗(C∗(u1, .., uK−1), uK) = ... = C∗(C∗(...C∗(C∗(u1, u2), u3), ..., uk−1), uK))
meaning the dependence structure between all the random variables is the same (Lo and Wilke,
2010).
4.2.1 Representation Result
One reason for using the copula model in (4.1) is because of the relative ease with which we
can simulate data having this joint survival function. Lee (1979) proved that in the bivariate case
(i.e. K = 2) with Weibull marginal Hk functions, the dependent random variables T1 and T2 can
be represented in terms of independent variables V1 and V2, where V2 ∼ Beta(1, 1) and V1 is a
mixture of Γ(2, 1) and Γ(1, 1) variables. Here we extend this result for an arbitrary finite number of
dependent random variables K and for arbitrary cumulative hazard functions Hk for k = 1, ..., K.
Specifically we have the following result.
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Theorem 1 Let K random variables T1, ..., TK have joint survival function










with 0 < δ ≤ 1, and H1, ..., HK arbitrary cumulative hazard functions.
Let Zk = Hk(Tk)
1








Then V1, ..., VK are independent with the following distributions: V2 ∼ Beta(1, 1), ..., VK ∼
Beta(K − 1, 1) and V1 is a mixture of the Gamma distributions Γ(K, 1), Γ(K − 1, 1), ..., Γ(2, 1),







K−1 + (−1)K−(K−1)aK,K−1vK−2 + ...
+ (−1)K−kaK,kvk−1 + ...
+ (−1)K−2aK,2v + (−1)K−1aK,1
)
where Γ(k) is the Gamma function, i.e. Γ(k) =
∫∞
0




aK,1 = (δ − (K − 1))aK−1,1;
aK,k = (kδ − (K − 1))aK−1,k + δaK−1,k−1, for 2 ≤ k ≤ K − 1.
The proof of this theorem is in Appendix H.
This can be used to simulate data by first drawing the independent V1, ..., VK which is very
simple for V2, ..., VK and relatively easy for V1. We can then calculate the Zk given the following
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relationships,
Z1 = V2 · · · VKV 1/δ1
Z2 = (1− V2)V3 · · · VKV 1/δ1
Z3 = (1− V3)V4 · · · VKV 1/δ1
...
ZK = (1− VK)V 1/δ1




k). Since theHk are cumulative hazard functions,
the inverse function H−1k exists.
4.2.2 Competing Risks and Identifiability
While there are several nice properties of the survival copula in (4.1) and the representation from
Section 4.2.1 allows for easy simulation, there may be concerns about identifiability. It is well
known that Tsiatis showed competing risks models in a latent failure time framework are not iden-
tifiable with the identified minimum alone (Tsiatis, 1975). Specifically given any joint distribution
for latent failure times there exists a distribution with independent failure times that gives the same
identified minimum distribution (Heckman and Honorè, 1989). Heckman and Honorè demonstrate
conditions under which including covariates as regressors circumvents non-identifiability for pro-
portional hazards and accelerated failure time models. Zheng and Klein (1995) established that if
the form of the copula is known, the marginal survival functions are identifiable from the identified
minimum in the bivariate case and Carrière (1995) extended this to the case with more than two
competing risks.
We chose to estimate using a Bayesian approach. Bayesian methods using both informative
and non-informative priors are discussed by Wang and Ghosh (2000). While Heckman and Honorè
prove identifiability for models of a certain form with a continuous covariate, Wang et al. (2015)
provide conditions for identifiability in bivariate frailty models related to Achrimedean copulas
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given a possibly discrete covariate. Escarela and Carrière (2003) also discuss bivariate competing
risks models using an Archimedean copula and they propose using a fully parametric model with an
assumed copula. Wang (2014) shows that assuming an Archimedean copula model, the marginal
survival functions of dependent survival times are functionals of the Archimedean copula and
therefore can be estimated. Also if one of the marginal functions is known, the joint survival
function can be determined for many common families of Acrhimedean copulas.
In Section 4.3 we lay out the framework for our joint model. The survival submodels are based
on the Archimedean copula model in (4.1) and we include a regression model with a continuous
covariate. Given the results above, our the parameters in our model will be identifiable.
4.3 Framework
Assume we have N subjects and subject i has Ji ≥ 1 longitudinal measurements for i =
1, ..., N . The observation times for subject i are τij for j = 1, ..., Ji with the longitudinal mea-
surement at τij denoted Yij . We will write the vector of longitudinal measurements as Yi =
(Yi1, ..., YiJi)
T for subject i. For the competing risks data, each subject can have an event with
one of K ≥ 2 causes or may be right-censored. Denote the observed event time for subject i as Ti.
We also have an event indicator matrix Di = (Di1, ..., Dik, ..., DiK)T where Dik = 1 if subject i
had an event with cause k (k = 1, ..., K) andDik = 0 otherwise. At most one of theDi1, ..., DiK is
equal to one; all Dik will be 0 if the subject is censored. In addition we have covariate information.
In the longitudinal model denote the covariate matrix by Xij for subject i and it may depend on
time j. We assume if these covariates depend on time they are exogenous (Rizopoulos, 2012, p.44).
In the survival submodel let Wi be the covariate matrix which we assume is time-independent for
simplicity. Theoretically Wi could depend on the event type k but again for simplicity we assume
it is independent of k. The Xij and Wi may but do not have to share covariates. Assume we have p
covariates in the longitudinal model and q in the survival model. Therefore Xij is a Ji × p matrix
and Wi is a q-vector.
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4.3.1 Longitudinal Submodel
We assume our longitudinal outcome Yi is continuous and normally distributed. Hence we use
a linear mixed effects model. Extension to a generalized linear mixed effects model for non-
Gaussian outcomes is straightforward. We have subject-specific random effects denoted Ui with
design matrix Ri, a p-vector of regression parameters β and random measurement errors εij . Let
εij ∼ N(0, σ2ε ) and εi = (εi1, ..., εiJi)T .
Yi = Xiβ +RiUi + εi (4.2)
Assume that the longitudinal measurements are independent given the random effects, i.e. Yi ⊥
Yl|Ui, Ul, i 6= l.
4.3.2 Competing Risks Survival Submodels
We will consider a specific case of (4.1) with cumulative hazard functions based on the common
parametric survival function Weibull. The Weibull distribution is part of the log-location-scale
family of distributions. This family has often been used to describe lifetimes (Hong et al., 2015).
The cumulative distribution function (CDF) for distributions in this family can be written in the





. Here µ is called the location parameter and γ the scale parameter.
Φ∗ is the standard CDF for the distribution (location = 0, scale = 1). We also chose to examine
this distribution since Weibull is both a proportional hazards as well as an accelerated failure time
model.
Define Hk(t) = µktγk giving us the following joint survival function.
















We put a regression model on the µk parameters.
log(µk) = Wiαk + θ
T
k Ui
Here Wi is a vector of covariates, Ui is the same random effect as in the longitudinal model in
(4.2), and θk measures the association between the longitudinal and survival data. Although we are
considering a regression model on the location parameter µk, it possible to instead or additionally
put a regression model on scale parameter γk or dependence parameter δ.
4.4 Bayesian Model and Estimation
We chose to estimate the parameters of our model with Bayesian techniques since this can be
less computationally intensive than frequentist techniques which often require an EM algorithm.
Additionally Bayesian models can account for additional variability. Fitting can be aided by incor-
porating any prior knowledge into the priors on the parameters.
We will use a random intercept only so Ri = 1, i = 1, ..., N and we will write Ui as U0i to
make clear the random effect is a scalar and θk is also a scalar. We assume U0i ∼ N(0, σ2U). For
our Bayesian model we put priors on our parameters.
β ∼MVN(mβ, s2βIp)






Since δ can be equal to 1, we will test for this case which is discussed in Section 4.5.
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4.4.1 Likelihood and Posterior
Let Ω = (β, σU , σε, α1, ..., αK , θ1, ..., θK , γ1, ..., γK , δ)T be the vector of parameters. The posterior,
p(Ω|Y, T,D,X,W ), is proportional to the product of the likelihood and priors. We write the
likelihood contribution from the longitudinal model as LY and from the survival model as LT . Let
p(Ω) denote the product of the prior density functions for the parameters in Ω.
p(Ω|Y, T,D,X,W,U) ∝ LYLTp(U |Ω)p(Ω)














(Yi −Xiβ − U0i)T (Yi −Xiβ − U0i)
}







hk(Ti|Di,k = 1,Wi, U0i, γk, αk, θk)Dik
)
·
S(Ti|Di,Wi, U0i, γ1, ..., γK , α1, ..., αK , θ1, ..., θK)
where hk and S are the cause-specific hazard function and joint survival function, respectively. We
will write the functions for K = 2 risks. With the Weibull marginals, these functions are




























Derivation of the hazard function hk is in Appendix B.4. Full conditionals are listed in Appendix
G.2. We fit our models using Hamiltonian Monte Carlo via Stan through the R package rstan
version 2.21.2 and using R version 4.0.4 (Guo et al., 2020).
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4.5 Testing for Independence
When introducing our general joint survival function in (4.1), we stated that the dependence
parameter δ could take any value in (0, 1]. Our Bayesian model in Section 4.4 puts a Beta prior
on δ which excludes the case when δ exactly equals 1, or the independent failure times case. We
therefore need to test whether the data supplies strong evidence for the δ = 1 case. To do this we
use a Bayes factor (Kass and Raftery, 1995).
Kass and Raftery state that Bayes factors can be used to evaluate the evidence in favor of a null
hypothesis. They explain Bayes factors as follows. We assume our data D arose under one of our
two hypotheses H0 and H1. The data have probability density Pr(D|H0) or Pr(D|H1) and the
hypotheses have a priori probabilities Pr(H0) and Pr(H1) = 1−Pr(H0). Posterior probabilities













which is called the Bayes factor.
In our situation the hypotheses are H0 : δ = 1 and H1 : 0 < δ < 1. We calculate the Bayes
factor with these two hypotheses using the bridgesampling R package (Gronau et al., 2020). To
do this we fit two Stan models to the data: (1) Model 1 as described in Section 4.4 assuming
δ is random and in (0, 1) and (2) Model 0 where δ is assumed fixed at 1. Documentation for
the bridgesampling package recommends running models that will be used for testing for more
iterations than are needed for only estimating the parameters. Therefore we run these models
for 50000 iterations after 10000 warm-up iterations. The log marginal likelihoods are calcu-
lated using the bridge_sampler function from the bridgesampling package which follows
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the bridge sampling described by Meng and Wong (Meng and Wong, 1996). Output from the
bridge_sampler is supplied to the bf function to calculate the Bayes factor. Kass and Raftery
say that the Bayes factor can be interpreted based on the following ranges. A Bayes factor of 1
to 3.2 is "not worth more than a bare mention", 3.2 to 10 is substantial, 10 to 100 is strong, and
greater than 100 is decisive evidence in favor ofH0.
4.6 Application to Adrenal Cancer Data
We apply our models to the 159 adrenocortical carcinoma (ACC) patients as in the previous
chapter. Again we define our competing risks outcome to be time until first disease status change
which can be either a progression or a regression. Death and loss to follow-up censor our out-
come. While in theory death may not be independent of disease state change we group deaths with
censoring events because there are very few patients that died before a progression or regression.
Data used are the same as described in Table 3.1. We fit our models to this data with a longitudi-
nal model for lean psoas muscle area (LPMA) (Y ) including a fixed time slope and covariates for
binary sex (X1, reference male) and (centered) age in decades (X2). In our survival submodel for
the observed event time Ti we included age as the only covariate.
Yi ∼ MVN
(
















with log(µik) = α0k + α1kX2i + θkU0i
(4.4)
Define β = (β0, β1, β2, β3)T and αk = (α0k, α1k)T for k = 1, 2. We set priors on the parameters as
in Section 4.4 with the following hyperparameters chosen so that our priors are weakly informative:
mβ = (1, 1, 1, 1)
T , sβ = 2, aU = aε = aγ = 3, bU = bε = bγ = 2, mα = (−1, 1)T , sα = 2,
mθ = (1,−1)T , sθ = 2, aδ = 1, and bδ = 1.
To test the sensitivity of the estimates for the δ parameter we also fit the model with different
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hyperparameters for the Beta prior. Priors for all other parameters were the same as above. We fit
four additional models. The Beta(0.03,0.07) and Beta(0.05,0.05) priors have density concentrated
near 0 and 1. The other two priors used are Beta(3,7) and Beta(5,5) and have densities centered
near 0.3 and 0.5. Figures 4.1 - 4.5 show histograms of the Beta priors.
As in the previous chapter, we fit the cause-specific proportional hazards (PH) model in 4.5
for comparison. A Weibull baseline hazard was used for simplicity. In this case the risks are
independent and so there is no δ parameter.
Yi ∼ N
(







T γk−1i exp (α1kX2i + θkU0i)
(4.5)
This model is fit in Stan with the same priors as in Section 4.4. The likelihood contributions have
the same form as in Section 4.4.1 with the survival functions below.
hk(Ti|Di,k = 1,Wi, Ui, γ1, γ2, α1, α2, θ1, θ2) =
γk
α0k
T γk−1i exp (α1kX2i + θkU0i)
















T γ1i exp (α1,1X2i + θ1U0i)−
1
α0,2
T γ2i exp (α1,2X2i + θ2U0i)
)
4.6.1 Results
Our models were fit using Stan with four chains with different initial values (see Appendix Section
F.2). The chains were run with 10000 warm-up iterations and an additional 1000 iterations after
warm-up. Trace plots are in Appendix F.3. Table 4.1 shows the results. We tested for δ = 1 as
described in Section 4.5 and found a Bayes factor of 1.62 in favor of H0 : δ = 1 over H1 : 0 <
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Parameter Mean CI Pr > 0
β0 3.45 (2.32, 4.50) 1.00
β1 -0.14 (-0.33, 0.05) 0.07
β2 -5.95 (-7.33, -4.52) 0.00
β3 -1.41 (-1.97, -0.85) 0.00
σU 4.31 (3.79, 4.89) 1.00
σε 2.04 (1.86, 2.24) 1.00
α0,1 -1.51 (-1.85, -1.20) 0.00
α1,1 0.05 (-0.12, 0.22) 0.74
α0,2 -1.98 (-2.53, -1.42) 0.00
α1,2 0.10 (-0.12, 0.32) 0.83
θ1 -0.04 (-0.11, 0.02) 0.12
θ2 0.00 (-0.07, 0.09) 0.53
γ1 0.74 (0.64, 0.85) 1.00
γ2 0.53 (0.41, 0.66) 1.00
δ 0.61 (0.14, 0.99) 1.00
DIC -1168.6 -1191.3; -1147.1
Table 4.1: Posterior Mean (Mean), 95% Credible Interval (CI) and probability the parameter is
greater than 0 (Pr > 0) for the model fit to the ACC data. The bottom row contains the mean and
2.5% and 97.5% quantiles for the DIC. Here aδ = 1 and bδ = 1.
δ < 1. This is not strong evidence in favor of δ = 1.
The results in Table 4.1 and show a slight negative time slope in the longitudinal model (β1).
The covariates were found to have significant negative coefficients with females and older patients
having lower LPMA measurements (β1, and β2, resp.). Age in the survival submodels (α1,1, α1,2)
had a small positive effect and the majority of estimates were greater than zero. We find a small
negative association between U0i and progression (θ1). There does not seem to be any association
between regression and U0i (θ2 ≈ 0). The model estimates δ to be about 0.6, although the credible
interval includes a large range of the possible values. The Bayes factor of 1.62 suggests that there
is no evidence for independence in this case.
Comparing to the model assuming independence in Chapter 3 (Table 3.2) we see that the results
for the longitudinal model (β, σU , σε) and the Weibull shapes (γ1, γ2) are very similar. Interestingly,
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when accounting for dependence between the risks in this chapter, we find different results for the
competing risks model than in Table 3.2. The estimates of α0,1 and α0,2 are much closer in value
than in the previous chapter. Here we find a small positive association for age for both progression
and regression (α1,1 and α1,2), resp.) Finally now the estimate for the association between U0i and
progression θ1 is negative. Since we found evidence in favor of dependence with the small Bayes
factor and δ estimate different from 1, we would argue that the dependence should be included in
the model.
Results for the models fit with different hyperparameters for the prior on δ are shown in Table
4.2, histograms of the estimates are shown in Figures 4.1 - 4.5 and trace plots are in Appendix
Figures F.7 - F.11. We see that the estimates for the parameters other than δ are consistent but the
estimates for δ differ depending on the prior. Figures 4.1 - 4.5 show that the posterior distributions
of θk are similar but not exactly the same as the priors. This suggests that the data does not supply
much information about δ. Based on DIC, the model with a Beta(5,5) has the best fit to the data.
Bayes factors for all models are in Table 4.3 and we see that there is not strong evidence for δ = 1
with any priors except Beta(0.03,0.07). The model with a Beta (0.03,0.07) has a Bayes factor of
5.23 which Kass and Raftery classify as substantial evidence in favor of δ = 1. Comparing DIC,
the model with a Beta(5,5) prior has the best fit to the data.
Table 4.4 shows the results for the cause-specific PH model. Estimates for the longitudinal
submodel parameters are similar to our model. The α0k parameters in the survival submodels
have different estimates but these are also included in each model differently and therefore are not
directly comparable. The α1k and θk parameters effect the µk in our models and effect the hazard
in the cause-specific PH model. Still we see similar estimates in our models and the cause-specific




Parameter Mean CI Pr > 0 Mean CI Pr > 0
β0 3.44 (2.35, 4.55) 1.00 3.47 (2.44, 4.57) 1.00
β1 -0.15 (-0.34, 0.04) 0.06 -0.15 (-0.32, 0.04) 0.06
β2 -5.94 (-7.33, -4.55) 0.00 -5.92 (-7.31, -4.61) 0.00
β3 -1.42 (-1.95, -0.86) 0.00 -1.42 (-1.96, -0.81) 0.00
σU 4.32 (3.80, 4.89) 1.00 4.31 (3.78, 4.91) 1.00
σε 2.04 (1.87, 2.23) 1.00 2.03 (1.85, 2.24) 1.00
α0,1 -1.68 (-1.95, -1.40) 0.00 -1.66 (-1.95, -1.35) 0.00
α1,1 0.04 (-0.14, 0.22) 0.68 0.05 (-0.13, 0.23) 0.69
α0,2 -2.32 (-2.72, -1.86) 0.00 -2.29 (-2.70, -1.68) 0.00
α1,2 0.12 (-0.14, 0.39) 0.82 0.12 (-0.14, 0.38) 0.83
θ1 -0.05 (-0.12, 0.02) 0.08 -0.05 (-0.12, 0.02) 0.08
θ2 0.02 (-0.07, 0.10) 0.66 0.02 (-0.07, 0.11) 0.62
γ1 0.75 (0.64, 0.88) 1.00 0.75 (0.64, 0.87) 1.00
γ2 0.52 (0.39, 0.66) 1.00 0.52 (0.39, 0.66) 1.00
δ 0.95 (0.51, 1.00) 1.00 0.92 (0.30, 1.00) 1.00
DIC -1169.1 -1192.4; -1148.1 -1168.0 -1190.6; -1146.7
Beta(3,7) Beta(5,5)
Parameter Mean CI Pr > 0 Mean CI Pr > 0
β0 3.43 (2.35, 4.49) 1.00 3.41 (2.37, 4.46) 1.00
β1 -0.14 (-0.33, 0.05) 0.07 -0.14 (-0.32, 0.05) 0.07
β2 -5.94 (-7.29, -4.55) 0.00 -5.93 (-7.26, -4.62) 0.00
β3 -1.40 (-1.98, -0.82) 0.00 -1.41 (-1.96, -0.83) 0.00
σU 4.31 (3.81, 4.91) 1.00 4.31 (3.80, 4.88) 1.00
σε 2.04 (1.87, 2.25) 1.00 2.04 (1.86, 2.24) 1.00
α0,1 -1.39 (-1.64, -1.16) 0.00 -1.46 (-1.72, -1.23) 0.00
α1,1 0.06 (-0.10, 0.22) 0.80 0.06 (-0.10, 0.21) 0.77
α0,2 -1.72 (-2.13, -1.39) 0.00 -1.90 (-2.31, -1.53) 0.00
α1,2 0.08 (-0.09, 0.25) 0.81 0.09 (-0.10, 0.29) 0.82
θ1 -0.04 (-0.10, 0.03) 0.13 -0.04 (-0.10, 0.03) 0.12
θ2 -0.01 (-0.07, 0.06) 0.43 0.00 (-0.07, 0.07) 0.52
γ1 0.72 (0.63, 0.82) 1.00 0.73 (0.63, 0.84) 1.00
γ2 0.55 (0.44, 0.67) 1.00 0.54 (0.42, 0.66) 1.00
δ 0.35 (0.13, 0.64) 1.00 0.51 (0.24, 0.80) 1.00
DIC -1171.4 -1193.6; -1150.3 -1173.5 -1197.1; -1152.0
Table 4.2: Results with different hyperparameters for delta. Posterior Mean (Mean), 95% Credible
Interval (CI) and probability the parameter is greater than 0 (Pr > 0) for the model fit to the ACC








Table 4.3: Bayes factors for models fit with differing priors on delta.
Parameter Mean CI Pr > 0
β0 3.42 (2.33, 4.45) 1.00
β1 -0.15 (-0.34, 0.03) 0.04
β2 -5.96 (-7.28, -4.56) 0.00
β3 -1.42 (-1.96, -0.85) 0.00
σU 4.32 (3.79, 4.93) 1.00
σε 2.04 (1.86, 2.24) 1.00
α0,1 4.97 (3.93, 6.22) 1.00
α1,1 0.05 (-0.14, 0.23) 0.68
α0,2 7.31 (5.75, 9.13) 1.00
α1,2 0.11 (-0.11, 0.32) 0.81
θ1 -0.05 (-0.12, 0.02) 0.07
θ2 0.01 (-0.07, 0.08) 0.57
γ1 0.73 (0.62, 0.85) 1.00
γ2 0.48 (0.36, 0.60) 1.00
δ NA NA NA
DIC -1183.8 -1207.4; -1163.3
Table 4.4: Posterior Mean (Mean), 95% Credible Interval (CI) and probability the parameter is
greater than 0 (Pr > 0) for the cause-specific proportional hazards model fit to the ACC data. The




















Figure 4.5: Prior (a) and estimates (b) from model fit with a Beta(5,5) prior.
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4.7 Simulations
We test our model with a simulation study by generating data to be similar to the ACC data. We
ran simulations for two sample sizesN = 160 as in the ACC data andN = 1000. Each subject has
two covariates a binaryX1i ∼ Bin(0.57) similar to sex, and continuousX2i ∼ N(0, 1.52) similar to
centered age in decades. We draw a random intercept U0i ∼ N(0, 4.32). We calculate longitudinal
measurements starting at time 0 and then every 0.125 years until 3 years, then every 0.5 years until
5 years and every 1 year until 8 years, so τ = (0, 0.125, 0.25, ..., 2.875, 3, 3.5, 4, 4.5, 5, 6, 7, 8)T .
These measurements times were chosen to increase the likelihood that subjects with a short event
time still have more than one observation and the time between observations increases to represent
that patients have less frequent scans as time since diagnosis increases. Random measurement
errors are drawn as εij ∼ N(0, 22) and the longitudinal outcome for subject i at time point j is
Yij = β0 + β1τj + β2X1i + β3X2i + U0i + εij
True values for β are set to be β0 = 3.4, β1 = −0.15, β2 = −6, β3 = −1.5.
For the competing risks data we generate times for K = 2 risks with Weibull marginals. We
calculate µik as
µik = exp(α0k + α1kX2i + θkU0i)
The true values used in the regression model are α1 = (−1.5, 0.1)T , α2 = (−2, 0.2)T , θ1 = −0.4,
θ2 = 0.5, γ1 = 0.75, and γ2 = 0.5. We also generate data for different levels of dependence with
δ = 0.5, 0.8, or 1.
In order to calculate the event times, we utilize the representation from the Theorem in Section
4.2.1. We can draw V2 ∼ Beta(1, 1) and independently draw V1 from a mixture of Γ(1, 1) and
Γ(2, 1) distributions with mixture proportion δ. We can calculateZ1 = V
1
δ




Then our dependent event times are Tk = H−1k (Z
δ
k), k = 1, 2 where the Hk is defined in Section
4.3 and derivations for the H−1k function is in Appendix B.5.
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We fit models as described in Section 4.4. Hyperparameters were the same as in Section 4.6.
We also tested for the δ = 1 case as detailed in Section 4.5 for 10 datasets. The small number of
datasets tested was due to the additional computational resources required.
4.7.1 Results
True Value N Param Mean Bias*1000 MSE*1000 CP N Param Mean Bias*1000 MSE*1000 CP
3.4 160 β0 3.19 -214 218 88 1000 β0 3.35 -53 31 92
-0.15 β1 -0.15 0 3 96 β1 -0.15 0 1 98
-6 β2 -5.76 237 193 86 β2 -5.96 43 22 95
-1.5 β3 -1.44 61 62 94 β3 -1.48 22 9 93
4.3 σU 4.22 -84 76 94 σU 4.28 -22 13 94
2 σε 2.00 1 1 94 σε 2.00 -1 0 93
0.1 α1,1 0.08 -20 21 92 α1,1 0.09 -11 3 94
0.2 α1,2 0.27 73 40 88 α1,2 0.21 11 4 92
-0.4 θ1 -0.45 -46 7 92 θ1 -0.41 -10 1 93
0.5 θ2 0.58 82 18 87 θ2 0.51 9 1 95
0.75 γ1 0.81 62 12 91 γ1 0.76 12 1 92
0.5 γ2 0.55 52 8 89 γ2 0.51 6 1 95
0.5 δ 0.55 54 26 98 δ 0.52 17 9 95
Table 4.5: Simulation results for data generated with δ = 0.5. Data was generated for either N=160
(left side) or N=1000 (right side). Data was generated 200 times. For each parameter the results
include the mean of the 200 posterior means, the bias*1000, the mean squared error (MSE)*1000,
and the coverage probability (CP).
We used Stan to fit the models with four chains each with 10000 burn-in iterations and 1000
additional iterations after burn-in. Tables 4.5, 4.6 and 4.7 show the results for δ = 0.5, δ = 0.8 and
δ = 1, respectively. Results from the boundary testing are shown in Table 4.8. Our results show
small bias and MSE for all parameters as well as good coverage for N = 160 and the results are
even better for N = 1000. We see similar results for the δ = 0.8 and δ = 1 cases. When testing for
independence, we find essentially no evidence for independence in the δ = 0.5 simulations since
the maximum Bayes factor value found was 2.37 with N = 160, below the threshold of 3.2 set by
Kass and Raftery (1995). In the δ = 0.8 case, some of the simulations found "substanial" evidence
of independence with a maximum Bayes factor of 5.45 with N = 160 and 9.17 with N = 1000
but the average Bayes factor value with N = 1000 was below the 3.2 threshold. In the δ = 1 case
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True Value N Param Mean Bias*1000 MSE*1000 CP N Param Mean Bias*1000 MSE*1000 CP
3.4 160 β0 3.16 -236 222 89 1000 β0 3.36 -44 30 94
-0.15 β1 -0.15 3 4 94 β1 -0.15 2 1 98
-6 β2 -5.73 266 224 86 β2 -5.97 30 21 98
-1.5 β3 -1.44 59 61 94 β3 -1.48 24 9 92
4.3 σU 4.21 -89 71 95 σU 4.28 -23 13 94
2 σε 2.00 1 2 94 σε 2.00 1 0 94
0.1 α1,1 0.08 -24 19 94 α1,1 0.10 -5 2 96
0.2 α1,2 0.25 45 30 94 α1,2 0.22 16 4 94
-0.4 θ1 -0.41 -13 5 96 θ1 -0.41 -7 1 95
0.5 θ2 0.54 39 11 90 θ2 0.51 9 1 96
0.75 γ1 0.78 34 7 96 γ1 0.76 10 1 96
0.5 γ2 0.54 40 7 92 γ2 0.51 8 1 96
0.8 δ 0.73 -72 26 98 δ 0.80 301 96 99
Table 4.6: Simulation results for data generated with δ = 0.8. Data was generated for either N=160
(left side) or N=1000 (right side). Data was generated 200 times. For each parameter the results
include the mean of the 200 posterior means, the bias*1000, the mean squared error (MSE)*1000,
and the coverage probability (CP).
we should find evidence for independence. We see that while some of the simulations did not find
evidence for independence with N = 160 (given the minimum Bayes factor of 1.05) the average
Bayes factor with N = 160 shows "substantial" evidence but the average with N = 1000 shows
"strong evidence" (Bayes factor of 10 to 100).
4.8 Discussion
In this chapter we propose jointly modeling longitudinal and competing risks data with survival
submodels from a multivariate copula. We explored a joint survival copula model with a general
structure and then in the specific cases with cumulative hazard functions from a Weibull distribu-
tion. This model is an alternative to the often used cause-specific proportional hazards models in
competing risks settings. We estimate via a Bayesian approach that makes use of the hierarchical
structure of the model. Bayesian techniques also allow us to incorporate prior information, if avail-
able, which can help alleviate some identifiability issues and are useful in joint modeling which
can be numerically challenging in a frequentist setting.
We examined performance of the models via a simulation study. Simulations showed generally
good performance even with a relatively small sample size of 160. Testing for independence with
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True Value N Param Mean Bias*1000 MSE*1000 CP N Param Mean Bias*1000 MSE*1000 CP
3.4 160 β0 3.14 -251 231 90 1000 β0 3.34 -60 35 92
-0.15 β1 -0.15 -1 4 93 β1 -0.15 0 1 94
-6 β2 -5.70 298 250 84 β2 -5.95 50 29 93
-1.5 β3 -1.44 64 59 94 β3 -1.47 23 10 92
4.3 σU 4.20 -101 76 94 σU 4.27 -28 13 90
2 σε 2.00 3 2 96 σε 2.00 -1 0 94
0.1 α1,1 0.09 -14 16 94 α1,1 0.09 -6 3 94
0.2 α1,2 0.24 44 28 94 α1,2 0.21 7 4 96
-0.4 θ1 -0.39 12 4 96 θ1 -0.39 8 1 94
0.5 θ2 0.51 15 9 92 θ2 0.49 -11 1 95
0.75 γ1 0.76 8 7 92 γ1 0.75 -2 1 96
0.5 γ2 0.54 35 7 92 γ2 0.50 2 1 96
1 δ 0.80 -196 48 NA δ 0.91 -90 10 NA
Table 4.7: Simulation results for data generated with δ = 1. Data was generated for either N=160
(left side) or N=1000 (right side). Data was generated 200 times. For each parameter the results
include the mean of the 200 posterior means, the bias*1000, the mean squared error (MSE)*1000,
and the coverage probability (CP). Note that coverage probabilities were not included for δ since
the model uses a Beta prior and so will not include the true value of 1.
N Mean Min Max N Mean Min Max
δ = 0.5 160 0.82 0.02 2.37 1000 0.02 0.00 0.09
δ = 0.8 160 3.30 0.05 5.45 1000 2.17 0.05 9.17
δ = 1 160 5.04 1.05 10.75 1000 11.45 3.32 22.12
Table 4.8: Simulation results Bayes factors testing δ = 1.
Bayes factors did show stronger evidence in favor of independence when δ = 1 as expected. We
also illustrated the technique by applying the joint model to the ACC data. We did not find a
significant association between the longitudinal LPMA and time to either disease state change but
there was evidence of dependence between the risks.
We explored the sensitivity of δ to the priors using the ACC data and found that the data may not
supply much information about the dependence parameter. In the simulations using the Beta(1,1)
prior we were able to accurately estimate the δ parameter when δ was 0.5 and 0.8 with small bias
and MSE. A larger bias was found when δ = 1. Additional sensitivity analyses to examine the
prior influence on δ in the simulations would be useful. The δ parameter may only be "weakly"
identifiable (Cao et al., 2013; Ho and Nguyen, 2016) and further study is needed.
We used Bayes Factors to test for independence between the competing risks, meaning δ = 1.
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The model we fit assumes that δ is actually between 0 and 1, not including 1. Another option
would be to allow δ to be exactly equal to 1 in the fitted model. This can be done by including
δ = 1 in the prior such as by using a spike-and-slab prior.
We applied our model with Weibull marginals. The Weibull distribution is a popular and simple
distribution which can be interpreted in both proportional hazards and accelerated failure time
form. Another option could be the log-Normal distribution which is popular in accelerated failure
time models. Both of these examples have ties to accelerated failure time models which are the
main alternative to the common proportional hazards models. Our model is developed such that
any cumulative hazard function could be substituted depending on the application. Also, while we
assumed that the cumulative hazard functions for each latent failure time were of the same form
with differing parameters, in theory we could use a different parametric form for each time. This
would complicate the likelihood derivation but adds flexibility.
In this work we considered the time to first disease progression or regression as a competing
risks endpoint. In fact, our motivating data from the ACC study includes more information on
disease states. Specifically, at each timepoint we know if the patient’s disease is stable, progressing
or regressing, as well as time of death or censoring. This is multistate data (Hougaard, 1999) and
incorporation of this type of data into joint models is beginning to be studied (Dantan et al., 2011;
Hu et al., 2012; Cai et al., 2017; Król et al., 2016; Ferrer et al., 2016; Mwanyekange et al., 2019;
Dessie et al., 2020). In addition, there are multiple longitudinal morphomics variables that were
measured at each scan. It is possible to incorporate more than one longitudinal submodel into a
joint model with a single survival endpoint (Hatfield et al., 2011; Tang and Tang, 2015; Hickey
et al., 2016; Mauff et al., 2020), competing risks (Andrinopoulou et al., 2013), or recurrent events
(Musoro et al., 2015). To the best of our knowledge combining both multiple longitudinal and
multi-state models has been explored only with a two-stage estimation technique (Alafchi et al.,
2021). The next chapter extends this model to a joint longitudinal and multistate model to fully
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understand the relationship between ACC disease and body morphomics.
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Chapter 5
Bayesian Joint Models for Multiple
Longitudinal Outcomes and Multi-State
Survival Data
5.1 Introduction
Our motivating data from adrenocortical carcinoma (ACC) patients at the University of Michi-
gan includes more information than has been utilized in our earlier chapters. To start, information
is available on disease states over time, more than just the time to first of progression or regres-
sion. We have information on whether the disease was stable, progressive or regressive at each
longitudinal timepoint as well as if the individual died or was censored. This falls into the category
of multistate data (Hougaard, 1999; Andersen and Keiding, 2002). Multi-state survival modeling
has recently been incorporated in joint models. Alafchi et al. (2021) developed a joint model for
multiple longitudinal processes and multi-state survival data which was estimated in two-stages.
Implementations which estimate using the full joint likelihood exclusively consider a single longi-
tudinal biomarker and generally use a proportional hazards format for the multistate hazards. This
includes Dantan et al. (2011) who modeled a longitudinal biomarker and an illness-death multi-
state model with latent state transitions. Ferrer et al. (2016) studied prostate cancer using a joint
linear mixed model and Markov multistate model. Dessie et al. (2020) studied viral load in HIV
patients with a similar model. Musoro et al. (2015) developed a joint model for two longitudinal
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biomarkers and two types of repeated events. Mwanyekange et al. (2019) describe a Bayesian joint
model for a single longitudinal process and a recurrent event with up to 3 recurrences plus a ter-
minal event using a Semi-Markov model. Other studies of joint models for a longitudinal process,
recurrent events and possibly a terminal event include Cai et al. (2017) using an accelerated failure
time model, Han et al. (2007) and Król et al. (2016).
In the ACC data multiple morphomics variables were repeatedly measured. These could be
related to the survival process in different ways and so it may be useful to include more than one
longitudinal outcome in the model. This has received some limited attention when joint modeling
with multistate data as described above. More work has been done on including multiple longi-
tudinal outcomes with a single survival time (Hatfield et al., 2011; Baghfalaki et al., 2014; Tang
and Tang, 2015; Musoro et al., 2015; Yang et al., 2016; Hickey et al., 2016; Long and Mills, 2018;
Mauff et al., 2020) and with a competing risks survival setting (Andrinopoulou et al., 2013, 2017).
We propose jointly modeling two longitudinal variables and the repeatedly measured multi-
state outcomes with a possible terminal event. We plan to use a joint survival function based on
the copula explored in 4 with parametric Weibull marginal survival functions to define the multi-
state survival information. Copulas have been explored in the multistate context by Rotolo et al.
(2013)and Diao and Cook (2014), for recurrent events by Huang et al. (2020) and Malehi et al.
(2015), and for semi-competing risks by Wu et al. (2020). To our knowledge there has been no
work including both multiple longitudinal outcomes and a multistate model derived from a cop-
ula. In this chapter we will develop a joint model based on the motivating study on adrenocortical
carcinoma first described in Section 1.5.
5.1.1 Motivating Study on Adrenocortical Carcinoma
The example timeline from Chapter 1 is replicated in Figure 5.1. Recall that each patient has an
initial scan and the state of disease at that scan is considered the reference state. It is determined
at the next scan whether the tumor did not change size significantly (stable), became larger (pro-
gressed) or became smaller (regressed). The latest disease state is then considered the reference
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state for the next scan and this continues for all the patient’s scans. The diagram in Figure 5.1
shows two scans before the end of follow-up, but this could be any number of scans. We also have
information on a terminal event, namely death. At the end of follow-up the patient may have died;
otherwise the patient would be censored.
Figure 5.1: Diagram of possible states over time in the adrenal cancer study.
Recall that twelve time-dependent morphomic variables were recorded at each scan listed in
Table 1.2 and described in Appendix A. As stated in Chapter 1, a previous study separately in-
vestigated the relationship between several morphomic variables and recurrence-free and overall
survival in ACC (Miller et al., 2012). The study found that psoas muscle density (PMD), lean psoas
muscle area (LPMA), and intra-abdominal (IA) fat had significant associations with the survival
outcomes.
Since the morphomic variables are measured from the scans, they will be subject to measure-
ment error. Therefore, a joint model for the longitudinal morphomic data and the survival data is
needed. We began with the simplest case in Chapter 2 and investigated the relationship between
a single morphomic variable, psoas density, and survival time using joint models within various
computational settings. In Chapters 3 and 4 we considered how the longitudinal and survival pro-
cesses are related when we incorporated the information on cancer progression. Specifically, we
treated the survival process as a competing risks problem. We investigated the relationship between
a single morphomic variable lean psoas muscle area (LPMA) and time to either first progression or
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death without progression. Those who have died without progression could have died from causes
other than their cancer. Analyzing the data as competing risks can help us learn about the relation-
ship between LPMA and worsening disease (progression) while accounting for the competing risk
of death not attributable to the disease. Finally here in Chapter 5 we will utilize more of the infor-
mation available via a multistate model. The data include recurrent events, from the declaration of
disease state at each scan, and these events can be one of multiple types (progression, regression,
or no event). We also have the terminal event of death. Further, we have multiple morphomic
variables and we would like to include more than one in our joint multistate model to examine
the relationship between the morphomics and disease state, while accounting for all aspects of the
data. We will do this with a joint model with two longitudinal outcomes and multistate survival
data.
5.2 Multi-state Survival Data
Assume we have N subjects indexed by i = 1, ..., N and R possible states. Subject i has Ki
state transitions. Let Dt denote the state at time t ≥ 0. The hazard function for going to state l
from state k at time t is defined in (Hougaard, 1999) (with slightly different notation here) as
λl|k(t | Du, u ∈ [0, t)) = lim
∆t↘0
Pr (Dt+∆t = l | Dt− = k,Ft−)
∆t
(5.1)





In the ACC data we have four possible states: (1) stable, (2) progressing, (3) regressing, and
(4) dead. State 4 (dead) is an absorbing state, so there can be no transitions out of this state. The
hazard functions for going between each state are labeled on the state diagram in Figure 5.2.
We will use the Markov assumption which states that instead of the full state process history
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Figure 5.2: Diagram of possible states in the ACC study.
we only need to know the last state before time t, i.e.
Pr(Dt = l|Du, u ∈ [0, v]) = Pr(Dt = l | Dv) (5.3)
Define the Markov transition probabilities as
Pl|k(t, v) = Pr(Dt = l | Dv = k) (5.4)
As in previous chapters we will use the joint survival function with Weibull marginal hazards.
Denote the time of the kth state transition for subject i by ti,k and the state at time ti,k by Di,k.
State transition times are measured as time from the start of the study (time since diagnosis in the
ACC data) and so we assume the times are increasing, ti,1 < ti,2 < ... < ti,Ki for each i.
















Using the Markov assumption, for transition at time ti,k we only need to know time ti,k−1 from
Markov assumption. So the relevant joint survival function for each transition is



































where Ci is the censoring time if the subject is censored after transition Ki (i.e. Ki is not an ab-
sorbing state). We need the conditional hazards λDk|Dk−1 for each possible Dk−1 and Dk. Shaked
and Shanthikumar (1987) defines this conditional hazard using the joint survival and joint proba-
bility density functions. We write this out for λ1|2 below and generalizing to any two states other
than states 1 and 2 is straightforward. See Appendix B.6 for details.
λ1|2(t | t2) = lim
∆t↘0
Pr (t < T1 ≤ t+ ∆t | T1 > t, T2 = t2)
∆t





The joint probability density function is f(t1, t2) =
(−1)2∂2S(t1,t2)
∂t1∂t2























































The denominator from (5.8) is
∂
∂t2



















































































































































Using these hazard functions we can write out the likelihood contribution for each subject as in
(5.7).
5.3 Multiple Longitudinal Outcomes
Suppose for each subject iwe haveM ≥ 1 different longitudinal processes measured over time
which we will call a biomarker. Subject i has Jim total measurements of biomarker m = 1, ...,M
at times τ (m)i = (τ
(m)





)T . Let Y (m)i,j be subject i’s biomarker m measurement at
time τ (m)ij and let Y
(m)




















i , m = 1, ...,M (5.11)
Here X(m)i is a covariate matrix with coefficients β
(m), U (m)i is a vector of random effects with
design matrix Z(m)i , and ε
(m)

















0i . The M biomarkers
may be correlated with each other so we assume a multivariate normal distribution for the random
intercepts with mean 0 and covariance matrix ΣU , (U
(1)





5.4 Bayesian Model and Estimation
5.4.1 Longitudinal Submodels
We will describe the Bayesian model that will be fit to our ACC data specifically. For the ACC
data we will consider M = 2 biomarkers: LMPA (Y (1)) and body depth (BD) (Y (2)). Examples of
the LPMA and BD measurements over time for selected patients are shown in Figures 5.3 and 5.4.
As in previous chapters we will include an intercept, time slope, binary sex X1i and centered
continuous age in decades X2i in the longitudinal models. Here we include the same baseline












2 X1i + β
(1)

















2 X1i + β
(2)




















For our multistate model the possible transitions shown in Figure 5.2 are 2|1, 3|1, 4|1, 1|2, 3|2,
4|2, 1|3, 2|3, and 4|3. No transitions are allowed out of state 4 (dead) since this is an absorbing
state. The conditional and total hazards for these transitions are as described in Section 5.2. We















Figure 5.3: Example plots of LPMA from the ACC data. A vertical red dashed line indicates time
of death. A vertical blue dot-dashed line indicates time of censoring. LPMA values in plots can be
negative because the values have been centered.
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Figure 5.4: Example plots of BD from the ACC data. A vertical red dashed line indicates time
of death. A vertical blue dot-dashed line indicates time of censoring. BD values in plots can be
negative because the values have been centered.
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HereWi are time-independent covariates, which may coincide with theX
(m)
i from the longitudinal
models, αk are regression coefficients, the U
(m)
i are the same random effects as in the longitudi-
nal submodels and the θ(m)k measure the strength of the association between the state k and the
















For our Bayesian model we put priors on our parameters as follows with m = 1, 2.
β(m) ∼ MVN(mβ, s2βI4)
ΣU ∼Wishart(aU , BU)
σ(m)ε ∼ Γ(ae, be)
αk ∼ MVN(mα, s2αI2)
θ
(m)
k ∼ N(mθ, s
2
θ)
γk ∼ Γ(aγ, bγ)
δ ∼ Beta(aδ, bδ)
Hyperparameters used are mβ = (2, 2, 2, 2)T , sβ = 4, aU = 4, BU =
1 0
0 1
, aε = 5, bε = 5,
mα = (2, 2)
T , sα = 4, mθ = 2, sθ = 4, aγ = 5, bγ = 5, aδ = 2, bδ = 2.
5.4.4 Likelihood
Denote the vector of parameters by




ε , α1, ..., α4, θ
(1)




1 , ..., θ
(2)
4 , γ1, ..., γ4, δ)
T . The posterior will
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be proportional to the product of the likelihood and the prior densities. Let
p(Ω|Y (1)i , Y
(2)




0i ) denote the posterior, LY the likeli-
hood contribution from the longitudinal submodels, LT the likelihood contribution from the mul-
tistate submodels, and p(Ω) be the product of the prior densities for all components of Ω. Then






































































We see that the likelihood contribution in LT contains integrals which can not be evaluated an-
alytically. Due to difficulties in using the Stan numerical integration function (integrate_1d)
we estimated these integrals using the midpoint method. Specifically,
∫ Tk
Tk−1






This is a crude approximation but since generally the time between state transitions, (Tk−1, Tk), is
relatively small using this approximation is reasonable. Time between transitions varied between
0.003 years and 7.97 years with a median of 0.31 years and third quantile of 0.78 years.
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5.5 Results
We fit our models using Hamiltonian Monte Carlo with Stan through the R package rstan
version 2.21.2 and R version 4.0.4 (Guo et al., 2020). Stan code is provided in Appendix E.4.
Initial values were generated automatically. Due to slow computation time the models were run
for 1000 iterations total with 500 iterations of warm-up for four chains. Despite the small number
of iterations, Rhat values for the parameters were between 1.00 and 1.01 indicating that the chains
have mixed. See Appendix Table F.2. Trace plots in Figures 5.5 - 5.10 also show mixing of the
two chains.
Results are shown in Table 5.1. As in previous chapters we see that LPMA tends to decrease
over time (β(1)1 < 0), females have significantly lower LPMA (β
(1)
2 < 0) and LPMA decreases





1 ≈ 0). In the multistate model, we see that age does not have a significant associ-
ation with stable (α1,1), regression (α1,3), or death states (α1,4). Older patients do tend to have a
shorter time to progression (α1,2 < 0). We find no significant association between LPMA and tran-
sition times for stable (θ(1)1 ) and progression (θ
(1)
2 ) states. Higher LPMA is associated with longer
transition time to regression (θ(1)3 ) and shorter time to death (θ
(1)
4 ). Unsurprisingly given the lack
of association found in the longitudinal model for body depth, we do not find significant associa-






4 ). The dependence parameter
δ is found to be 1 indicating independence between the transition times. This is an interesting
result that warrants further study. The dependence between specific states (say progression and
death) may be different than dependence between other states and this model cannot capture such
heterogeneity in the single dependence parameter δ.
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Parameter Mean CI Pr > 0 Parameter Mean CI Pr > 0
β
(1)
0 9.37 (7.19, 11.51) 1.00 α0,1 1.03 (0.36, 1.71) 1.00
β
(1)
1 -0.22 (-0.31, -0.12) 0.00 α1,1 -0.04 (-0.17, 0.08) 0.26
β
(1)
2 -6.73 (-7.8, -5.57) 0.00 α0,2 0.68 (-0.01, 1.39) 0.97
β
(1)
3 -1.34 (-1.77, -0.89) 0.00 α1,2 -0.21 (-0.35, -0.06) 0.00
β
(2)
0 -0.01 (-0.04, 0.02) 0.19 α0,3 -1.06 (-2.22, 0.07) 0.03
β
(2)
1 0.00 (0.00, 0.00) 0.40 α1,3 0.12 (-0.07, 0.33) 0.88
β
(2)
2 -0.02 (-0.03, 0.00) 0.01 α0,4 -0.81 (-1.70, 0.03) 0.03
β
(2)
3 0.00 (0.00, 0.01) 0.96 α1,4 -0.10 (-0.27, 0.07) 0.14
σ1 3.77 (3.32, 4.26) 1.00 θ
(1)
1 0.00 (-0.06, 0.05) 0.46
σ2 0.04 (0.04, 0.05) 1.00 θ
(1)
2 0.00 (-0.06, 0.05) 0.55
ρ 0.15 (-0.02, 0.31) 0.96 θ(1)3 0.09 (0.02, 0.16) 0.99
σ
(1)
ε 3.02 (2.87, 3.17) 1.00 θ
(1)
4 -0.17 (-0.25, -0.10) 0.00
σ
(2)
ε 0.02 (0.02, 0.02) 1.00 θ
(2)
1 2.57 (-1.54, 6.61) 0.89
δ 1.00 (0.99, 1.00) 1.00 θ(2)2 3.83 (-0.32, 7.91) 0.97
γ1 0.70 (0.55, 0.86) 1.00 θ
(2)
3 -0.07 (-5.34, 4.98) 0.49
γ2 0.50 (0.37, 0.63) 1.00 θ
(2)
4 4.26 (-0.47, 8.96) 0.96
γ3 0.30 (0.16, 0.45) 1.00
γ4 0.74 (0.56, 0.93) 1.00
Table 5.1: Posterior Mean (Mean), 95% Credible Interval (CI) and probability the parameter is
greater than 0 (Pr > 0) for the joint model fit to the ACC data.
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Figure 5.5: Trace plots for beta parameters.
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Figure 5.6: Trace plots for standard deviation and correlation parameters.
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Figure 5.7: Trace plots for alpha parameters.
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Figure 5.8: Trace plots for theta parameters.
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Figure 5.9: Trace plots for gamma parameters.
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Figure 5.10: Trace plot for delta parameter.
5.6 Discussion
In this chapter we developed a joint model based on the motivating ACC data. This included
more than one longitudinal outcome and a multistate model for the survival part. We worked under
the Markov assumption, a common simplifying assumption in multistate modeling. One extension
would be to weaken this assumption such as assuming a semi-Markov situation. While the possible
transitions described in this work were based on the ACC data, the hazards for transition from state
k to l are general and could be applied to a problem with any possible transitions.
As in other chapters we use a joint survival function from an Archimedean copula with Weibull
marginals. Archimedean copulas have some nice properties as discussed in Chapter 4 and Weibull
is a common distribution in event time analysis. This formulation is an alternative to the often used
proportional hazards models for transition hazards. Utilizing a copula also allows us a way to study
the dependence between the times between state transitions. One limitation to the model studied
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in this chapter is that the dependence is quantified in a single parameter. One may be interested
in dependence between specific transitions more than others or differences in dependence between
different transitions. Future work could consider how to extend this model to measure dependence
with multiple parameters. Additional flexibility could be added to the multistate model by allowing
the marginal distributions for the transition times to be from different distributions (instead of all
Weibull). This would require careful considerations of what distributions are best suited to each
transition time and coding and model interpretation would be more complicated.
Our longitudinal outcomes are both continuous but using a generalized linear mixed model
for binary, count or other non-continuous outcomes is straightforward. We included only a single
random intercept in each longitudinal submodel. Additional or different random effects could be
included such as a random slope. This would obviously require estimating additional variance and
correlation parameters for these added random effects. We also included the random intercepts
from both longitudinal submodels in the regression models for the multistate data. Another option























































random intercept and slope model. We chose to put the regression model on the shape parameter
of the Weibull distribution but instead a regression model could be put on the scale parameter γk
or the dependence parameter δ.
Our code to fit the model relied on a crude approximation to integrals in the likelihood. Future
work ideally would use an approximation method expected to have less bias. We also were only
able to run the model for a relatively small number of iterations and in the future could run the
model for longer to hopefully verify the results are similar. We showed that this model can be
applied to the ACC data. A simulation study would be useful to verify that the inferences from this
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In this dissertation we have explored joint models for longitudinal and survival data of multiple
types. In particular we considered a standard joint model with a single survival event in Chapter
2, with competing risks in Chapters 3 and 4. In Chapter 5 we generalized the model to explore
survival data with multiple states over time as well as multiple longitudinal biomarkers. This
work was motivated by a study of adrenocortical carcinoma in the University of Michigan’s Rogel
Cancer Center, but these models can be applied to other problems including other cancers such as
progression and regression in prostate cancer and association longitudinal PSA levels (Ferrer et al.,
2016).
Medical studies often collect both longitudinal and time-to-event data which necessitate a joint
modeling approach to fully account for all dependencies in the data. But these joint models can be
difficult to implement for clinicians and statisticians who do not work with these models frequently.
This has motivated the creation of various software packages for implementing the most common
joint models seen in practice. Comparing these software implementations was the focus of Chapter
2. In later chapters of this dissertation we explored extensions in the survival data including com-
peting risks and multistate data. Software to implement these types of models would help facilitate
increased use in practical settings. There has been limited development of joint longitudinal and
competing risks software but developing user-friendly software for implementing these models is
a constant source of future work.
In Chapter 3 we discussed how the model we developed could be used for dynamic prediction.
Dynamic prediction with joint models quickly became an area of interest once joint modeling
became more accessible and common. These predictions can be directly utilized in a clinical
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setting if implemented in a way clinicians can access such as a website (Taylor et al., 2013). While
we detailed the algorithm for calculating dynamic predictions using our models in Chapter 3, there
is still work that could be done. The model and predictions have not been validated. Sensitivity
analyses investigating the influence of our priors and other model assumptions could be performed.
Additional parametric distributions could also be used. Finally the dynamic predictions could be
extended to use the models with dependence in Chapter 4 and the models with multistate data in
Chapter 5.
This work has focused on developing joint models that fit the ACC study and are also novel
in the way the survival submodels are defined. We have described possible settings where these
models may be more appropriate than standard joint models which often use proportional hazards
formulations. These settings include when a proportional hazards assumption does not fit the data.
In this work we concentrated on describing the models and demonstrating through simulation
that the model estimates are close to the true values. A useful area of future work would be
to use simulation studies to discover how these models compare to the more common, usually
proportional hazards, models. It would be useful to advocating for the use of these models to know
when our new models have better fit to the data.
We chose to focus on parametric and copula-based survival submodels but there are other
options that could be explored. First, in Chapters 4 and 5 we used Weibull cumulative hazards
and marginals, respectively, but we could have considered using the log-Normal distribution as in
Chapter 3 or another distribution. Both Weibull and log-Normal are from the log-location-scale
family and so other members of that family are possible candidates for study. We could also
study joint models in a competing risks setting using a Fine-and-Gray model defining the survival
submodel through the subdistribution functions (Fine and Gray, 1999). This option has received
little consideration in the literature (Deslandes and Chevret, 2010; Musoro et al., 2018)
A related area that could use future study is goodness of fit and model diagnostics in joint
modeling. We used DIC to compare the Weibull and log-Normal model fits to the ACC data in
Chapter 3 but this is a generic measure output by the Bayesian software Stan. Diagnostics have
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received some study in joint modeling with a single longitudinal outcome and single survival event
(Dobson and Henderson, 2003; Rizopoulos et al., 2010; Park and Qiu, 2014) (Rizopoulos, 2012,
Chapter 6)(Elashoff et al., 2017, p.198). Variable selection is another important consideration that
has received little attention in the joint modeling context (Chen and Wang, 2017)(Elashoff et al.,
2017, p.202). Extension of model diagnostics and variable selection methods to joint models with
competing risks and with multistate data has, to the best of our knowledge, yet to be explored.
We hope that the work in this dissertation encourages future exploration into different aspects
of joint modeling. We have considered unique parametric and copula-based approaches that we
believe deserve further study.
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Appendix A
Description of Morphomic Variables in
Adrenocortical Carcinoma Data
Below is a short description of each of the morphomics variables in the adrenal cancer study.
This information is from the online Morphomics Data Dictionary (Holcombe et al., 2016). These
measurements are taken from CT scans of the chest, abdomen, or pelvis. Most measurements are
taken at each vertebral level and are reported as a function of body region. Some measures of
muscle density are reported in Hounsfield Units (HU) (Hounsfield, 1980).
Average psoas perimeter mean
Mean pixel intensity of all pixels in psoas region of scan, a measure of psoas muscle, in HU.
Body depth
Distance between front and back of body (aligned to body habitus), a body measure, in mm.
Central back fat depth
Distance from posterior tip of spinous process to back skin, a body measure, in mm.
Central sub-cutaneous depth
Linear distance from anterior fascia to anterior skin, a body measure, in mm.
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Central visceral depth
Central visceral depth, distance from anterior of vertebral body to anterior fascia, a body measure,
in mm.
Fascia area
Cross-sectional area of the fascia region, a body measure, in mm2.
Fascia depth
Central sub-cutaneous depth, linear distance from anterior fascia to anterior skin, in mm.
Lean psoas
From Holcombe et al. (2016): “ “lean psoas" is a mathematical combination of measures of psoas
cross sectional area (mm2) and psoas density (in HU) inside the muscle boundary... This can be
thought of as "normalizing a muscle’s density between -85 HU (very fatty and low density) and
+85 HU (very dense)". The values of ±85 were chosen by inspection of some of our sickest and
healthiest individuals’ data points. " The formula for lean psoas is given as:
(lean psoas) =
(mean psoas density) + 85
170
· (psoas cross sectional area)
LMPA lean psoas muscle area
Area covered by psoas muscles in cross-sectional image, usually sampled at the L4 vertebral level.
LPMD lean psoas muscle density
Measure of fatty infiltration in psoas muscles found in cross-sectional image.
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Psoas muscles
Core muscles running alongside the lumbar spine.
Total psoas perimeter area
Total area within the perimeter of the left and right psoas, a measure of psoas muscle, in mm2.
VB2 front skin
Central visceral depth, distance - anterior of vertebral body to anterior fascia, in mm.
Visceral fat area










Mean pixel intensity of all
pixels in psoas region of scan,
a measure of psoas muscle, in
HU
244 21
body depth Distance between front and
back of body (aligned to body
habitus), a body measure, in
mm
240 21
central back fat depth Distance from posterior tip of
spinous process to back skin,




Linear distance from anterior
fascia to anterior skin, a body
measure, in mm
238 21
central visceral depth Distance from anterior of ver-
tebral body to anterior fascia,
a body measure, in mm
243 21
fascia area Cross-sectional area of the
fascia region, a body measure,
in mm2
243 21
fascia depth Central sub-cutaneous depth,
linear distance from anterior
fascia to anterior skin, in mm
243 21
lean psoas muscle area Area covered by psoas mus-
cles in cross-sectional image,
usually sampled at the L4 ver-




Measure of fatty infiltration in
psoas muscles found in cross-
sectional image, in HU
243 21
total psoas perimeter, Total area within the perime-
ter of the left and right psoas,
a measure of psoas muscle, in
mm2
244 21
vb2 front skin Central visceral depth, dis-
tance - anterior of vertebral
body to anterior fascia, inmm
240 21
visceral fat area Area inside fascia meeting fat
density thresholds (-205 to -51
HU), a fat measure, in mm2
240 21




B.1 Generation of Survival Times in Chapter 2 Simulations
The generalized hazard function for the survival submodel of Scenario 2 is
hi(t) = h0(t) exp(γ0 + γ1X1i + γ2X2i + αmi(t)) (B.1)
where, in general terms,
Yi(t) = mi(t) + ei(t) = β0 + β1t+ β2X1i + β3X2i + U0i + U1it+ ei(t)
We set h0(t) = 1 and have a constant γ0 absorbed into the exponential. After dropping the
subscript i,
h(t) = exp(γ0 + γ1X1 + γ2X2 + α(β0 + β1t+ β2X1 + β3X2 + U0 + U1t))








exp(γ0 + γ1X1 + γ2X2 + α(β0 + β1y + β2X1 + β3X2 + U0 + U1y))dy
=




Let V ∼ Unif(0, 1) be a random survival probability and set H(t) = − log(V ). Then




− log(V )(αβ1 + αU1)
exp(γ0 + αβ0 + αU0 + (γ1 + αβ2)X1 + (γ2 + αβ3)X2)
+ 1
α(β1 + U1)t = log
(
− log(V )(αβ1 + αU1)









− log(V )(α(β1 + U1))
exp(γ0 + αβ0 + αU0 + (γ1 + αβ2)X1 + (γ2 + αβ3)X2)
+ 1
)
The calculation for a random intercept only model (Scenario 1) is the same but with U1 = 0.
Calculation for Scenario 3 (a shared parameter model) is simpler with mi(t) replaced by just Ui in
(B.1).
B.2 Chapter 2 Simulation Model Reparameterization
In Scenario 1, we fit a shared parameter model as in (2.7) with joineR while the data was
generated from the current-value model described in (2.5) and (2.6). So the data are generated
from
Y = β0 + β1t+ β2X1 + β3X2 + U + e
and
h(t) = exp(γ0) exp(γ1X1 + γ2X2 + α(β0 + β1t+ β2X1 + β3X2 + U)) (B.2)
The longitudinal submodel is the same for joineR but the survival submodel is of the form







Rearranging terms in (B.2),
h(t) = exp(γ0) exp(γ1X1 + γ2X2 + α(β0 + β1t+ β2X1 + β3X2 + U))
= exp(γ0 + αβ0 + αβ1t) exp((γ1 + αβ2)X1 + (γ2 + αβ3)X2 + αU)
Comparing this to (B.3) we see that
γ∗1 = γ1 + αβ2
γ∗2 = γ2 + αβ3
(B.4)
Since joineR assumes an unspecified baseline hazard, the form of the baseline hazard does not
matter when estimating. When calculating the bias and MSE for the joineR model, we compare
the estimates output to the combination of true parameters on the left hand side of the equations in
(B.4). In order to calculate the coverage probabilities for γ∗1 and γ
∗
2 , we estimate standard errors by
bootstrapping. Specifically, we select, with replacement, data for 500 subjects and run a model on
that bootstrap sample. We do this 100 times for each of the 100 simulated datasets and calculate
γ∗1 − αβ2 and γ∗2 − αβ3. We then use the standard deviation of these values as an estimate of the
standard error.
The coefficients for the covariates in the survival submodel of Scenario 2 work out to be exactly
the same as above and standard errors were again found by bootstrapping.
In Scenario 3 the JM model is in a different form than the true model. The data are generated
from
Y = β0 + β1t+ β2X1 + β3X2 + U + e
h(t) = exp(γ0) exp(γ1X1 + γ2X2 + αU)
Whereas JM fits a model of the form




2X2 + α(β0 + β1t+ β2X1 + β3X2 + U))
= h0(t) exp(α(β0 + β1t)) exp((γ
∗
1 + αβ2)X1 + (γ
∗
2 + αβ3)X2 + αU)
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So we see that
γ∗1 + αβ2 = γ1
γ∗2 + αβ3 = γ2
Bias and MSE for γ∗1 and γ
∗
2 are calculated compared to the combinations γ1−αβ2 and γ2−αβ3,
respectively. Standard errors are estimated with bootstrapping similar to the method described
above for Scenario 1.
B.3 Chapter 3 Cause-Specific Proportional Hazards Model
Survival Functions Derivations
For Model W PH




















− exp (α1kX2i + θkU0i)
1
α0k






T γki exp (α1kX2i + θkU0i)
)
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B.4 Chapter 4 Cause-specific Hazard Function Derivations
We have






















































































































B.6 Transition Hazards in Multistate Submodel from Chapter
5
We write this out for λ1|2 below and generalizing to any two states other than states 1 and 2 is
straightforward.
λ1|2(t | t2) = lim
∆t↘0
Pr (t < T1 ≤ t+ ∆t | T1 > t, T2 = t2)
∆t





The joint probability density function is f(t1, t2) =
(−1)2∂2S(t1,t2)
∂t1∂t2
























































































































































































































































































































































































































































































































































Other Joint Modeling Software Implementations
C.1 PROC NLMIXED in SAS
Both the %JM and %JMfit SAS macros call PROC NLMIXED to fit the joint model. PROC
NLMIXED can also be used separately to fit a joint model in SAS that can not be fit with the macros
described above. The NLMIXED procedure was designed for fitting nonlinear mixed models but
has been used for fitting joint models (Gould et al., 2014; SAS Institute, 2015b,a; Schabenberger,
2004)(Littell et al., 2006, p.595). The user must specify the joint likelihood of the joint model but
this procedure allows for much more flexibility. The association can take any form that the user
writes into the joint likelihood. PROC NLMIXED fits the models by approximating the likelihood
integrated over the random effects and then maximizing (SAS Institute, 2015b). Different options
are available for integral approximation including adaptive Gaussian quadrature and first-order
Taylor series expansion.
C.2 %JMfit Macro in SAS
The %JMfit macro for the SAS software was created to fit joint models and while simultane-
ously assessing the fit of the models. A full description of the macro is given by (Zhang et al.,
2016). The %JMfit macro fits only shared parameter models as in (1.3). This macro can fit a joint
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model in one of four forms: SPM1L, SPM1Q, SPM2L, and SPM2Q described in (C.1).
SPM1L: hi(t) = h0(t)exp{Xi2γ + α(U0i + U1it)}
SPM1Q: hi(t) = h0(t)exp{Xi2γ + α(U0i + U1it+ U2it2)}
SPM2L: hi(t) = h0(t)exp{Xi2γ + α(U0i + U1i)}
SPM2Q: hi(t) = h0(t)exp{Xi2γ + α(U0i + U1i + U2i)}
(C.1)
One addition to %JMfit not readily available in other software is built-in decomposition of AIC,
BIC, ∆AIC, and ∆BIC for examining goodness-of-fit, and comparing between the joint model
forms (SPM1L, SPM1Q, SPM2L, and SPM2Q) (Zhang et al., 2016). Estimation is done with the
PROC NLMIXED procedure. This macro was not able to fit joint models to our simulated data
or the adrenal cancer data. This macro generally had issues with the optimization convergence or
quadrature accuracy.
C.3 gsem Command in Stata
The gsem command in the Stata software was created to fit generalized structural equation
models and multilevel data. It can be used for joint modeling with flexible latent processes but
the survival outcome must be modeled parametrically (Marchenko, 2016)(Stata Corp LP, 2015,
p.449-473). Common distributions for the survival submodel can be specified such as Exponential,
Weibull, Gamma, or log-Normal (Stata Corp LP, 2015, p.95,467). The association is through
shared parameters as in (1.3) but it is flexible since any random terms can be included.
C.4 jmxtstset Command in Stata
The unofficial Stata command jmxtstcox fits joint models (Marchenko, 2016) and is cur-
rently available from the authors. The joint model in this command has a random-intercept Cox
model and uses nonparametric maximum likelihood for estimation of model parameters. This
command can also accommodate stratification and standard post-estimation commands in Stata
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such as text, predict, and lincom (Marchenko, 2016). The jmxtstcox command does
not yet support random coefficients models; only a random intercept shared parameter model can
be fit, but extensions are planned.
C.5 MATLAB
MATLAB, a mathematical programming language, has been used for joint modeling. Estimation
of parameters from the joint likelihood can be achieved with the fmisearch and fmincon
functions, which are unconstrained and constrained nonlinear optimization function, respectively.





D.1 Additional Simulations with Conditionally Independent
Competing Risks in Chapter 3
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True surv. True Value N Param Mean Bias*1000 MSE*1000 CP
Weibull 3.4 160 β0 2.90 -495 478 82
(Model W) -0.15 β1 -0.14 5 4 95
-5.8 β2 -4.99 809 1038 75
-1.4 β3 -1.37 32 55 96
4.3 σU 4.25 -50 66 94
2.2 σε 2.20 3 1 95
1.3 α0,1 1.34 36 33 95
-0.1 α1,1 -0.09 6 14 94
3.2 α0,2 3.11 -93 187 95
-0.2 α1,2 -0.20 -1 43 96
0.1 θ1 0.10 4 2 95
-0.1 θ2 -0.09 14 7 93
0.75 γ1 0.75 4 5 95
0.5 γ2 0.54 42 7 93
Weibull 3.4 1000 β0 3.30 -97 55 93
(Model W) -0.15 β1 -0.15 1 1 97
-5.8 β2 -5.66 137 97 92
-1.4 β3 -1.39 11 8 94
4.3 σU 4.30 -4 11 95
2.2 σε 2.20 1 0 96
1.3 α0,1 1.31 8 5 95
-0.1 α1,1 -0.10 2 2 96
3.2 α0,2 3.18 -23 45 92
-0.2 α1,2 -0.20 -3 8 97
0.1 θ1 0.10 1 0 96
-0.1 θ2 -0.10 3 1 96
0.75 γ1 0.75 2 1 97
0.5 γ2 0.51 8 1 93
Table D.1: Scenario 2 simulation results for data generated with Model W as the truth. Data was
generated for either N=160 (top) or N=1000 (bottom). Data was generated 200 times. For each
parameter the results include the mean of the 200 posterior means, the bias*1000, the mean squared
error (MSE)*1000, and the coverage probability (CP).
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True surv. True Value N Param Mean Bias*1000 MSE*1000 CP
log-Normal 3.4 160 β0 2.88 -515 518 85
(Model L) -0.15 β1 -0.15 4 4 96
-5.8 β2 -4.98 817 1061 77
-1.4 β3 -1.35 54 56 94
4.3 σU 4.24 -57 54 97
2.2 σε 2.20 -3 2 94
0.7 α0,1 0.69 -10 29 96
-0.05 α1,1 -0.04 8 11 96
2.8 α0,2 2.50 -302 259 88
-0.25 α1,2 -0.24 10 47 97
0.1 θ1 0.10 3 1 98
-0.1 θ2 -0.09 7 6 97
1.6 γ1 1.61 10 17 96
3.2 γ2 2.89 -306 185 86
log-Normal 3.4 1000 β0 3.32 -81 48 93
(Model L) -0.15 β1 -0.15 1 1 94
-5.8 β2 -5.67 129 96 93
-1.4 β3 -1.39 6 9 96
4.3 σU 4.29 -7 11 95
2.2 σε 2.20 0 0 95
0.7 α0,1 0.69 -11 5 94
-0.05 α1,1 -0.05 1 1 96
2.8 α0,2 2.71 -86 49 93
-0.25 α1,2 -0.24 8 9 94
0.1 θ1 0.10 0 0 96
-0.1 θ2 -0.10 3 1 96
1.6 γ1 1.59 -12 3 96
3.2 γ2 3.13 -68 32 92
Table D.2: Scenario 2 simulation results for data generated with Model L as the truth. Data was
generated for either N=160 (top) or N=1000 (bottom). Data was generated 200 times. For each
parameter the results include the mean of the 200 posterior means, the bias*1000, the mean squared
error (MSE)*1000, and the coverage probability (CP).
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True surv. True Value N Param Mean Bias*1000 MSE*1000 CP
Weibull 3.0 160 β0 2.92 -81 144 94
(Model W) -1.0 β1 -0.99 11 6 96
-2.0 β2 -1.91 85 113 94
-1.0 β3 -0.94 57 58 91
4.0 σU 3.92 -76 73 93
2.0 σε 2.00 0 3 96
1.0 α0,1 1.02 20 164 94
-1.5 α1,1 -1.44 62 71 93
3.0 α0,2 2.83 -170 295 95
-1.0 α1,2 -1.04 -36 85 94
1.0 θ1 1.04 36 11 94
-1.0 θ2 -0.98 23 18 95
0.75 γ1 0.82 70 20 96
0.5 γ2 0.55 47 7 90
Weibull 3.0 1000 β0 3.00 4 22 96
(Model W) -1.0 β1 -1.00 3 1 95
-2.0 β2 -1.98 17 22 93
-1.0 β3 -1.00 -3 7 96
4.0 σU 3.98 -22 10 95
2.0 σε 2.00 0 0 95
1.0 α0,1 1.02 21 26 93
-1.5 α1,1 -1.51 -9 8 97
3.0 α0,2 2.97 -31 72 94
-1.0 α1,2 -0.99 14 15 94
1.0 θ1 1.00 4 1 97
-1.0 θ2 -1.00 3 3 93
0.75 γ1 0.76 8 2 98
0.5 γ2 0.50 2 1 97
Table D.3: Scenario 3 simulation results for data generated with Model W as the truth. Data was
generated for either N=160 (top) or N=1000 (bottom). Data was generated 200 times. For each
parameter the results include the mean of the 200 posterior means, the bias*1000, the mean squared
error (MSE)*1000, and the coverage probability (CP).
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True surv. True Value N Param Mean Bias*1000 MSE*1000 CP
log-Normal 3.0 160 β0 2.94 -64 177 90
(Model L) -1.0 β1 -1.00 4 4 95
-2.0 β2 -1.85 147 166 92
-1.0 β3 -0.98 22 37 98
4.0 σU 3.94 -60 73 94
2.0 σε 2.00 3 2 96
1.0 α0,1 0.99 -8 185 96
-1.5 α1,1 -1.47 28 61 97
3.0 α0,2 2.62 -378 485 90
-1.0 α1,2 -0.98 20 106 93
1.0 θ1 1.01 8 9 96
-1.0 θ2 -0.95 52 21 95
2.0 γ1 1.89 -108 61 91
3.0 γ2 2.76 -244 153 85
log-Normal 3.0 1000 β0 2.99 -6 26 93
(Model L) -1.0 β1 -1.00 -1 1 93
-2.0 β2 -1.97 27 24 94
-1.0 β3 -1.00 2 9 93
4.0 σU 4.00 -4 10 95
2.0 σε 2.00 1 0 94
1.0 α0,1 1.01 7 28 98
-1.5 α1,1 -1.50 5 13 93
3.0 α0,2 2.94 -63 84 92
-1.0 α1,2 -1.01 -6 18 96
1.0 θ1 1.00 5 1 96
-1.0 θ2 -0.99 7 3 95
2.0 γ1 1.99 -15 9 95
3.0 γ2 2.93 -72 25 92
Table D.4: Scenario 3 simulation results for data generated with Model L as the truth. Data was
generated for either N=160 (top) or N=1000 (bottom). Data was generated 200 times. For each
parameter the results include the mean of the 200 posterior means, the bias*1000, the mean squared
error (MSE)*1000, and the coverage probability (CP).
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D.2 Chapter 4 Chain Initial Values for Simulation
Parameter Chain 1 Chain 2 Chain 3 Chain 4
β0 3.5 2.5 1.5 2
β1 0.15 0.55 -0.15 0.05
β2 2 1 3 0.5
β3 3 2 4 1.5
σU 0.5 1 2 1.5
σε 2 1 3 0.5
α0,1 1.2 2.2 0.2 0.6
α1,1 -0.4 0.4 -1.4 -0.2
α0,2 1.1 2.1 0.1 0.5
α1,2 -0.5 0.5 -1.5 -0.1
θ1 -1.1 1.1 -2.1 -0.1
θ2 -0.9 0.9 -1.9 -0.5
γ1 5 6 4 5.5
γ2 8 7 6 9
δ 0.4 0.3 0.7 0.6
U0i 0 1 2 0.5




















#Software Comparison Simulation Data


























































































method="weibull-PH-aGH", parameterization = "value")
JMfits.weib[[k]]=JM.model






























#separate models are input to joint model
#fit joint model
JM.model=jointModel(lmemodel,coxmodel,"timevar",
method="piecewise-PH-aGH", parameterization = "value")
JMfits.pw[[k]]=JM.model













#separate models are input to joint model
#fit joint model
JM.model=jointModel(lmemodel,coxmodel,"timevar",
method="spline-PH-aGH", parameterization = "value")
JMfits.spl[[k]]=JM.model















#for longitudinal model need: longitudinal measurements,
#time of measurements, ID
lmedata.joineR=simdataLongit[[k]][,c("Y","subjID","timevar")]





















#put names on runtimes table for easier interpretation
runtimes=as.data.frame(runtimes)
colnames(runtimes)=softwareNames
### Calc total run time for R
totalruntime=proc.time()[1]-t.tot.start
totalruntime=totalruntime/60 #time in minutes
totalruntime.h=totalruntime/60 #time in hours










































































































































































#for longitudinal model need: longitudinal measurements,
#time of measurements, ID
lmedata.joineR=simdataLongit[[k]][,c("Y","subjID","timevar")]





























#for longitudinal model need: longitudinal measurements,
#time of measurements, ID
lmedata.joineR=simdataLongit[[k]][,c("Y","subjID","timevar")]























#put names on runtimes table for easier interpretation
runtimes=as.data.frame(runtimes)
colnames(runtimes)=softwareNames
### Calc total run time for R
totalruntime=proc.time()[1]-t.tot.start
totalruntime=totalruntime/60 #time in minutes
totalruntime.h=totalruntime/60 #time in hours




#printing mean runtimes for software
colMeans(runtimes)
######################################################


























































#for longitudinal model need: longitudinal measurements,
#time of measurements, ID
lmedata.joineR=simdataLongit[[k]][,c("Y","subjID","timevar")]





















#put names on runtimes table for easier interpretation
#runtimes=as.data.frame(runtimes)
#colnames(runtimes)=softwareNames
### Calc total run time for R
totalruntime=proc.time()[1]-t.tot.start
totalruntime=totalruntime/60 #time in minutes
totalruntime.h=totalruntime/60 #time in hours





#printing mean runtimes for software
colMeans(runtimes)
E.1.2 SAS Code





/* Load for the %JM macro (must change working folder to folder




































/* Run JM macro for each dataset 1,...,100*/
















EventCovariates = Z1 Z2,
NLMIXEDOptions = GCONV=0 QTOL=0.0005 QPOINTS=1 METHOD=GAUSS,
SharedParam = CURRENT_VALUE,







/* Random Coefficients Model */
















EventCovariates = Z1 Z2,
NLMIXEDOptions = GCONV=0 QTOL=0.0005 QPOINTS=1 METHOD=GAUSS,
SharedParam = CURRENT_VALUE,























EventCovariates = Z1 Z2,



















log using softwSimstjm, text replace
set rmsg on, perm
set more off, perm
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stset time2 if dataset==1, id(subjID) enter(time1)
failure(event==1)
stjm Y Z1_x Z2_x if dataset==1, panel(subjID) survmodel(weibull)
rfp(0) gh(25) survcov(Z1_x Z2_x) difficult
estimates store model1
stset time2 if dataset==1, id(subjID) enter(time1)
failure(event==1)
stjm Y Z1_x Z2_x if dataset==1, panel(subjID) survmodel(weibull)
rfp(1) gh(25) survcov(Z1_x Z2_x) difficult
estimates store model1
stset time2 if dataset==1, id(subjID) enter(time1)
failure(event==1)
stjm Y Z1_x Z2_x if dataset==1, panel(subjID) survmodel(weibull)
rfp(0) gh(25) survcov(Z1_x Z2_x )
difficult nocurrent intassociation
estimates store model1
E.2 Stan Code for Joint Model with Conditionally
Independent Competing Risks in Chapter 3
E.2.1 For Model W
functions{







for(i in 1:num_elements(t)){ ////// num elements t = N
for(j in 1:num_elements(gam)){ ////// num elements gam = K
probs[i] = probs[i] + d[i,j]*(log(gam[j]) -









int K; // Number of competing risks
//(not including independent censoring)
int Ntot; // length of vector of all
//longitudinal outcome observations
int N; // number of subjects
int P; // number of covars in longitudinal model
int<lower=1,upper=N> subj[Ntot]; // subject ID
vector[Ntot] Y; // longitudinal outcome
int Q; // num covars in survival model
vector[N] surt; // survival times
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matrix[N,K] D; // failure indicators
matrix[Ntot,P] XL; // covariates
matrix[N,Q] XS;















vector[P] beta; // longitudinal regression coeffs
real<lower=0> sigmau; // std dev of random intercept
real<lower=0> sigmaeps; // std dev of longitudinal error
vector[N] u0; // subject-specific random intercept
matrix[K,Q] alpha; // survival regression coeffs
vector<lower=0>[K] gamma; // Weibull shape param





























mus[i,j] = exp(XS[i]*(alpha[j]’) + theta[j]*u0[i]);
}
}
surt ~ mysurv(D, mus, gamma);
}
E.2.2 For Model L
functions{
























int K; // Number of competing risks
//(not including independent censoring)
int Ntot; // length of vector of all
//longitudinal outcome observations
int N; // number of subjects
int P; // number of covars in longitudinal model
int<lower=1,upper=N> subj[Ntot]; // subject ID
vector[Ntot] Y; // longitudinal outcome
int Q; // num covars in survival model
vector[N] surt; // survival times
matrix[N,K] D; // failure indicators
matrix[Ntot,P] XL; // covariates
matrix[N,Q] XS;
















vector[P] beta; // longitudinal regression coeffs
real<lower=0> sigmau; // std dev of random intercept
real<lower=0> sigmaeps; // std dev of longitudinal error
vector[N] u0; // subject-specific random intercept
matrix[K,Q] alpha; // survival regression coeffs
vector<lower=0>[K] gamma; // Weibull shape param





























mus[i,j] = XS[i]*(alpha[j]’) + theta[j]*u0[i];
}
}
surt ~ mysurv(D, mus, gamma);
}
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E.3 Stan Code for Joint Models with Dependent Competing
Risks in Chapter 4
E.3.1 For Model Fitting
functions{







for(i in 1:num_elements(t)){ // num elements t = N
for(j in 1:num_elements(gam)){ // num elements gam = K
probs[i] = probs[i] +
d[i,j]*( (delta-1)*log( (chi[i,1]*(t[i]^gam[1]))^(1/delta) +
(chi[i,2]*(t[i]^gam[2]))^(1/delta) ) +
((1/delta)-1)*log( chi[i,j]*(t[i]^gam[j]) ) + log(chi[i,j]) +












int K; // Number of competing risks
//(not including independent censoring)
int Ntot; // length of vector of all
//longitudinal outcome observations
int N; // number of subjects
int P; // number of covars in longitudinal model
int<lower=1,upper=N> subj[Ntot]; // subject ID
vector[Ntot] Y; // longitudinal outcome
int Q; // num covars in survival model
vector[N] surt; // survival times
matrix[N,K] D; // failure indicators
matrix[Ntot,P] XL; // covariates
matrix[N,Q] XS;



















vector[P] beta; // longitudinal regression coeffs
real<lower=0> sigmau; // std dev of random intercept
real<lower=0> sigmaeps; // std dev of longitudinal error
































chik[i,1] = exp(XS[i,1]*alpha[1,1] +
XS[i,2]*alpha[1,2] + theta[1]*u0[i]);




surt ~ mysurv(D, chik, gamma, delta);
}
E.3.2 For Bayes Factors
Code for Model with 0 < δ < 1:
functions{







for(i in 1:num_elements(t)){ // num elements t = N
for(j in 1:num_elements(gam)){ // num elements gam = K
probs[i] = probs[i] +
d[i,j]*( (delta-1)*log( (chi[i,1]*(t[i]^gam[1]))^(1/delta) +
(chi[i,2]*(t[i]^gam[2]))^(1/delta) ) +
((1/delta)-1)*log( chi[i,j]*(t[i]^gam[j]) ) +













int K; // Number of competing risks
//(not including independent censoring)
int Ntot; // length of vector of all
//longitudinal outcome observations
int N; // number of subjects
int P; // number of covars in longitudinal model
int<lower=1,upper=N> subj[Ntot]; // subject ID
vector[Ntot] Y; // longitudinal outcome
int Q; // num covars in survival model
vector[N] surt; // survival times
matrix[N,K] D; // failure indicators
matrix[Ntot,P] XL; // covariates
matrix[N,Q] XS;



















vector[P] beta; // longitudinal regression coeffs
real<lower=0> sigmau; // std dev of random intercept
real<lower=0> sigmaeps; // std dev of longitudinal error












target += normal_lpdf(beta[i] | mbeta[i],sbeta);
}
target += gamma_lpdf(sigmau | au,bu);
target += gamma_lpdf(sigmaeps | aeps,beps);
target += normal_lpdf(u0 | 0,sigmau);
for(i in 1:K){
for(j in 1:Q){
target += normal_lpdf(alpha[i,j] | malpha[i,j],salpha);
}
target += normal_lpdf(theta[i] | mtheta[i],stheta);
target += gamma_lpdf(gamma[i] | agamma,bgamma);
}
target += beta_lpdf(delta | adelta,bdelta);
// Longutudinal Model
for(i in 1:Ntot){
mul = XL[i]*beta + u0[subj[i]];





chik[i,1] = exp(XS[i,1]*alpha[1,1] +
XS[i,2]*alpha[1,2] + theta[1]*u0[i]);
chik[i,2] = exp(XS[i,1]*alpha[2,1] +
XS[i,2]*alpha[2,2] + theta[2]*u0[i]);
}
target += mysurv_lpdf(surt | D, chik, gamma, delta);
}
Code for Model with δ = 1:
functions{






for(i in 1:num_elements(t)){ // num elements t = N
for(j in 1:num_elements(gam)){ // num elements gam = K
probs[i] = probs[i] +













int K; // Number of competing risks
//(not including independent censoring)
int Ntot; // length of vector of all
//longitudinal outcome observations
int N; // number of subjects
int P; // number of covars in longitudinal model
int<lower=1,upper=N> subj[Ntot]; // subject ID
vector[Ntot] Y; // longitudinal outcome
int Q; // num covars in survival model
vector[N] surt; // survival times
matrix[N,K] D; // failure indicators
matrix[Ntot,P] XL; // covariates
matrix[N,Q] XS;

















vector[P] beta; // longitudinal regression coeffs
real<lower=0> sigmau; // std dev of random intercept
real<lower=0> sigmaeps; // std dev of longitudinal error










target += normal_lpdf(beta[i] | mbeta[i],sbeta);
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}
target += gamma_lpdf(sigmau | au,bu);
target += gamma_lpdf(sigmaeps | aeps,beps);
target += normal_lpdf(u0 | 0,sigmau);
for(i in 1:K){
for(j in 1:Q){
target += normal_lpdf(alpha[i,j] | malpha[i,j],salpha);
}
target += normal_lpdf(theta[i] | mtheta[i],stheta);




mul = XL[i]*beta + u0[subj[i]];




chik[i,1] = exp(XS[i,1]*alpha[1,1] +
XS[i,2]*alpha[1,2] + theta[1]*u0[i]);




target += mysurv_lpdf(surt | D, chik, gamma);
}
E.4 Stan Code for Joint Models with Multiple Longitudinal
Outcomes and Multi-state Data in Chapter 5
functions{
real myintegrand(real x, real delt, real m1, real g1,
real m2, real g2){
// integrate over x
real intval;
intval = (1/delt)*(
(m1^(1/delt))*g1*( x^( (g1/delt)-1 ) )*(
(1-delt)*( ( ( m1*( x^g1 ) )^(1/delt) )^(-1) ) +





real mysurv_lpdf(vector t, int Nsurv, vector D, matrix mu,












t[i]^( (gam[1]/delta)-1 ) )*
( (1-delta)*(
( (mu[i,1]*(t[i]^(gam[1]) ))^(1/delta) +
(mu[i,2]*(t[i-1]^(gam[2]) ))^(1/delta) )^(-1)






t[i]^( (gam[1]/delta)-1 ) )*
( (1-delta)*(
( (mu[i,1]*(t[i]^(gam[1]) ))^(1/delta) +
(mu[i,3]*(t[i-1]^(gam[3]) ))^(1/delta) )^(-1)







t[i]^( (gam[2]/delta)-1 ) )*
( (1-delta)*(
( (mu[i,2]*(t[i]^(gam[2]) ))^(1/delta) +
(mu[i,1]*(t[i-1]^(gam[1]) ))^(1/delta) )^(-1)






t[i]^( (gam[2]/delta)-1 ) )*
( (1-delta)*(
( (mu[i,2]*(t[i]^(gam[2]) ))^(1/delta) +
(mu[i,3]*(t[i-1]^(gam[3]) ))^(1/delta) )^(-1)






t[i]^( (gam[3]/delta)-1 ) )*
( (1-delta)*(
( (mu[i,3]*(t[i]^(gam[3]) ))^(1/delta) +
(mu[i,1]*(t[i-1]^(gam[1]) ))^(1/delta) )^(-1)







t[i]^( (gam[3]/delta)-1 ) )*
( (1-delta)*(
( (mu[i,3]*(t[i]^(gam[3]) ))^(1/delta) +
(mu[i,2]*(t[i-1]^(gam[2]) ))^(1/delta) )^(-1)






t[i]^( (gam[4]/delta)-1 ) )*
( (1-delta)*(
( (mu[i,4]*(t[i]^(gam[4]) ))^(1/delta) +
(mu[i,1]*(t[i-1]^(gam[1]) ))^(1/delta) )^(-1)






t[i]^( (gam[4]/delta)-1 ) )*
( (1-delta)*(
( (mu[i,4]*(t[i]^(gam[4]) ))^(1/delta) +
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(mu[i,2]*(t[i-1]^(gam[2]) ))^(1/delta) )^(-1)






t[i]^( (gam[4]/delta)-1 ) )*
( (1-delta)*(
( (mu[i,4]*(t[i]^(gam[4]) ))^(1/delta) +
(mu[i,3]*(t[i-1]^(gam[3]) ))^(1/delta) )^(-1)






(D[i-1] == 1)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,2],
gam[2], mu[i,1], gam[1])+
(D[i-1] == 1)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,3],
gam[3], mu[i,1], gam[1])+
(D[i-1] == 1)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,4],
gam[4], mu[i,1], gam[1])+
(D[i-1] == 2)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,1],
gam[1], mu[i,2], gam[2])+
(D[i-1] == 2)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,3],
gam[3], mu[i,2], gam[2])+
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(D[i-1] == 2)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,4],
gam[4], mu[i,2], gam[2])+
(D[i-1] == 3)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,1],
gam[1], mu[i,3], gam[3])+
(D[i-1] == 3)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,2],
gam[2], mu[i,3], gam[3])+
(D[i-1] == 3)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,4],
gam[4], mu[i,3], gam[3])+
(D[i-1] == 4)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,1],
gam[1], mu[i,4], gam[4])+
(D[i-1] == 4)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,2],
gam[2], mu[i,4], gam[4])+
(D[i-1] == 4)*myintegrand((t[i-1]+t[i])/2, delta, mu[i,3],
gam[3], mu[i,4], gam[4])+
(D[i] == 5)*(D[i-1] == 1)*myintegrand((t[i-1]+t[i])/2, delta,
mu[i,2],gam[2], mu[i,1], gam[1])+
(D[i] == 5)*(D[i-1] == 1)*myintegrand((t[i-1]+t[i])/2, delta,
mu[i,3],gam[3], mu[i,1], gam[1])+
(D[i] == 5)*(D[i-1] == 1)*myintegrand((t[i-1]+t[i])/2, delta,
mu[i,4], gam[4], mu[i,1], gam[1])+
(D[i] == 5)*(D[i-1] == 2)*myintegrand((t[i-1]+t[i])/2, delta,
mu[i,1], gam[1], mu[i,2], gam[2])+
(D[i] == 5)*(D[i-1] == 2)*myintegrand((t[i-1]+t[i])/2, delta,
mu[i,3], gam[3], mu[i,2], gam[2])+
(D[i] == 5)*(D[i-1] == 2)*myintegrand((t[i-1]+t[i])/2, delta,
mu[i,4], gam[4], mu[i,2], gam[2])+
(D[i] == 5)*(D[i-1] == 3)*myintegrand((t[i-1]+t[i])/2, delta,
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mu[i,2], gam[2], mu[i,3], gam[3])+
(D[i] == 5)*(D[i-1] == 3)*myintegrand((t[i-1]+t[i])/2, delta,
mu[i,1], gam[1], mu[i,3], gam[3])+
(D[i] == 5)*(D[i-1] == 3)*myintegrand((t[i-1]+t[i])/2, delta,










int K; // Number of possible states
//(not including independent censoring)
int Ntot1; // length of vector of
// all longitudinal outcome observations
int Ntot2;
int N; // number of subjects
int Nsurv; // length of survival vectors
int P1; // number of covars in longitudinal model
int P2;
int<lower=1> subj1[Ntot1]; // subject ID,




int<lower=1> subj3[Nsurv]; // subjid repeated
//number of transition times
vector[Ntot1] Y1; // longitudinal outcome
vector[Ntot2] Y2;
int Q; // num covars in survival model
vector[Nsurv] surt; // survival times
vector[Nsurv] D; // failure indicators























vector[P1] beta1; // longitudinal regression coeffs
vector[P2] beta2;
real<lower=0> sigmaeps1; // std dev of longitudinal error
real<lower=0> sigmaeps2;























































muk[i,1] = exp(XS[i,1]*alpha[1,1] + XS[i,2]*alpha[1,2] +
theta1[1]*u0[subj3[i],1] + theta2[1]*u0[subj3[i],2]);
muk[i,2] = exp(XS[i,1]*alpha[2,1] + XS[i,2]*alpha[2,2] +
theta1[2]*u0[subj3[i],1] + theta2[2]*u0[subj3[i],2]);
muk[i,3] = exp(XS[i,1]*alpha[3,1] + XS[i,2]*alpha[3,2] +
theta1[3]*u0[subj3[i],1] + theta2[3]*u0[subj3[i],2]);







Additional Data Analysis Results
F.1 Data Analysis Trace Plots for Joint Model with
Conditionally Independent Competing Risks in Chapter 3
210
Figure F.1: Trace plots for Model W from ACC data.
211
Figure F.2: Trace plots for Model L from ACC data.
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F.2 Chapter 4 Chain Initial Values for Data Analysis
Parameter Chain 1 Chain 2 Chain 3 Chain 4
β0 3.5 2.5 1.5 2
β1 0.15 0.55 -0.15 0.05
β2 2 1 3 0.5
β3 3 2 4 1.5
σU 0.5 1 2 1.5
σε 2 1 3 0.5
α0,1 1.2 2.2 0.2 0.6
α1,1 -0.4 0.4 -1.4 -0.2
α0,2 1.1 2.1 0.1 0.5
α1,2 -0.5 0.5 -1.5 -0.1
θ1 -1.1 1.1 -2.1 -0.1
θ2 -0.9 0.9 -1.9 -0.5
γ1 5 6 4 5.5
γ2 8 7 6 9
δ 0.4 0.1 0.7 0.6
U0i 1 -1 2 -2
Table F.1: Initial values for four chains used to fit Model W to the ACC data.
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F.3 Data Analysis Trace Plots for Joint Longitudinal and
Dependent Competing Risks in Chapter 4
Figure F.3: Trace plots for beta parameters.
214
Figure F.4: Trace plots for standard deviation parameters.
215
Figure F.5: Trace plots for alpha parameters.
216
Figure F.6: Trace plots for theta and gamma parameters.
217
Figure F.7: Trace plot for delta parameter with Beta(1,1) prior.
218
Figure F.8: Trace plot for delta parameter with Beta(0.03,0.07) prior.
219
Figure F.9: Trace plot for delta parameter with Beta(0.05,0.05) prior.
220
Figure F.10: Trace plot for delta parameter with Beta(3,7) prior.
221
Figure F.11: Trace plot for delta parameter with Beta(5,5) prior.
222
F.4 Additional Information from Data Analysis with
Multistate Model in Chapter 5
Parameter N eff Rhat Parameter N eff Rhat Parameter N eff Rhat
β
(1)
0 570 1.00 α0,1 1952 1.00 α0,3 2222 1.00
β
(1)
1 1683 1.00 α1,1 2341 1.00 α1,3 2705 1.00
β
(1)
2 460 1.01 θ
(1)





3 553 1.00 θ
(2)





0 367 1.00 γ1 3081 1.00 γ3 2660 1.00
β
(2)
1 1984 1.00 α0,2 1571 1.00 α0,4 1411 1.00
β
(2)
2 448 1.00 α1,2 1511 1.00 α1,4 1498 1.00
β
(2)
3 402 1.00 θ
(1)
2 2827 1.00 θ
(1)
4 2056 1.00
σ1 1919 1.00 θ
(2)
2 4013 1.00 θ
(2)
4 3072 1.00
σ2 2345 1.00 γ2 3733 1.00 γ4 2593 1.00








G.1 Full Conditionals for Joint Longitudinal and









































(Yi −Xiβ − ZiUi)T (Yi −Xiβ − ZiUi)−
1
2σ2pβ

























































































































































































































(θk −mθ)T (θk −mθ)
}]
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G.2 Full Conditionals for Joint Longitudinal and Dependent
Competing Risks in Chapter 4
The posterior is proportional to the following.





























































































































(Yi −Xiβ − Ui)T (Yi −Xiβ − Ui)
− 1
2s2pβ



















































































































































































































































































Proof of Representation Theorem from Chapter 4
Extending a distribution in Lu and Bhattacharyya’s paper (Lu and Bhattacharyya, 1990), con-
sider the following multivariate (joint) survival distribution for K variables T1, ..., TK :











where 0 < δ ≤ 1, and H1, ..., HK are arbitrary cumulative hazard functions. If each Hk(t) is a cu-
mulative hazard function then there exists an inverse functionH−1k (t) which is also non-decreasing.
Additionally, for any cumulative hazard function Hk(t) and δ in (0, 1], Hk(t)
1
δ is also a valid cu-
mulative hazard function.
Let Zk = Hk(Tk)
1
δ , k = 1, ..., K. We can write the joint survival function of the Zk using the
joint survival function of the Tk in (H.1).
SZ(z1, ..., zK) = Pr(Z1 > z1, ..., ZK > zK)





































− [z1 + ...+ zK ]δ
)
Define the random variable Y(K) = Z1 + ... + ZK , with realization y(K) = z1 + ... + zK . The
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joint density of the Z’s is given by
fZ(z1, ..., zK) =
∂K




































The aK,k coefficients are defined recursively.
a1,1 = δ;
aK,K = δaK−1,K−1;
aK,1 = (δ − (K − 1))aK−1,1;
aK,k = (kδ − (K − 1))aK−1,k + δaK−1,k−1, for 2 ≤ k ≤ K − 1
(H.5)
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See Section H.2.1 of the appendix for the proof of (H.3) - (H.5).
Define the random variables V1, ..., VK
V1 = (Z1 + ...+ ZK)






Z1 + Z2 + Z3
...
VK =
Z1 + ...+ ZK−1
Z1 + ...+ ZK−1 + ZK
We can write the Z1, ..., ZK in terms of the V variables.
Z1 = V2 · · · VKV 1/δ1
Z2 = (1− V2)V3 · · · VKV 1/δ1
Z3 = (1− V3)V4 · · · VKV 1/δ1
...
ZK = (1− VK)V 1/δ1
(H.6)
Note that y(K) = v
1
δ
1 . Call the Jacobian matrix of this transformation J(K). The determinant of the
















5 · · · vK−2K (H.7)
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The joint density of V1, ..., VK is derived in Section H.4 and is equal to
fV (v1, v2, ..., vK) =












1 + (−1)K−(K−1)aK,K−1vK−21 + ...
+ (−1)K−kaK,kvk−11 + ...+ (−1)K−2aK,2v1 + (−1)K−1aK,1
)
(H.8)
Since fV (v1, v2, ..., vK) factors, V1, ..., VK are independent. The kernel of the marginal density for
each Vk will have the same form as the terms with vk in the joint density. So we can see that
V2 ∼ Beta(1, 1)
V3 ∼ Beta(2, 1)
...
VK ∼ Beta(K − 1, 1)









1 + (−1)K−(K−1)aK,K−1vK−21 + ...
+ (−1)K−kaK,kvk−11 + ...
+ (−1)K−2aK,2v1 + (−1)K−1aK,1
) (H.9)
where Γ(x) is the Gamma function, i.e. Γ(k) =
∫∞
0
xk−1e−xdx. See Section H.4 of the appendix
for proof that fV1(v) is a valid distribution.
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H.1 Proof of the Joint density of the Z Variables
Define the random variable Y(K) = Z1 + ...+ ZK , with realization y(K) = z1 + ...+ zK . Note
that the derivative of y(K) with respect to any zk is 1, i.e.
∂y(K)
∂zk
= 1, ∀k = 1, ..., K. And so
∂
∂zk









− (z1 + ...+ zK)δ
)
















Extending this, for any k1, k2, ..., km ∈ {1, 2, ..., K}
∂m
∂zk1∂zk2 · · · ∂zkm








H.2 Verifying (H.1) is a Survival Function
It is easy to see that for all t1, ..., tK , (H.1) is non-negative, so ST (t1, ..., tK) ≥ 0.
Now tk ≥ 0 and Hk is a cumulative hazard function so it has range [0,∞) for k = 1, 2, ..., K,
235
and 0 < δ ≤ 1. So






































⇒ST (t1, ..., tK) ≤ 1





















































































⇒ST (a, t2, ..., tK) ≥ ST (b, t2, ..., tK)
This also holds for if a and b are substituted for any of t2, ..., tK . Hence ST is non-increasing.
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Note that Hk(0) = 0 for all k so
























































This holds for tk →∞ for any k = 1, ..., K. Finally
ST (t1, 0, ..., 0) = exp (−H1(t1)) = exp (− (− log(S1(t1))) = S1(t1)
Similarly for any k = 2, ..., K, tk 6= 0 and tl = 0, for all l 6= k.
So ST in (H.1) is a valid survival function.
H.2.1 Proof of Formula for Joint Density of Z1, ..., ZK in (H.3 - H.5)
We will prove by induction.
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We will write fZ(K)(z) for the joint density of the K random variables (Z1, .., ZK). For ease of
notation we will drop the subscripts on Y(K) and y(K).











We have a1,1 = δ and the form for gK(y) holds for K = 1.
For K = 2, Y = Y(2) = Z1 + Z2 and











= (−δyδ−1)(−δyδ−1) exp(−yδ) + exp(−yδ)(−δ(δ − 1)yδ−2)
= exp(−yδ)
(






Hence a2,2 = δ2 = δa1,1, and a2,1 = (δ − 1)δ = (δ − (2− 1))a1,1. The formula holds for K = 2.
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For K = 3, Y = Y(3) = Z1 + Z2 + Z3.

























δ(δ − 1)(δ − 2)yδ−3
)








− δ2(2δ − 2)y2δ−3 + δ3y3δ−3 + δ(δ − 1)(δ − 2)yδ−3






δ2(2δ − 2) + δ2(δ − 1)
]
y2δ−3




(−1)0a3,3y3δ−3 + (−1)1a3,2y2δ−3 + (−1)2a3,1yδ−3
)
and the formula holds for K = 3.
Assume that (H.4) holds for someK. Note that ∂
K
∂yK
exp(−yδ) = (−1)KgK(y). Then forK+1
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variables


























































⇒ fZ(K+1)(z1, ..., zK+1) = (−1) exp(−yδ)
(
aK,K(Kδ −K)yKδ−K−1




















+ (−1)K−(K−1)+1(δ + (Kδ −K))aK,K−1·
yKδ−(K+1)






+ (−1)K+1−2 [δaK,2 + (3δ −K)aK,3] y3δ−(K+1)
+ (−1)K+1−1 [δaK,1 + (2δ −K)aK,2] y2δ−(K+1)
+ (−1)K−1(δ −K)aK,1yδ−(K+1)
)




+ (−1)(K+1)−K [(Kδ −K)aK,K + δaK,K−1] yKδ−(K+1)
+ ...
+ (−1)K+1−k [(kδ −K)aK,k + δaK,k−1] ykδ−(K+1)
+ ...














The right hand side is (H.4) for K + 1 variables and the result is shown.
H.3 Proof of Transformation Jacobian in (H.7)












5 · · · vK−2K


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣ ∣
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This is an upper triangular matrix so the determinant is the product of the diagonal entries. We
see a pattern where v3 is only in the first diagonal term, v4 is in the first two diagonal terms, v5 in
the first three, and so on until vK which is in K-2 terms. And −v
1
δ



















































5 · · · vK−2K
H.4 Proof of Mixture Distribution for V1
The joint density of V1, ..., VK is
fV (v1, v2, ..., vK) =
∣∣det (J(K))∣∣ fZ(z1, ..., zK)
=
∣∣det (J(K))∣∣ fZ(v2 · · · vKv1/δ1 , (1− v2)v3 · · · vKv1/δ1 , ..., (1− vK)v1/δ1 )
=
∣∣det (J(K))∣∣ gK(v2 · · · vKv1/δ1 + (1− v2)v3 · · · vKv1/δ1 + ...+ (1− vK)v1/δ1 )
=
∣∣det (J(K))∣∣ gK(v1/δ1 (v2 · · · vK +−v2v3 · · · vK + v3 · · · vK + ...+ 1− vK))
=
∣∣det (J(K))∣∣ gK(v1/δ1 )




















































































+ (−1)K−(K−1)aK,K−1vK−21 + ...














1 + (−1)K−(K−1)aK,K−1vK−21 + ...
+ (−1)K−kaK,kvk−11 + ...+ (−1)K−2aK,2v1 + (−1)K−1aK,1
)
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+ (−1)K−(K−1)aK,K−1vK−21 + ...

































The integrands are kernels of Gamma densities Gamma(k, 1), k = K, ..., 1. Γ(k) denotes the
gamma function, i.e. Γ(k) =
∫∞
0









+ (−1)K−(K−1)Γ(K − 1)aK,K−1 + ...














+ (−1)K−(K−1) (K − 2)!
(K − 1)!
aK,K−1 + ...
+ (−1)K−k (k − 1)!
(K − 1)!
aK,k + ...
+ (−1)K−2 (2− 1)!
(K − 1)!
aK,2





We will prove by induction that the sum on the RHS of (H.4) equals 1. Recall the definition of the
aK,k in (H.5).


















So it holds for K = 1.
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δ2 − (δ − 1)δ
]
=δ − δ + 1
=1
And the integral equals 1 for K = 2.









+ (−1)3−2 (2− 1)!
(3− 1)!
a3,2







































δ2 − (δ − 1)δ
]
=1
It holds for K = 3.
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+ (−1)K−(K−1) (K − 2)!
(K − 1)!
aK,K−1 + ...
+ (−1)K−k (k − 1)!
(K − 1)!
aK,k + ...
+ (−1)K−2 (2− 1)!
(K − 1)!
aK,2












[(K + 1− 1)!
(K + 1− 1)!
aK+1,K+1
+ (−1)K+1−K (K + 1− 2)!
(K + 1− 1)!
aK+1,K+1−1 + ...
+ (−1)K+1−k (k − 1)!
(K + 1− 1)!
aK+1,k + ...
+ (−1)K+1−2 (2− 1)!
(K + 1− 1)!
aK+1,2
+ (−1)K+1−1 (1− 1)!









[(K + 1− 1)!
(K + 1− 1)!
δaK,K
+ (−1)K+1−K (K + 1− 2)!
(K + 1− 1)!
((Kδ −K)aK,K + δaK,K−1) + ...
+ (−1)K+1−k (k − 1)!
(K + 1− 1)!
((kδ −K)aK,k + δaK,k−1) + ...
+ (−1)K+1−2 (2− 1)!
(K + 1− 1)!
((2δ −K)aK,2 + δaK,1)
+ (−1)K+1−1 (1− 1)!



















(−1)K+1−K (K − 1)!
K!
δaK,K−1
+ (−1)K+1−(K−1) (K − 1)!
K!
δaK,K−1+









(−1)K+1−k (k − 1)!
K!
δaK,k−1




















(−1)K−K (K − 1)!
(K − 1)!
aK,K
+ (−1)K−(K−1) (K − 2)!
(K − 1)!
aK,K−1 + ...
+ (−1)K−k (k − 1)!
(K − 1)!
aK,k + ...
+ (−1)K−2 (2− 1)!
(K − 1)!
aK,2




=1 (by the induction hypothesis)
We have proved that
∫
fV1(v)dv = 1 for any K. Therefore fV1(v) is a valid density function ∀K.
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